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Preface. 
The heat shock response was originally described as a phenomenon of inducible gene 
expression in Drosophila in response to hyperthermia, but has rapidly become 
recognised as a ubiquitous response by virtually all cell types to a wide variety of 
environmental stresses. Much of the early work on heat shock protein (hsp) structure 
and function concentrated on the analysis of heat shock gene expression in Drosophila, 
but it soon became clear from studies involving higher eukaryotes and prokaryotes that 
the heat shock response is highly conserved and a high degree of homology in the nucleic 
acid sequence of related heat shock genes is evident in all species from bacteria to man. 
Over the past decade, the study of heat shock protein expression has diversified into 
broad areas of biological research. The importance of heat shock proteins as molecular 
chaperones which mediate the folding and assembly of polypeptide chains has led to a re- 
examination and broadening of our understanding of the principles of protein folding and 
transport. In immunology, heat shock proteins have been shown to act as major antigens 
involved in the immune response to pathogens, and mechanisms involving heat shock 
proteins have been implicated in the pathogenesis of a variety of autoimmune diseases, 
including rheumatoid arthritis and systemic lupus erythematosus. 
At the conception of this research, evidence existed that expression of heat shock 
proteins was related to the differentiation of cells, including haemopoietic cells, and 
abnormal expression in some tumour cells had been reported, although not in leukaemic 
cells. It was against this background that the ideas for this research project were 
conceived. Based in the Department of Haematology at Warwick Hospital, I had access 
to samples from leukaemic patients, providing an opportunity to examine heat shock 
protein expression in malignant cells from these patients. As the project evolved, the 
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significance of lisp expression was addressed by studying the relationship between heat 
shock protein expression and apoptosis. This mode of cell death has recently been shown 
to be crucial in carcinogenesis. A tumour is known to develop if the balance between cell 
division and cell death by apoptosis is disturbed, permitting a potentially malignant clone 
of cells to escape elimination. In addition, most, if not all, the cytotoxic drugs used to 
target malignant cells are known to exert their effects via the induction of apoptosis. The 
expression of genes which influence the susceptibility of cells to chemotherapy-induced 
apoptosis may therefore have a bearing upon the efficacy of chemotherapeutic regimens. 
Since heat shock proteins have been shown to protect cells against apoptosis induced by 
a variety of stresses, their expression in leukaemic cells is particularly worthy of 
investigation, both in terms of leukaemogenesis and the response of leukaemic cells to 
chemotherapy. 
This research project has therefore evolved to question the role of heat shock proteins in 
the biology and treatment of leukaemia and to establish their role in the control of 
apoptosis, with particular reference to the stress response of cells exposed to the 
chemotherapeutic agents used in the treatment and clinical management of these 
malignancies. 
14 
Chapter 1 
Introduction 
15 
1.1 Biology and function of heat shock proteins. 
1.1.1. Heat shock proteins and the heat shock response. 
The term heat shock protein (lisp) is used to describe several families of proteins whose 
expression is induced by hyperthermia. The first description of this phenomenon, now 
termed the heat shock response, arose from the observation that Drosophila larvae 
raised at 25 °C exhibited a novel puffing pattern on their giant salivary gland 
chromosomes when they were exposed to higher temperatures of 30-32 ° C. (Ritossa, 
1962). These chromosome puffs, indicative of DNA transcription, were subsequently 
shown by Ritossa to be also induced in the midgut and hindgut of the larvae, indicating 
that the heat shock response was not tissue-specific. Furthermore, the same puffing 
pattern could be induced in isolated salivary glands by treatment with 2,4-dinitrophenol, 
sodium salicylate, sodium azide and release from anoxia. These early observations 
already hinted at two important features of the heat shock response; namely, the 
universality of the response in all cell types, and the variety of cellular stresses which will 
induce this pattern of specific gene expression. 
For many years, all research on heat shock gene expression was performed solely using 
Drosophila larvae and it was not until the late 1970's that the ubiquity of the heat shock 
response was demonstrated. The same typical pattern of gene expression in response to 
heat shock was then shown in chicken embryo fibroblasts (Kelley and Schlesinger, 1978) 
and in Escherichia Coli (Lemaux et al, 1978), and similar observations were soon 
reported in yeast (McAlister and Finkelstein, 1980) and plants (Barnett et al, 1980). The 
heat shock response has since been observed in all organisms examined, from 
archaebacteria to eubacteria, yeasts, plants, invertebrates and vertebrates, including 
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humans. Examination of the nucleic acid sequence of heat shock genes from distant 
species, and protein analysis using monoclonal antibodies, has since demonstrated that 
the heat shock proteins are among the most abundant and highly conserved proteins in 
nature (Hunt and Morimoto, 1985, Bardwell and Craig, 1987, Hartl, 1996). 
Although the term `heat shock protein' is still used widely, it has become clear that a 
variety of other cellular insults can induce the heat shock response. Ritossa's early 
experiments demonstrated that 2,4-dinitrophenol, sodium salicylate and sodium azide 
also generated the novel puffing pattern characteristic of heat shock gene transcription. 
Subsequently, a large number of both environmental and pathophysiological stresses (see 
figure 1.1) have been shown to induce the response, including heavy metals, ethanol, 
amino acid analogues, fever, and viral or bacterial infection (Lindquist and Craig, 1988). 
For this reason, the heat shock proteins are frequently referred to as `stress proteins'. It 
should be noted that many of these inducers share a capacity to cause protein 
denaturation, a fact which hints at the major functional role of the heat shock proteins as 
molecular chaperones. This function, which is vital to the cell, both under normal 
circumstances and following cellular stress, will be discussed in greater detail later. 
In the literature, terms used to describe heat shock proteins and molecular chaperones 
have frequently tended to be used interchangeably. A brief description of the terminology 
used to describe these groups of proteins therefore follows. 
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Patbophysiological Stresses: 
Oxidative stress 
Inflammation 
Viral/chemical transformation 
Oncogenes and protooncogenes 
/ Normal conditions: 
Cell cycle regulation 
Proliferation and differentiation 
Growth factors 
Environmental Stresses: 
Heat shock 
Amino acid analogues 
Heavy metals 
Ethanol 
lz 
Qý 
Hsp 
Figure 1.1. The induction of heat shock proteins by a wide variety of environmental and 
pathophysiological stresses is a universal response common to all cell types and 
organisms. 
18 
1.1.2. Nomenclature. 
Some confusion still arises in the literature regarding the nomenclature used to describe 
heat shock proteins, molecular chaperones and a sub-group of molecular chaperones 
known as chaperonins (cpn6O). Heat shock proteins are also frequently referred to as 
`stress proteins', a term which reflects the fact that hsp expression is induced by a wide 
variety of cellular insults other than hyperthermia, and is therefore perhaps a more 
appropriate nomenclature. Throughout this thesis, however, the prefix hsp will be used 
to describe these stress-inducible proteins. 
The term heat shock protein covers an ever growing number of proteins which have in 
common the induction of their expression in response to a hyperthermic stress. 
Molecular chaperones are defined as a family of unrelated classes of protein which 
mediate the assembly of other cellular polypeptides, but which are not components of the 
final functional polypeptide structure (Ellis and Hemmingson, 1989). As will be 
described, the ability of molecular chaperones to interact with other cellular proteins is 
vital to the cell, both during normal cell growth and when the cell is subjected to some 
form of environmental or pathophysiological insult. Many, but not all, molecular 
chaperones can be classified as heat shock proteins since their expression can be induced 
by hyperthermia and a variety of other cellular stresses. Similarly, most heat shock 
proteins are now known to perform a molecular chaperone function, and the importance 
of this function will be discussed. Finally, the term chaperonin is used to describe a 
specific sub-group of the molecular chaperones, comprising a class of sequence-related 
molecular chaperones which have been found in all bacteria, mitochondria and plastids so 
far examined (Ellis and van der Vies, 1991). One of the remarkable features of the 
chaperonins is the very high degree of structural and functional homology between 
members of this group indicating that these proteins are true evolutionary homologues. It 
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has been suggested that their distribution in the plastids and mitochondria of eukaryotes 
derives from a prokaryotic origin, providing further evidence for the evolution of 
eukaryotic cellular organelles via an endosymbiotic mechanism (Gupta et al, 1989, 
Gupta, 1998). 
A growing number of cellular proteins whose expression is induced by hyperthermia and 
which have homology between species have been identified. The conservation of both 
structure and function between these groups has led to the classification of these hsp into 
four major families, and a discussion of the major features of each of these families 
follows. 
1.1.3. Heat shock protein families. 
Several distinct families of heat shock proteins have been identified in both eukaryotes and 
prokaryotes (see Table 1.1). The majority of these belong to four groups which are generally 
classified according to their approximate molecular weight, and although this varies slightly 
from organism to organism, a strong degree of homology between the amino acid sequences 
of proteins within these families allows easy identification of constituent members. Thus, the 
hsp90 family includes proteins with an apparent molecular weight of 9OkD in mammals 
(83kD in yeast and bacteria), while the hsp70 family comprises several closely related 
members including the 73kD and 72kD proteins seen in mammals and the 70kD dnaK protein 
of E. coli. 
The hsp60 (chaperonin 60) family comprises two subgroups: the GroEL family and the 
members of the TCP-1 ring complex (TRiC) Family. The GroEL-type chaperonins found i 
eubacteria, mitochondria and chloroplasts are made up of two stacked heptameric rings of 
approximately 6OkD, while the TRiC chaperonins in the eukaryotic cytosol are 8- or 9- 
membered double rings containing subunits of 55kD. Finally, the small heat shock proteins 
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comprise a number of related family members whose size generally ranges from 20 to 30kD 
in animals. 
1.1.3.1. The hsp9O family. 
This group includes cytosolic proteins with an apparent molecular weight of 9OKd in 
mammals and 83Kd in Drosophila and bacteria. Hsp9O is an abundant cytosolic protein, 
comprising 1-2% of total soluble protein under normal conditions and becoming even more 
abundant under stress. Hsp9O homologues have been found in the endoplasmic reticulum of 
higher eukaryotes, and have been present in all prokaryotic organisms so far examined 
(Parsell and Lindquist, 1993). It is only in recent years that evidence has emerged to indicate 
that hsp9O can act as an ATP-independent molecular chaperone, involved in protein folding 
and unfolding events (Jacob and Bukner, 1994, Bose et al., 1996). Members of this family 
associate with a diverse range of cellular proteins including retroviral transforming proteins, 
steroid hormone receptors, cellular protein kinases, actin and tubulin (Hutchison et al, 1992; 
Dittmar, D. et al., 1997), the coffin feature of most of these interactions being the 
stabilisation of the target protein in an inactive or unassembled state. For example, hsp9O is 
involved in both the initial folding of steroid hormone receptors and subsequent modulation 
of their DNA binding activities (Joab et al., 1984, and reviewed by Pratt and Toft, 1997). 
Newly synthesised steroid hormone aporeceptors form a complex with hsp9O in which the 
receptor is partially unfolded and unable to bind DNA, and the subsequent binding of steroid 
hormones promotes dissociation of this complex allowing the receptor to bind to DNA. Only 
those receptors which are complexed with hsp9O are capable of binding to steroid hormones, 
which suggests that hsp9O maintains the receptor in a conformation which is competent for 
hormone binding, rather than simply inactivating the hormone-free receptors. 
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Another important group of proteins which interact with hsp90 are protein kinases (Parnell 
and Lindquist, 1993, ) ). An example is the viral protein, v-Src, which forms stable complexes 
with hsp9O and is thus chaperoned until it becomes attached to the plasma membrane. It 
has 
been shown that the number of active, membrane-bound v-Src molecules is lower in cells 
which have reduced levels of hsp9O, suggesting that the chaperoning activity of hsp9O 
is 
involved in the maturation of v-Src (Xu and Lindquist, 1993). 
The finding that hsp90 was frequently isolated in complex with specific substrate proteins 
such as steroid receptors and kinases originally suggested that hsp9O is a highly specialised 
binding protein, but it has recently become clear that hsp9O has general molecular chaperone 
properties and is involved with protein folding within the cell This property, which is 
common to all four major hsp families will be discussed in greater detail later. 
1.13.2. The hsp70 family. 
Members of this family are highly conserved ATPases, identified in both prokaryotes and 
most compartments of eukaryotic cells. In eukaryotes, three major members of the hsp70 
system are found; a constitutively expressed protein with a molecular weight of 73Kd, and a 
highly heat-inducible protein of 72Kd, both of which are predominantly localised within the 
cytosol, and a third member, Grp78 (BiP), which is found in the lumen of the endoplasmic 
reticulum. Studies suggest that members of the hsp70 family function in a wide variety of 
processes, both under normal growth conditions and when the cell is stressed. Their role as 
molecular chaperones has long been appreciated and known to be important in the unfolding 
of cytoplasmic proteins and their translocation into mitochondria and endoplasmic reticulum 
(Petham, 1986). Inside these compartments they then facilitate refolding of the transferred 
proteins to an active form, and also assist in the assembly of oligomeric complexes. 
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Mechanistic studies of hsp70 function have revealed just how adaptable the hsp70 chaperone 
machinery is, and an understanding of the sequence of events in the chaperone-mediated 
creation of a functional protein is beginning to become clear (Hartl, 1996). The adaptability of 
hsp70 in terms of substrate and function arises from the ability of the molecular chaperone 
system to function co-operatively, and hsp70 family members are known to act in concert 
with specific partner proteins which modulate the binding and release by hsp70 of other 
polypeptides (reviewed by Rassow et al., 1995). For example, the hsp70 homologue in 
E. coli, DnaK, is regulated by a -40kD chaperone (DnaJ) and a constitutively expressed 
20kD protein (GrpE). These three proteins function in cohort to perform a number of specific 
cellular processes, which in general relate to de novo protein folding and maintenance of the 
structural integrity of existing proteins under stressful conditions. There is increasing evidence 
that in eukaryotic cells, similar cooperative pathways of chaperone function exist, providing a 
highly coordinated pathway which has evolved in order to assist nascent proteins along the 
folding and transport pathways. 
When mammalian cells are heat shocked, levels of the inducible hsp72 protein increase and 
both hsp72 and hsp73 migrate from the cytosol to the nucleus. This response to stress is 
presumed to involve the association of hsp70s with unfolded or heat-denatured polypeptides 
which tend to aggregate and form insoluble complexes within the nucleus. Accordingly, most 
experimental studies which have examined the role of hsp in the stress response have focused 
on members of the hsp70 family, and in particular the heat- and stress-inducible hsp72 
protein. For example, cells which are subjected to a mild heat shock acquire resistance to 
subsequent lethal heat stress, a phenomenon known as thermotolerance, and this state has 
been shown to correlate with hsp70 levels (Amin et al, 1995). Hsp70 has also been 
demonstrated to have a protective effect against a variety of other cellular stresses, both 
environmental and pathophysiological (see figure 1.1), and the protective role of the heat 
shock response will be discussed in further detail later (section 1.1.5. ). 
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Hsp70 has been shown to interact with a variety of cellular proteins, including certain cell 
cycle-regulatory proteins . It appears that 
hsp70 may play a regulatory role in the cintrol of 
the cell cycle. For example, hsp70 expression varies throughout the cell cycle (Hang and Fox, 
1996; He and Fox, 1997), but most interesting in terms of this project is the interaction with 
certain growth regulatory proteins, particularly the tumour suppressor protein, p53, and the 
retinoblastoma gene product, pRb (Nihei, et al., 1994), The involvement of p53 and pRb in 
the development of tumours is well established, and it is therefore interesting that the 
interaction of these two tumour suppressor gene products with hsp70 has been suggested to 
modulate their function (Lane et al., 1993; Hansen et al., 1996). In addition, hsp70 can 
protect cells against the cytotoxic effects of tumour necrosis factor (Jaattela et al, 1992) and 
from monocyte-mediated cytotoxicity (Jaattela and Wissing, 1993). These observations 
suggest that overexpression of this hsp could allow pre-cancerous cells to elude the normal 
mechanisms of immune surveillance, and the potential involvement of hsp70 in the 
development of malignancies will be discussed in greater detail later in this introduction. 
1.1.3.3. The hsp6O (chaperonin) family. 
The chaperonin fay of hsp comprise two major subgroups: the GroEL (hsp60) family, and 
members of the TCP-1 ring complex (TRiC) family. Both have an essential function in 
promoting the ATP-dependent folding of proteins during normal growth and following 
cellular stress. (reviewed by Hartl, 1996). Members of the GroEL family are found in 1) 
eubacteria, where they have been shown to promote phage assembly, 2) mammalian 
mitochondria, where their major function is to promote the folding and assembly of imported 
proteins and the binding of heat-denatured mitochondrial proteins, and 3) in plant chloroplasts 
where they promote assembly and folding of imported proteins, e. g rubisco. The TRiC 
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chaperonins are found in archaebacteria and the eukaryotic cytosol, and although fewer 
studies on the function of this subgroup have been reported, the available data on the 
structure of these proteins suggests that they are also important in providing a folding 
compartment for polypeptide assembly. 
1.1.3.4. The Small heat shock Proteins. 
The family of small hsp encompasses a number of related species, with plant cells 
expressing about 20 different small hsp in the cytosol and chloroplasts, while yeast and 
mammalian cells have only one representative (Arrigo and Landry, 1994). Although the 
overall homology between different small hsp is rather low, they are grouped together 
according to the presence of conserved regions within the carboxy- terminus region of 
the protein, and by the similarities in their monomeric size. Despite their low molecular 
weights, the small hsp exist in vivo as higher ordered structures of 600-900 kDa (Waters 
et al., 1996). The formation of these large oligomeric structures is a dynamic process, 
dictated by the physiology of the cells, whether they are subjected to stress, and by the 
phosphorylation status of these proteins (Arrigo, 1998). 
In common with other hsp, small heat shock proteins perform a molecular chaperone 
function and can selectively recognise and bind non-native proteins, as well as promoting 
functional folding of polypeptides in an ATP-independent manner. Members of this 
family have also been implicated in a wide variety of different cellular processes, 
including RNA stabilisation (Nover et al., 1989), growth and differentiation (Spector et 
al., 1993), interaction with the cytoskeleton (Nicholl and Quinlan, 1994) and an 
association with non-native (unfolded or damaged) proteins following heat shock 
(Ehrnsperger et al., 1997). 
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The functions listed above suggest an important role for the small heat shock proteins in 
the cellular response to stress. Indeed, during the last few years it has become clear that 
expression of the small hsp protects cells against various stresses, including heat shock 
and cytotoxic drugs (see Introduction, section 1.1.7), and the importance of the latter 
observation has been particularly highlighted by the finding that small hsp levels are a 
prognostic indicator in certain solid tumours, including breast cancer (Fuqua et al., 
1994). 
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1.1.4. Heat shock proteins as molecular chaperones. 
Although originally noted for the induction of their expression during conditions of 
cellular stress, the majority of heat shock proteins are also synthesised constitutively, and 
*t is now realised that they have numerous cellular functions which are not confined to 
protection against stresses such as heat shock. Most heat shock proteins function as 
molecular chaperones, a term originally used to define a group of unrelated classes of 
proteins which mediate the correct assembly of other cellular proteins (Ellis and 
Hemmingson, 1989; Ellis, 1993). It is now clear that molecular chaperones play a varied 
and complex role in facilitating the fate of other proteins within the cell. The controlled 
binding and release of proteins by molecular chaperones is important, for example, 
during oligomeric assembly and in transport to and from subcellular compartments 
(reviewed by Hartl, 1996). Molecular chaperones also influence clathrin lattice dynamics, 
viral replication and transcriptional actvation, and they have been shown to have an 
important role in the maintenance and organisation of the cytoskeleton (Liang and 
McRae, 1997). Under conditions of stress, by extension of their role as mediators of 
protein folding/unfolding, some molecular chaperones prevent the denaturation of 
proteins while others act by dissociating protein aggregates and refolding the monomers 
thus derived. It has also been shown that molecular chaperones have a role in the 
disposal of denatured proteins by proteolytic degradation (Hayes and Dice, 1996). 
The term molecular chaperone was first used to describe the function of nucleoplasmin, a 
nuclear protein which promotes the assembly of nucleosomes from individual histones 
and DNA (Laskey et al, 1978). The molecular chaperone concept was then further 
developed as a result of studies at Warwick University on the biogenesis of the plant 
enzyme, ribulose-bisphosphate carboxylase (rubisco), which is involved in the 
photosynthetic pathway of carbon dioxide fixation. The rubisco holoenzyme comprises 
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eight large subunits which are synthesised in the chloroplasts and eight smaller subunits 
which are imported into the chloroplasts following synthesis in the cytosol. Before 
assembly of the holoenzyme in the chloroplasts, rubisco subunits form a complex with a 
large binding protein from which they subsequently dissociate in an ATP-dependent 
reaction (Barraclough and Ellis, 1980). This binding protein was subsequently 
identified 
as the chloroplast homologue of bacterial GroEL and the mitochondrial hsp60 
(Hemmingsen et al., 1988), leading to the hypothesis that interaction between non-native 
rubisco and chloroplast cpn60 is required for assembly of the functional enzyme. As it 
became clear that molecular chaperones were involved in the folding of a variety of 
proteins, the term `molecular chaperone' was introduced to describe how these proteins 
assist non-native polypeptide structures through the rigours of folding and oligomeric 
assembly, and in transport to and from subcellular compartments. 
Under conditions of normal cellular growth, the many vital functions which are served by 
molecular chaperones derive from their ability to recognise and modulate the state of 
folding of other cellular proteins (reviewed by Ellis and van der Vies, 1991, Kelley and 
Georgopoulos, 1992, Hartl et al, 1994, Hartl, 1996). In the cell, nascent polypeptide 
chains emerge from ribosomes as unfolded linear chains and a comparable situation 
exists when polypeptide chains are transported across intracellular membranes in an 
extended state. In such an extended or partially folded state, hydrophobic surfaces 
become exposed, raising the possibility of aberrant inter- or intramolecular interactions 
and the formation of polypeptide aggregates. The major role of molecular chaperones 
appears to be the prevention of these incorrect intermolecular associations between 
unfolded polypeptide chains, thereby preventing their aggregation and assisting in the 
maintenance of polypeptide chains in a translocation-competent state during transport 
across intracellular membranes. 
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In terms of assisting protein folding, two distinct mechanisms of chaperone action have 
evolved to ensure the correct folding of polypeptide chains. Firstly, exposed hydrophobic 
surfaces are shielded by interaction with a molecular chaperone in order to prevent 
aggregation, particularly during synthesis or membrane translocation when productive 
folding is not yet possible. Secondly, molecular chaperones will sequester a completed 
but as yet unfolded protein, protecting it from the cellular environment whilst allowing 
folding to the native state to proceed. These two molecular chaperone functions are 
generally carried out by members of the hsp70 and hsp60 families respectively, in a 
sequential pathway of chaperoned protein folding (reviewed by Hartl et al, 1994). For 
example, in the synthesis and import of mitochondrial proteins, the first step involves 
cytosolic hsp70 interacting with nascent polypeptide chains as they are synthesised on 
ribosomes. In a translocation-competent state, the hsp70-polypeptide complex crosses 
the mitochondrial membranes where the still extended polypeptide chain interacts with 
mitochondrial hsp70 in the matrix compartment. Once in their correct cellular 
environment, chaperone-mediated folding and/or oligomeric assembly then occurs to 
give rise to the native protein structure. 
A full discussion of the complex mechanisms whereby protein folding is achieved by 
molecular chaperones and their accessory proteins is beyond the scope of this 
introduction. However, the point to be made is that hsp, as molecular chaperones, are 
capable of interacting with a variety of proteins, including many growth regulatory 
proteins, and this has consequences which may impinge upon normal growth and cellular 
differentiation. 
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1.1.5. Heat shock protein expression during stress. 
First noted for the induction of their expression following heat shock, the hsp were 
generally accepted as playing a role in the protection of cells against hyperthermia and 
those other stresses which were known to result in elevated hsp expression. Although the 
mechanisms by which hsp alleviate the cytotoxic effects of such a variety of stresses were 
not, and are still not, fully understood, it follows that elevated hsp expression during 
stress is a response to an increased requirement for molecular chaperone function in 
order to deal with the increased number of abnormally folded or damaged proteins which 
would arise following such cellular perturbations. The best studied aspect of the 
protective nature of hsp is, unsurprisingly, their role in the development of 
thermotolerance 
1.1.5.1. Heat shock protein expression and thermotolerance. 
Pre-exposure of cells to heat or other types of stress (e. g sodium arsenite, ethanol, H202) 
can lead to the acquisition of a transient resistance against the cytotoxic effects of a 
subsequent thermal stress (reviewed by Kampinga, 1993). This phenomenon, known as 
thermotolerance, involves a reduced susceptibility for protein denaturation and 
aggregation to occur. Although the mechanisms involved are not completely understood, 
it has been demonstrated that hsp clearly play a role in this thermal resistance. In a 
variety of systems, it has been shown that a positive correlation exists between levels of 
hsp70 and thermotolerance following heat shock (e. g Li et al., 1982; Landry et al, 
1989). Further evidence provided by studies using overexpression of specific hsp genes 
in leukaemic cell lines has revealed that hsp70 and hsp25 are particularly important in 
conferring resistance to thermal stress (Li et al., 1991, Wissing and Jaattela, 1998). The 
reciprocal approach, using micro-injection of anti-hsp70 antibodies and antisense cDNA 
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to inhibit hsp70 expression has also demonstrated the role of this protein in thermal 
resistance (Johnston et al., 1988; Riabowol et al., 1988). 
As mentioned, the exact mechanisms involved in hsp-mediated thermotolerance are 
unknown, although it can be speculated that the ability of hsp to interact with unfolded 
protein structures plays a part. Protein denaturation and the formation of protein 
aggregates are known to be the main processes involved in thermal cytotoxicity, 
implying that the protective effect of hsp derives from their ability as molecular 
chaperones to prevent this occurring. In support of this, in vitro experiments have shown 
that DnaK, the hsp70 homologue in E. coli, has the capacity to solubilise the aggregates 
of certain heat-denatured proteins. In vivo, it is therefore likely that stress-induced 
unfolding is associated with chaperone binding to proteins, preventing aggregation 
taking place. Other hsp-mediated mechanisms may also be important. For example, it has 
recently been suggested that a role for hsp in the recovery of cells from hyperthermia 
involves the improved ability of cells to re-establish the heat-induced shut-off of RNA 
and protein synthesis (Carper et al., 1997), while other reports have hypothesised that 
protection of the actin microfilament network by hsp is a crucial factor in thermal 
resistance (Huot et al., 1996). 
The value of describing the thermotolerant cell in relation to aspects arising within this 
study is that the mechanism(s) involved in the development of a thermotolerant state 
probably share a common theme with those which are involved in the protective nature 
of hsp against a variety of environmental stresses. In particular, the potential role of hsp 
in protecting leukaemic cells against the cytotoxic effects of chemotherapeutic agents 
may occur in a similar fashion. It is relevant that the action of certain cytotoxic drugs 
(e. g the alkylating agents) results in the appearance of abnormal or damaged cellular 
proteins and thus one could envisage that hsp overexpression could be an adaptive 
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response of tumour cells to drug exposure thus leading to the acquisition of a 
drug 
resistant phenotype. 
1.1.5.2. Heat shock proteins protect cells from certain pathophysiological stresses. 
Expression of hsp, particularly members of the hsp70 family, has been shown to 
influence the susceptibility of cells to several stresses which may be of pathophysiological 
importance. For example, overexpression of hsp70 protects cells against monocyte- 
mediated cytotoxicity (Jaattela and Wissing, 1993), and the cytotoxic effects of tumour 
necrosis factor are inhibited by overexpression of hsp72 (Jaattela et al., 1992). These 
two observations suggest a mechanism via which tumour cells could escape the normal 
immune surveillance mechanisms. This is particularly relevant since hsp expression has 
been reported as abnormal in a variety of tumour cells, and in recent years a number of 
studies have focussed, as this project has, on the relationship between hsp levels in 
tumour cells and clinical parameters such as drug sensitivity. A review of the published 
data relating to abnormal hsp expression in tumour cells appears later in this discussion 
(section 1.1.8). 
1.1.5.3. How do beat shock proteins prevent stress-induced cell damage? 
As has been mentioned, many of the cellular perturbations which lead to the induction of 
hsp expression have in common the effect of protein denaturation, causing the 
accumulation of abnormally folded proteins. For example, agents such as amino acid 
analogues will affect the folding of nascent proteins, while other stresses such as heat 
shock and alkylating agents will interfere with the folding of both nascent and mature 
protein structures. Such proteins will obviously become targets for molecular chaperone 
interaction via binding to exposed polypeptide surfaces (Beckmann et al., 1992). The 
importance of this function under conditions of stress is illustrated by the fact that some 
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denatured or aggregated proteins can be repaired or restored back to their native 
conformation by the action of hsp60 or hsp70 (Martin et al, 1992). 
On the other hand, certain pathophysiological stresses, such as hypoxia, the cytopathic 
effects of TNFa, and immune-mediated cytotoxicity, do not directly give rise to protein 
denaturation, but they may indirectly affect protein structure. All of these perturbants 
involve the intracellular generation of reactive oxygen species (ROS), with the potential 
result of protein oxidation. The finding that hsp overexpression enhances cellular 
resistance to oxidising agents such as hydrogen peroxide (Huot et al., 1996) has led to 
the hypothesis that the hsp protect against pathophysiological stresses such as TNF by 
inhibiting the action of ROS (reviewed by Arrigo, 1998). Thus, the unifying theme of hsp 
protective action appears to derive from their molecular chaperone function permitting 
the repair of abnormal proteins and the accelerated recovery from the shutdown of 
normal RNA and protein synthesis. In addition, hsp are also involved in the elimination 
of proteins which are beyond repair, and a brief discussion of their role in protein 
degradation follows. 
1.1.5.4. The role of heat shock proteins in protein degradation. 
Molecular chaperones also stimulate the breakdown of proteins, and there is evidence to 
suggest that the function of chaperones in preventing or reversing protein aggregation is 
linked with their role in presenting misfolded polypeptides to the cellular mechanism for 
proteolytic degradation (reviewed by Hayes and Dice, 1996). This role is obviously 
important in cells following stress in order to prevent the formation of large aggregates 
of abnormal proteins which are beyond repair. However, it is equally important under 
normal conditions of growth that a mechanism for removing unwanted, short lived 
proteins exists. In mammalian cells, several pathways exist for the proteolytic 
degradation of proteins and these have been shown to be induced by cellular stress. One 
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of the best known examples is the ubiquitin pathway in which proteins are targeted for 
proteasomal degradation by ubiquitin `tagging' (Ciechanover, 1994). Ubiquitin, itself a 
heat shock protein, requires several accessory proteins (these too are induced by heat 
shock) in order to effect the degradation of damaged proteins. The involvement of other 
hsp in this pathway is suggested by the observation that hsp70 promotes ubiquitin 
conjugation to abnormal proteins in reticulocyte extracts (Hayes and Dice, 1996). A 
second important pathway of protein degradation involves lysosomal proteolysis and it 
has been shown that hsp70 is required for the targetting of certain cytosolic protein to 
this site of destruction (Dice et al., 1994). 
Thus, as well as preventing protein aggregation, hsp play a more specific role in the 
breakdown of proteins via their ability to physically interact with damaged proteins and 
assist in their targeting towards the proteolytic machinery of the cell. A working model 
for hsp function during conditions of stress such as heat shock or exposure to cellular 
toxins therefore would be that when they fail in their functions of protein folding or 
disassembly, by acting as molecular chaperones they facilitate protein degradation. 
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1.1.6. Regulation of heat shock proteins during cell growth and 
differentiation. 
One of the major reasons for the decision to examine hsp expression in leukaemic cells 
Curing the planning of this research project was the increasing volume of evidence 
demonstrating that hsp expression was linked to the growth and differentiation of cells. 
The differentiation of haemopoietic cells is a fundamental cellular programme which, in 
conjunction with cell growth, plays a critical role in the control of haemopoietic cell 
numbers. Although relatively little is known about the mechanisms regulating the 
differentiation process, its importance is highlighted by the fact that dysregulation of 
differentiation pathways is known to contribute to leukaemogenesis. It is therefore 
interesting that over recent years a relatively large volume of reports have been published 
which suggest that hsp expression is intimately linked to cell growth and differentiation, 
both in haemopoietic cell lines and a variety of other systems. This association cell 
growth was first suggested a decade ago by the observation that hsp70 and hsp90 are 
induced in lymphocytes by mitogenic stimuli (Ferris et al., 1988; Haire et al., 1988), and 
a report from the same year found that heat shock, or agents known to induce the heat 
shock response, resulted in the differentiation of HL-60 cells (Richards et al., 1988). 
Since that time, a variety of studies using myeloid leukaemia cell lines have demonstrated 
that the expression of all four major hsp families is differentially regulated during the 
process of differentiation. 
Developmental studies have revealed that the expression of specific hsp genes is co- 
ordinately regulated during early embryogenesis and many differentiation processes 
(Walsh et al., 1993; Shakoori et al., 1992), and it has been shown that induction of hsp 
by heat shock, or chemical agents which induce hsp synthesis, results in the 
differentiation of cultured embryonal cells (Stoklosinski et al., 1994). Furthermore the 
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importance of hsp expression in development has been demonstrated by the report that 
inhibition of hsp28 by anti-sense technology was found to abort the differentiation of 
murine embryonic stem cells via the induction of apoptosis (Mehlen et al., 1997). 
In haemopoietic systems, studies of myeloid differentiation have shown that expression 
of hsp70 is induced by a variety of agents which cause differentiation of myeloid cell 
lines, including 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in both HL-60 
(promyelocytic) and U-937 (monoblastoid) cells (Shakoori et al., 1992; Twomey et al., 
1993), and levels of hsp70 and hsp28 showed transient increases following exposure of 
the same two cell lines to sodium butyrate, another agent which induces myeloid 
maturation (Garcia-Bermejo et al., 1995). Retinoic acid-induced differentiation of HL-60 
cells is accompanied by increasing levels of hsp28 protein, but a progressive reduction in 
mRNA levels, suggesting that the changes in protein levels are mediated post- 
transcriptionally (Spector et al., 1995). The mechanism involved in the post- 
transcriptional modification of hsp28 probably involves phosporylation of this small hsp, 
as suggested by the observation that differentiation of HL-60 cells towards a 
macrophage-like phenotype is associated with increased phosphorylation and levels of 
hsp28 (Minowada and Welch, 1995). 
Expression of hsp90 has also come into the picture with the finding that this stress 
protein plays a role in cell cycle control and differentiation of the monoblastoid cell line, 
U937 (Galea-Lauri et al., 1996a). 
It is not clear how hsp expression influences development and differentiation. Their 
expression may be a primary regulatory mechanism or it may reflect the phenotype of the 
cell in terms of its differentiation state. However, part of the explanation could be the 
ability of hsp to bind to growth factors such as p53 and pRb, as well as other cellular 
proto-oncogenes such as c-myc and pp60"' which are involved in the control of cellular 
differentiation and proliferation. 
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1.1.7. Cell cycle-dependent expression of hsp, 
A number of reports have been published describing changes in the levels of hsp and 
their localisation during progression through the cell cycle in a variety of cultured cell 
lines, but no clear picture of hsp expression in relation to the cell cycle is apparent. 
Patterns of hsp70 expression throughout the cell cycle have generally been examined 
using established mammalian cell lines and the results do not present a consistent picture, 
possibly due to the different cell lines used in these studies. Some authors have reported 
that in normal cells (such as mitogen-stimulated lymphocytes), hsp expression is cell 
cycle-regulated, wheras in tumour cells this is lost (e. g Ferrarini et al., 1993), suggesting 
deregulation of hsp may be involved in the malignant phenotype. A previous study by 
Milarski et al., (1989) found that hsp70 expression was cell cycle-regulated, with the 
subcellular localisation of hsp70 varying throughout the cell cycle. Co-precipitation 
experiments using nondenaturing immunoprecipitations demonstrated that these changes 
in the localisation of hsp70 were related to the formation of complexes between hsp70 
and other unidentified proteins. It was noted that hsp70 associated with some proteins 
only at specific points in the cell cycle, whilst others could be co-precipitated throughout 
all phases of the cell cycle. These cell cycle-specific interactions were short lived, 
suggesting that hsp70 is involved in dynamic associations with specific cellular proteins 
throughout the growth cycle under normal circumstances. At the time of writng, the 
identity of these proteins which are transiently associated with hsp70 remains largely 
unknown, although it would seem likely that these interactions involve growth-related 
factors which are expressed at specific points in the cell cycle. The identification of the 
proteins whose expression and/or transport may be modulated by hsp70 remains an 
interesting enigma whose solution would shed light on the role of hsp in the control of 
cell growth. 
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By contrast, a study examining several different cell lines, including HeLa, CHO, and 
normal human skin cells, found that under normal conditions levels of hsp70 were not 
regulated through the cell cycle. However, following heat shock, substantial variations in 
both the inducible and constitutive forms of hsp70 became apparent, although this cell 
cycle-specific regulation varied for different cell lines (Hang and Fox, 1996; He and Fox, 
1997). In a more recent report, using a sensitive PCR-based approach to analyse cDNA 
libraries prepared from cells in distinct phases of the cell cycle, hsp70 gene expression 
was shown to be linked with the S to G2/M phase transition of the cell cycle, in this case 
under normal growth conditions in the absence of stress (Dittmar et al., 1997). 
Developmental studies on embryonic cells have also shown that hsp gene expression is 
tightly regulated throughout the cell cycle. For example, Hsp90 expression is enhanced 
at the Go, and hsp70 increased at the G2/M phases of the cell cycle in neuroectodermal 
cells (Walsh et al, 1993). Furthermore, heat shock of these cells resulted in acquired 
thermo-tolerance whereby cell progression was delayed at the G1/S and S/G2 boundaries 
of the cell cycle, leading the authors of this report to suggest that hsp act as cell cycle 
regulators during neuroectoderm induction and differentiation. 
1.1.8. Abnormal hsp expression in tumour cells. 
Although there is no direct evidence linking hsp expression with tumourigenesis, the 
abnormal expression of hsp is likely to have detrimental effects on a variety of processes 
involved with the control of cell growth and differentiation. As outlined earlier (see 
section 1.1.7. ), levels of most major hsp are intimately linked to these processes and it is 
therefore interesting to find that abnormal expression of hsp has been reported in some 
tumour cell types. For example, increased levels of hsp have been demonstrated in virus- 
transformed and chemically-induced tumour cells (La Thangue and Latchman, 1988; 
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Finlay et al., 1988). It is difficult to be certain whether this represents a chronic stress 
response to abnormal proteins expressed in viral or chemically transformed cells, or 
simply that elevated lisp expression reflects an actively growing malignant pheotype. 
Ferrarini et al. (1992) demonstrated elevated expression of hsp90 in a range of tumour 
cell lines as well as high levels of the inducible hsp70 (hsp72) in some cell lines and some 
fresh tumour cells (lung and kidney carcinomas). Moreover, those cell lines which 
constitutively expressed hsp72 did not show increased synthesis of this heat-inducible 
protein following heat shock, suggesting that hsp72 expression was deregulated in these 
cells. 
More recent reports have identified abnormal expression in primary tumour tissues, in 
particlar hsp28 which has been suggested to have prognostic relevance in some of the 
hormone-responsive tumours such as breast cancer and cervical cancer. In breast cancer, 
hsp90 and hsp70 mRNA is expressed at much higher levels in cancerous tissue than in 
non-cancerous tissue, and a close positive correlation between hsp expression and the 
proliferating cell nuclear antigen labeling index has been observed (Yano et al., 1996). In 
endometrial carcinomas, hsp28 correlates with the degree of tumour differentiation, as 
well as the presence of oestrogen and progesterone receptors, whilst hsp28 is 
predominantly expressed in well-differentiated squamous cell carcinomas in patients with 
cervical cancer (reviewed by Ciocca et al., 1993). 
Despite the connection between abnormal levels of hsp in tumour cells, the significance 
of elevated hsp expression is unclear. It is impossible to be certain whether deregulated 
or high levels of hsp expression contribute to tumourigenesis, or whether they reflect the 
malignant cell phenotype as a consequence of the differentiation state or abnormal 
growth of these cells. 
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1.1.9. Abnormal localisation of hsp to the cell surface in some tumour 
cells. 
In addition to reports of abnormal levels of hsp expression in tumour cells, a growing 
volume of evidence suggests that many tumour cells differ from normal cells in that they 
express hsp on the cell surface. Under normal growth conditions, most hsp are located 
within the cytoplasm where their specific localisation is dictated by their individual function as 
molecular chaperones. For example, hsp70 family members are found in the cytosol, 
endoplasmic reticulum (ER) and mitochondria, where they perform biochemically similar 
functions in all three compartments but have access to distinct sets of protein substrates. 
Hsp70 members in the mitochondria and ER are involved with the folding of newly 
ft=located proteins as well as the translocation process itself Similarly, members of the 
hsp90, hsp60 and small lisp families are found within subcellular compartments where they 
perform individual functions as part of the larger whole molecular chaperone machinery. 
At the outset of this work, cell surface localisation of hsp was controversial. Some authors 
had found no evidence of cell surface expression (Ferm et al., 1989) whereas others had 
reported hsp expression on the surface of certain cell types. For example, human Y/S T 
cells express a cell surface antigen which is recognised by a monoclonal antibody to 
hsp58 (P1), the human homologue of the Escherichia coil groEL protein (Jarjour et al., 
1990). Also, murine bone marrow-derived macrophages have been shown to express an 
epitope which is recognised by a monoclonal antibody, ML30, which has specificity for 
mycobacterial hsp60 (Wand-Wtirttenberger et al., 1991). Surface expression of hsp72, 
the inducible form of hsp70, was also reported on some tumour cell lines and fresh 
tumour cells (Ferrarini et al., 1992), although the significance of this remained unclear. 
More recently, several reports have appeared which confirm the presence of hsp on the 
surface of certain cells, and a picture has emerged which suggests that they play an 
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important role as immunogenic determinants, particularly in stressed or transformed 
cells. Heat shock has been shown to induce cell surface expression of the inducible hsp72 
on tumour cells, including Ewing's sarcoma and osteosarcoma cells, but not on normal 
peripheral blood lymphocytes or fibroblasts (Multhoffet al., 1995). These authors 
suggested that the restricted stress-induced surface expression of hsp72 could be used as 
a means to target a tumour-specific immune response. Indeed, it has been recently 
reported by the same authors that the expression of hsp72 on the surface of tumour cells 
is a recognition structure for natural killer cells, and that the sensitivity of cells to lysis by 
natural killer cells correlates with the amount of hsp72 that is expressed on the cell 
surface (Multhoffet al., 1997). 
The ability of hsp to act as immunogenic targets probably derives from the involvement 
of hsp with intracellular antigen processing and the presentation of cell membrane- 
anchored antigens (Srivastava et al., 1994; Li and Srivastava, 1994). By acting as 
molecular chaperones, hsp may mediate peptide transfer during presentation by MHC 
class I-restricted T cells. Heat shock proteins are associated with a broad spectrum of 
peptides, and it has been suggested that hsp-peptide complexes can be used as the basis 
for cancer immunotherapy (Srivastava and Udono, 1994). Recently, the potential clinical 
application of this observation has been demonstrated by the finding that, in an in vivo 
murine model, immunotherapy of mice by vaccination with hsp preparations derived 
from autologous tumour cells resulted in reduced tumour growth and prolonged survival 
(Tamura et al., 1997). 
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1.2. Tumour suppressor genes and their implications for 
leukaemogenesis. 
1.2.1. The role of p53 in haematological malignancies. 
Considerable attention has been focused on the tumour suppressor gene, p53, because 
mutations of this gene, located on chromosome 17, represent the most common genetic 
abnormality found in human cancer to date (Nigro et al, 1989, Hollstein et al, 1991). 
Although the precise molecular mechanisms of p53 function are unknown, it appears that 
p53 plays an important role in growth control, particularly during periods of cellular 
stress, and a model for p53 function has arisen whereby normal p53 acts as a monitor of 
genome integrity (Lane, 1992). The exposure of cells to DNA-damaging agents induces a 
dramatic increase in the levels of p53 protein which results in cell cycle arrest and 
suppression of cell proliferation (Michalovitz et al, 1990, Kastan et al, 1991). 
Overexpression of wild-type p53 has also been shown to induce apoptosis in 
haemopoietic cells (Yonish-Rouach et al, 1991). Thus, p53 would appear to function as 
a cell cycle checkpoint control for DNA damage, halting the cell cycle to allow repair 
mechanisms to correct any genetic alterations. However, if repair fails, p53 may 
alternatively trigger apoptosis, thereby removing a potentially malignant cell. This model 
implies that loss of p53 function would permit escape of genetically damaged and 
potentially malignant cells from the normal mechanisms of surveillance and thereby be an 
important mechanism in carcinogenesis (Figure 1.2). Consistent with this hypothesis is 
the observation that loss of wild-type p53 expression is associated with a high frequency 
of gene amplification and genomic rearrangements (Livingstone et al, 1992, Yin et al, 
1992). 
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Indeed, inactivation of the tumour suppressor function of normal p53 protein has been 
shown to be a critical event in the induction of malignant transformation. Inactivation at 
the DNA level most commonly occurs via point mutations of the p53 gene, but may 
occur by several other molecular mechanisms, including gene rearrangements, viral 
insertions and gene deletions, all of which lead to absence of expression or production of 
inactive mutant p53 protein. At the protein level, p53 function can be inactivated by 
binding to viral proteins such as the SV40 T antigen (Lane and Crawford, 1979). In 
SV40-transformed cells, the p53 protein is normal but the tumour suppressor activity is 
lost because of complex formation with the viral large T antigen. Similarly, wild-type 
p53 has been shown to form complexes with other viral proteins such as the Elb of the 
adenovirus (Sarnow et al, 1982) and the EBNA antigen of the Epstein Barr virus 
(Szekely et al, 1993) leading to loss of function, whilst binding to E6 proteins from 
papillomaviruses has been shown to promote the degradation of p53 protein (Werness et 
al, 1990). 
In haematological malignancies, alterations in p53 expression have been detected in a 
variety of disease states (reviewed by Imamura et al, 1994, Prokocimer and Rotter, 
1994), and p53 mutations are often associated with disease progression. For example, in 
chronic myeloid leukaemia (CML), p53 alterations are rare during the chronic phase of 
the disease, but progression to CML with blast crisis is associated with the detection of 
p53 gene abnormalities in 20-30 % of cases ( Foti et al, 1991). Also, in the 
lymphoproliferative disorders, chronic lymphocytic leukaemia (CLL) and follicular 
lymphoma, p53 alterations are often acquired during the progression to a more malignant 
phenotype (Gaidano et al, 1991, Ichikawa et al, 1992). In cases of acute myeloid 
leukaemia (AML), p53 genotypic alterations are less common, the reported mutational 
frequency being about 6-15 % (Slingerland et al, 1991, Fenaux et al, 1992). However, 
despite the relative infrequency of p53 mutations, it has been shown that loss of tumour 
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suppressor function does occur in AML by mechanisms which act at the protein level. In 
a study of p53 expression in 49 AML patients, Zhang and Deisseroth (1992b) 
demonstrated that leukaemic cells from the majority (37/49) of these patients had 
elevated levels of p53 when measured by immunoprecipitation using monoclonal 
antibodies recognising both normal and mutant forms of p53. Furthermore, an antibody 
specifically recognising a mutant conformation of p53, normally associated with point 
mutations, immunoprecipitated the p53 protein from 32 of those 37 expressing high 
levels of p53. This was despite the finding that point mutations could be detected in only 
3 patients by single-stranded conformation polymorphism (SSCP) analysis. It was later 
demonstrated by the same group that wild-type p53 protein in A NE cells switches to a 
mutant conformation in response to growth factor stimulation, leading to the suggestion 
that conformational changes in normal p53 protein represent an important mechanism for 
the regulation of cell proliferation (Zhang and Deisseroth, 1994). Further evidence to 
support this theory comes from the observation that different conformations of p53 
protein in AML cells relate to the in vitro growth characteristics of the cells, and this can 
be regulated by either exogenous or autocrine haemopoietic growth factors (Zhu et al, 
1993). 
In AML cells, as in many other tumour types, it is likely that the biochemical properties 
of either wild-type or mutant p53 are determined by the cellular environment and in 
particular by their interaction with other cellular proteins which influence the 
conformation of the p53 protein (Montenarh, 1992). It is clear that normal p53 protein 
can switch conformation from a normal wild-type which has tumour suppressor function, 
to an immunologically `mutant' conformation which has tumour promoter properties. In 
light of the molecular chaperone function of certain heat shock proteins, it is therefore 
intriguing to find that p53 protein is frequently found complexed to members of the 
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hsp70 family, and there is evidence to suggest that this interaction with hsp70 has a role 
in the regulation of p53 conformation and therefore its activity. 
1.2.2. Heat shock proteins interact with p53 protein and modulate its 
tumour suppressor function. 
Evidence that members of the hsp70 family bind to p53 initially came from observations 
that various transformed cell lines expressing elevated levels of p53 co- 
immunoprecipitated a protein with an approximate molecular weight of 70kDa when 
probed with antibody to p53 (Pinashi-Kimhi, et al, 1986, Hinds et al, 1987). It was 
subsequently demonstrated that the formation of oligomeric complexes with the 
constitutively expressed hsp70 (hsc70) produced a mutant p53 protein which was more 
efficient at transforming a rat fibroblast cell line with the ras oncogene than the parent 
p53 (Finlay et al, 1988). The authors also showed that complex formation with hsc70 
increased the half-life of p53, and therefore increased the concentration of p53, which 
they suggested may play a role in the enhanced ability of this complexed p53 to 
transform these cells. 
As outlined earlier, p53 is capable of existing in a wild-type conformation and a `mutant' 
as determined by immunochemical analysis using antibodies which react exclusively with 
the two different conformational forms of the protein (Bartek et al, 1990, Gannon et al, 
1990). It has been demonstrated that hsp70 is involved in the switch between these two 
conformational phenotypes (Hainaut and Milner, 1992). These authors used a mutant 
murine p53 allele which is temperature sensitive in terms of p53 conformation; when 
expressed in vitro - at 30°C, the expressed p53 exists in the wild-type phenotype, while 
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at 37°C the mutant phenotype is adopted. Using a rabbit reticulocyte lysate in vitro 
translation system, they found that the formation of p53-hsp70 complexes took place 
after post-translational switching from the wild-type to mutant phenotype, a process 
which was ATP-independent. Conversely, the switch back from mutant to wild-type 
required hydrolysis of ATP and involved hsp70. 
Further evidence to support the role of hsp in the regulation of p53 function comes from 
studies involving the expression of recombinant human p53 in bacterial systems and the 
study of DNA binding by p53 using a gel mobility shift assay (Hupp et al, 1992). The 
effect of several cellular factors including E. coli dnaK, a bacterial homologue of hsp70 
which has previously been shown to bind p53 (Clarke et al, 1988), on the DNA-binding 
activity of p53 were studied. It was found that dnaK activated p53 DNA binding in an 
ATP-dependent manner. The ability of this hsp70 homologue to enhance the DNA- 
binding function of p53 is intriguing and may have important implications in terms of the 
control of cell growth and the response to cell damage. The current model of p53 
function as part of a damage control pathway fits in very well with the idea that a stress- 
inducible molecular chaperone should be able to modulate the activity of p53. 
The ability of a stress-inducible molecular chaperone to regulate the tumour suppressor 
function of p53 suggests that the examination of heat shock protein expression in AML 
cells may be useful both in terms of tumourigenesis and the stress response of leukaemic 
cells exposed to chemotherapeutic agents. 
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Figure 1.2. A proposed model for the role of p53 protein in the cellular response to 
DNA damage and the implicated role of inactivated p53 in carcinogenesis. 
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1.3. Apoptosis (Programmed cell death). 
1.3.1 Introduction. 
The term apoptosis is derived from a Greek word describing the process of leaves falling 
from trees. It was introduced to describe a type of cell death which exhibited a distinct 
set of morphological features (Kerr, et al., 1972). One of the most characteristic of these 
features is the activation of endonucleases which cleave DNA at the internucleosomal 
sections. This reduces the DNA of apoptotic cells to a series of fragments, comprising 
multiples of 180-200 base pairs, and thus producing the characteristic DNA ladder seen 
on agarose gel electrophoresis. This event is closely followed by a cascade of other 
morphological changes including compaction and segregation of chromatin against the 
nuclear membrane, and condensation of the cytoplasm. Cell shrinkage occurs and 
individual cells become detached from their surrounding neighbours with preservation of 
the organelles, and nuclear and cytoplasmic budding takes place leading to the formation 
of membrane-bound fragments which are known as apoptotic bodies. These structures 
are shed from the cell, and in vivo, apoptotic bodies are phagocytosed by neighbouring 
cells including professional scavengers such as macrophages, but also cells of epithelial 
or fibroblast origin (reviewed by Majno and Joris, 1995). An important feature of this 
process is that apoptosis usually affects individual cells rather than all the cells in a 
particular area. The phagocytosis of apoptotic bodies and their degradation within the 
lysosomes of surrounding cells, avoids the induction of an inflammatory response due to 
the release of cellular contents. This is a crucial feature since it permits cell death without 
damage to adjacent cells. In addition, the process is rapid, with the onset of apoptosis 
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and formation of apoptotic bodies occurring within minutes of the apoptotic signal 
being 
interpreted by the cell. 
1.3.2. The physiological role of apoptosis. 
Apoptosis is a physiological mode of cell death which is now realised to play a major 
role in the maintenance of homeostasis in all systems of the body. It is particularly 
important during embryogenesis and metamorphosis, for example in the regression of the 
tadpole tail of frogs and for removal of interdigital webs during limb development in 
mammals (reviewed by Milligan and Schwartz, 1997). In adult mammals, the process 
plays a critical role in tissue turnover by maintaining the balance between cell number 
and cellular proliferation. For example, a balance between apoptosis and mitosis is 
required to maintain an equilibrium in the cell numbers of tissues which have slowly 
proliferating populations, such as the epithelium surrounding intestinal crypts and 
differentiating spermatozoa. The same principle applies to the haemopoietic system, 
where the demands of cell growth and differentiation are counterbalanced by the removal 
of unwanted cells by apoptosis (Lotem and Sachs, 1996). The triad of proliferation, 
differentiation and apoptosis are all controlled by a complex network of haemopoietic 
growth factors, and it is when dysregulation of these processes takes place that 
leukaemias may develop. This theme will be developed further in a later section. 
The process is also especially important in the immune system. For example, it is 
responsible for the deletion of autoreactive T-cells in the thymus thereby permitting self 
tolerance, and for the selection of B-cells in germinal centres during humoral immune 
responses (reviewed by Ekert and Vaux, 1997). Cell-mediated immune responses are 
also effected by apoptosis; in vitro studies have demonstrated that T-cells and natural 
killer cells exert their cytotoxic effects on target cells by induction of apoptotic pathways 
(Shi, et al, 1992, Bishop & Whiting, 1983), and enhanced apoptosis is seen in vivo 
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during cellular immune rejection of allografts and in graft-versus-host disease (Kerr, et 
al, 1987). 
1.3.3. Apoptosis is induced by a variety of stimuli. 
To date, a myriad of stimuli have been reported to induce apoptosis, with a diverse array 
of cellular targets (reviewed by Wertz and Hanley, 1996). These include 1) reagents 
which act at the cell surface via receptor ligands, 2) disrupters of the cytosolic and 
organellar compartments, such as oxidants, 3) agents which disrupt the cytoskeleton, 
such as the anti-tumour drugs taxol and vincristine, and 4) reagents which act within the 
nucleus, such as certain chemotherapeutic drugs. 
An example of the first category of molecular inducers is tumour necrosis factor (TNF), 
a cytokine which is responsible for cell death associated with septic shock, inflammatory 
disorders and anti-tumour activity (Smith et al., 1994). The cellular response to TNF is 
mediated via cell surface receptors (TNFR), of which there are more than a dozen family 
members, including Fas. These receptors are responsible for regulating the survival and 
development of specific cells in response to environmental factors such as growth 
factors, and are particularly important in the haematopoietic system (Sachs, 1996). 
Although, the complete mechanism of the receptor-mediated death response is unknown, 
several components of the pathway have been identified, providing a link between the 
initial signal and the proteolytic activation of the caspases, enzymes which are the 
ultimate effectors of the biochemical changes which characterise apoptosis (see next 
section). Signaling through the TNFR or Fas receptor involves the recriutment and 
formation of complexes with adaptor proteins, such as FADD/MORTI (from Fas- 
associated death domain protein) and FLICE (fas-activated protein-like ICE). The latter 
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is a protein which contains an ICE-related protease domain and can activate the caspase 
cascade (reviewed by Haimovitz-Friedman et al., 1997). 
Intracellular oxidants, such as menadione, cause damage to the cytosolic and organellar 
compartments and induce apoptosis via the generation of reactive oxygen species 
(Nockenberry, 1995). One of the consequences of oxidative damage is protein alteration, 
a factor known to induce heat shock protein expression. The induction of the heat shock 
response following oxidative damage may play an important role in the decision of the 
cell to commit itself to repair or cell death. This theory, in relation to other examples of 
apoptosis, will be elaborated upon elsewhere. 
Of relevance to the treatment of leukaemia, the other two cellular targets mentioned 
above are both sites for chemotherapy-mediated cellular damage. For example, the anti- 
tumour drugs taxol and vincristine both exert their primary cytotoxic effect via the 
disruption of microtubule organisation, thereby inhibiting mitosis. This is particularly 
interesting in terms of the potential protective effect of hsp against cytotoxic agents, 
since members 
Despite the diversity in targets and the variety of inducers of apoptotic cell death, the 
response of a cell to a particular inducer varies according to a range of factors including 
cell type and the pattern of characteristic gene expression in that cell, the differentiation 
state of the cell, and the cellular environment, in particular trophic factors such as 
hormones and growth factors. Thus different cell types appear to have the ability to 
sense and respond to similar insults in a fashion appropriate to their particular milieu. 
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1.3.4. Effector mechanisms in apoptosis. 
The process of apoptosis can be divided into two phases. The first is the signalling phase 
whereupon the apoptotic machinery is activated, and the second is the effector phase of 
death. The key components of the second phase are a family of cysteine protases 
(caspases) that are related to the interleukin-lß-converting enzyme (ICE) (reviewed by 
Alnmeri, 1997). Members of this family of enzymes are involved in both the initial 
signalling events and the downstream proteolytic cleavages which result in the 
morphological events characterising apoptosis. They are all synthesised as proenzymes 
that are proteolytically processed to their active forms in response to an apoptosis- 
inducing stimulus. 
ICE was first implicated in cell death when it was found to be homologous to the 
Caenorhabditis elegans death gene, ced3. Genetic studies have shown that ced3 is 
involved in the apoptotic cell death that occurs during the development of this nematode 
worm. A total of ten caspases of human origin have now been identified, and these are 
known to act via a cascade mechanism to cleave a number of protein substrates within 
the cell (reviewed by Whyte, 1996; Nicholson, 1996). For example, caspase-3 is 
responsible for the cleavage of poly(ADP-ribose) polymerase and DNA-dependent 
protein kinases, proteins which are involved in DNA repair pathways. It has been 
suggested that degradation of these proteins cripples DNA repair and thereby permits the 
efficient action of endonucleases which leads to the degradation of DNA that is observed 
during apoptosis. 
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1.3.6. Apoptosis and the haematopoietic system. 
1.3.6.1. The role of apoptosis in normal haematopoiesis. 
Haematopoiesis is the term used to describe the normal production of the formed 
elements of the blood, including red blood cells (erythrocytes), white blood cells 
(monocytes, granulocytes, lymphocytes) and platelets. Each of these mature cell types 
has specific functions such as oxygen transport, response to infection, antibody 
production, etc., and the controlled production of these different haematopoietic cells is 
essential for the survival and development of a normal individual. It is when 
abnormalities in the normal developmental programme for blood cell formation occur, 
that haematological diseases such as leukaemia are seen. 
Throughout life, the different lineages of blood cell are continuously produced to replace 
cells which have reached the end of their life span. In addition, the process must be 
flexible, allowing the increased production of one or more lineages in order to meet 
challenges such as infection or blood loss. Both in vivo and tissue culture studies of bone 
marrow cells have demonstrated that all blood cells of different lineages are derived from 
the same primary cell, referred to as the haematopoietic pluripotent stem cell. This stem 
cell is shown to have several important characteristics, including the ability to 
differentiate along several lineages, the capacity for extensive proliferation and self 
renewal, and the ability to respond to its environment via interaction with specific growth 
factors (reviewed by Minden, 1995). An overall view of haematopoiesis has arisen from 
these in vivo and in vitro studies whereby mature blood cells are derived from small 
numbers of pluripotent stem cells within the bone marrow, via the generation of 
progenitor cells which are committed to proceed along one of the maturation pathways 
(figure 1.4). 
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Figure 1.4. Normal haematopoiesis in the bone marrow gives rise to the formed cellular 
elements of the blood via a hierarchical organisation of differentiation and maturation 
from a pluripotent stem cell. 
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This ordered production of normal blood cells is the culmination of a series of 
interactions between a network of growth factors and receptors which control the 
maturation and differentiation of immature precursor cells. Over the past decade, the 
development of cell culture systems for the growth of haematopoietic cells has led to the 
discovery of an ever growing number of proteins which are responsible for regulating the 
proliferation and differentiation of immature cells along developmental lines of restricted 
lineage (reviewed by Sachs, 1996). These same growth factors also regulate cell viability, 
and protect both normal and leukaemic cells from apoptotic cell death. For example, 
normal myeloid progenitor cells, when cultured in vitro, require the availability of certain 
colony-stimulating factors (CSF) and interleukins (IL) in order to maintain viability, 
otherwise they will rapidly undergo apoptosis (Williams et al., 1990). This programme 
for activation of apoptotic death in response to growth factor availability is retained 
throughout the developmental pathway, and cells at all stages of differentiation are 
subject to control by a complex network of signals, thus coupling the three processes of 
differentiation, multiplication and apoptosis. 
Disorders in this normal developmental pathway give rise to leukaemias, and the 
haemopoietic system provides many examples of the significance of apoptosis, not only 
as a regulatory mechanism in normal haematopoiesis, but also as an element in the 
pathogenesis of the haematological malignancies. The implications of deregulated 
apoptosis in the development of leukaemia is therefore discussed in the following 
section. 
1.3.6.2. Leukaemogenesis and apoptosis. 
The homeostatic maintenance of cell numbers within a particular tissue or organ is 
delicately balanced between cellular proliferation and cell death. This balance is 
maintained by a complex regulatory network of growth factors which impinge upon both 
these processes, and under normal circumstances this permits considerable flexibility to 
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respond to changing requirements for cell numbers, as well as being important in the 
removal of unwanted or senescent cells. Over recent years it has become clear that in 
cancers, this balance between the rates of cell division and cell death is disturbed and that 
mechanisms which promote or suppress apoptosis can influence these rates. Thus, 
environmental circumstances or genetic lesions which affect the apoptotic pathway may 
lead to the expansion of a potentially malignant population of cells. The haematological 
malignancies provide many examples of the mechanisms which may be involved when 
deregulated apoptosis becomes a factor in the development of a malignant cell. 
As outlined in the previous section, haematopoietic cells require the availability of 
various growth factors to maintain viability, and their absence results in rapid apoptotic 
cell death. Likewise, leukaemic cells are not immortal, and cells from most patients 
maintain the programme for apoptotic cell death which can be activated by the 
withdrawal of growth factors, as evidenced by the apoptotic cell death of leukaemic cells 
cultured in vitro. Interestingly, there are leukaemic cells from some patients which do 
not require exogenous growth factors in order to survive, and this reduced propensity to 
undergo apoptosis is associated with a worse prognosis (Lowenberg et al., 1993; Hunter 
et al., 1993). Haematopoietic growth factors also protect leukaemic cells against 
apoptosis induced by chemotherapeutic agents (Kaplinsky et al., 1996), and this has 
implications for the treatment of leukaemia patients, not only because the production of 
autologous growth factors will influence the propensity of cells to undergo apoptosis, 
but also due to the fact that some chemotherapeutic regimens include the administration 
of certain haemopoietic growth factors. 
In addition to the influence of growth factors, a number of genetic lesions have been 
identified, many of them already identified as oncogenes, whose expression is known to 
influence the apoptotic response of malignant haematopoietic cells. 
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1.3.6.3. Genes associated with apoptosis in the haematological malignancies. 
Molecular analysis of apoptosis has revealed a number of genes whose expression is 
associated with this mode of cell death. In mammalian systems, many of these genes are 
also recognised as genes which modulate cell proliferation and/or growth, and have been 
implicated in leukaemogenesis. These include bcl-2, p53 and c-myc, genes whose 
expression has been shown to influence the susceptibility of cells to apoptosis induced by 
a variety of agents, including chemotherapeutic agents. 
One of the most extensively studied of these regulators of apoptosis is the bcl-2 
oncogene, encoding an integral membrane protein which occurs in nuclear membrane, 
endoplasmic reticulum, and mitochondrial membranes. Deregulated expression of bcl-2 
can inhibit apoptosis in many cell types and in response to a variety of inducing 
treatments, including cytotoxic drugs (Korsemeyer, 1992; Chiou et al, 1994). In 
haemopoietic neoplasms, particularly the lymphoproliferative disorders, translocation of 
the bcl-2 gene to the heavy chain Ig locus (t14: 18) is a common genetic abnormality 
which leads to deregulated bcl-2 expression and an associated resistance to apoptosis. 
The mechanism(s) by which bcl-2 inhibits apoptosis is poorly understood, although 
studies on the nematode, Caenorhabditis elegans, demonstrate that ced-9 (a bcl-2 
homologue) acts by inhibiting the activation of caspases (Alnmeri et al, 1997). Caspases 
are protein kinases which, as discussed earlier, are key effector molecules in the 
apoptotic process. 
Many other genes resembling bcl-2 have now been identified (reviewed by Reed, 1995), 
some of which inhibit cell death (e. g bcl-xL, bcl-w), whereas others promote cell death 
(e. g bax, bak, bad). It is known that bcl-2 specifically interacts with other members of 
the family, forming homo- or heterodimers, and it is the resulting ratio of pro- and anti- 
apoptotic bcl-2 members which controls the activation of apoptotic pathways. 
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Another important genetic regulator of apoptosis is p53, a tumour-suppressor gene 
whose activity is abrogated by mutation or deletion in many human cancers, including 
leukaemias (Prokocimer and Rotter, 1994; Imamura et al., 1994). The expression of p53 
is known to be a critical response to cellular damage induced, for example, by ionising 
radiation and other DNA-damaging agents (Kastan et al., 1991). Exposure of 
mammalian cells to ionising radiation can result in transient arrests of the cells at the G, 
and G2 phases of the cell cycle (Kuerbitz et al., 1992), and in apoptotic cell death 
(Cohen et al., 1992). Early evidence that p53 may actually modulate apoptosis came 
from the observation that radiation-induced apoptosis of thymocytes requires p53 
expression (Lowe et al., 1993), although p53-independent mechanisms of apoptosis do 
exist as demonstrated by the fact that p53-null thymocytes undergo apoptosis in response 
to dexamethasone (Clarke et al., 1993). A role for p53 as a Gt cell cycle checkpoint is 
suggested by the observation that , whereas cells with wild-type p53 arrest in G1 
following DNA damage, cells with mutant p53 genes lack this checkpoint and go on to 
arrest in G2. It has been suggested that this checkpoint provides the cell with a window 
within which DNA damage can be repaired, or else, if the damage is too great, the cell 
commits itself to apoptosis. 
The decision of cells to undergo p53-mediated cell cycle arrest or apoptosis following 
cellular damage depends upon a variety of factors, including the extent of damage, 
growth factors, and the expression of other genes such as bcl-2 which influence the 
induction of apoptosis by p53 (Carman and Kastan, 1995). The inability of a cell to 
undergo apoptosis following DNA damage obviously has implications both for 
tumourigenesis and in the treatment of cancers. Mutations in the p53 gene may be one 
mechanism whereby potentially malignant cells could escape from apoptosis, while an 
inability to undergo p53-mediated apoptosis could be the cause of resistance to 
radiotherapy and chemotherapy. 
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Although mutations in the p53 gene are less common in haematological malignancies 
than in solid tumours, they have been associated with disease progression and poor 
prognosis (Foti et al, 1991; Gaidano et al, 1991; Ichikawa et al, 1992), an observation 
which may, in part, be due to impairment of p53-mediated apoptosis in response to 
chemotherapy. 
The potential involvement of p53 in leukaemogenesis and the response of cell to 
chemotherapeutic agents was an important part of the rationale behind the ideas for this 
research project. As discussed in greater detail earlier (see Introduction, section 1.2.2), 
one of the interesting features of the heat shock proteins is their ability to modulate the 
conformation, and therefore the function, of p53 (Hainaut and Milner, 1992). 
Hypothetically, hsp expression and interaction with growth regulatory factors such as 
p53, may have implications for the control of growth versus apoptosis, as well as being 
an element in the response of tumour cells to drug-induced apoptosis mediated through 
p53-dependent pathways. 
The expression of c-myc is an important regulator of the growth response of cells, 
influencing the decision of a cell to undergo proliferation or apoptosis in response to the 
availability of appropriate growth factors (Evan et al., 1992). Enforced expression of c- 
myc promotes neoplastic transformation, and elevated expression of the protein is seen in 
a wide variety of tumour types (Packham and Cleveland, 1995). Paradoxically, in certain 
growth factor-dependent myeloid leukaemia cell lines which are maintained under 
growth restrictive conditions, deregulated expression of c-myc induces apoptosis rather 
than proliferation (Harrington et al., 1994). It is thought that this apparent dual role is 
related to the relative abundance of appropriate growth factors, with cells in growth 
arrest being highly susceptible to apoptosis when c-myc is induced. In haemopoietic 
cells, the ability of deregulated c-myc to induce apoptosis or cell proliferation is also 
dependent upon p53 expression. For example, transfection with mutant p53 in a myeloid 
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cell line with deregulated c-myc expression suppresses the increased susceptibility to 
apoptosis induced by c-myc (Lotem and Sachs, 1996). These observations suggest that 
the suppression, by mutant p53, of this enhanced susceptibility to apoptosis is a 
cooperative mechanism in leukaemogenesis. 
Finally, with regard to c-myc, it is interesting to note that heat shock of lymphoid cells 
has been shown to induce c-myc expression, as well as that of c-fos and c-jun (Bukh et 
al., 1990), while studies using the regressing rat prostate gland as a model of apoptosis 
have demonstrated that the onset of apoptosis is accompanied by the expression of c fos 
closely followed by the sequential induction c-myc and hsp70 (Buttyan et al., 1988). It is 
difficult to be certain that these new transcripts are integral to the apoptotic process, and 
not simply part of an abortive stress response, but the co-ordinated expression of hsp70 
with these oncogenes raises the possibility that it may be directly involved in the control 
of apoptosis. 
Another gene whose expression has been linked with changes in apoptosis is c-abl, a 
cellular oncogene which is involved in a reciprocal chromosomal translocation t(9; 22) 
(q34; ql 1) with the BCR gene generating the so-called Philadelphia chromosome. This 
rearrangement is found in approximately 95% of chronic myeloid leukaemia (CML) 
patients, and 25% of adult acute lymphoblastic leukaemias cases. The resulting bcr-abl 
fusion protein has an oncogenic activity which is mediated via deregulation of abi 
tyrosine kinase function (Fernandes et al., 1996). Expression of the bcr-abl protein 
confers resistance to apoptosis in CML cells following growth factor withdrawal (Bedi et 
al., 1994), as well as death induced by a variety of chemotherapeutic agents (Bedi et al., 
1995; Dubrez et al., 1998). In addition, anti-sense oligonucleotides for bcr-abl, when 
transfected into CML cells, increase the susceptibility of cells to apoptosis induced by 
certain cytotoxic agents (Rowley et al., 1996). This mode of resistance to apoptosis due 
to specific gene expression is a good example of how deregulated apoptotic mechanisms 
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are implicated in the leukaemogenic process, and also suggests why Philadelphia 
chromosome-positive leukaemias are particularly refractory to chemotherapy. 
1.3. The Biology of Leukaemia. 
Leukaemias are clonal disorders of haematopoietic tissue which arise due to a failure in 
the normal feedback control of clonal growth. This is usually caused by genetic changes 
in the regulatory gene sites of various growth factors or transcription factors, leading to 
the overproduction of one particular clone of cells representing a particular state of 
lineage maturation. 
Leukaemias are broadly classified according to their myeloid or lymphoid lineage, and 
upon their maturation state. Acute myeloid or lymphoid leukaemias are characterised by 
clonal proliferation of their respective early precursor (blast) cells, whilst the chronic 
leukaemias are represented by myeloid or lymphoid cells at a later stage of 
differentiation. In each case the clonal proliferation leads to the replacement of normal 
haematopoietic cells in the bone marrow, invariably leading to anaemia, 
granulocytopaenia, and thrombocytopaenia, with the accompanying clinical 
manifestations of fatigue, infection and haemorrhages. 
1.3.2. Acute myeloid leukaemia (AML) 
1.3.2.1. Targets of transformation in AML. 
This disease results from the transformation of progenitor cells in the bone marrow 
exhibiting characteristics of one of the non-lymphoid lineages (granulocytes, monocytes, 
erythrocytes and platelets). AML is a therefore a heterogeneous disease, arising from the 
clonal proliferation of multipotent or lineage restricted precursors. In some cases of 
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AML, particularly in elderly patients, there is morphological evidence of trilineage 
involvement, the leukaemic cells exhibiting granulocytic, erythroid and megakaryocytic 
features, suggesting that leukaemic transformation has occurred at the level of a 
multipotent stem cell. This multiple lineage has been confirmed by both cytogenetic 
analysis and fluorescence in-situ hybridisation techniques (Van Lom et al, 1996, 
Keinanen et al, 1988). By contrast, AML in children and younger adults generally 
reveals that the disease is restricted to the granulocytic lineage without involvement of 
the erythroid and megakaryocytic populations. This implies that in these cases the 
leukaemia has arisen in a lineage restricted, committed granulocytic precursor cell 
(Figure 1.5). 
Pluripotent stem cell 
Myeloid stem cell (multipotent) 
AML and secondary AML 
""ýý Committed lineage 
precursors 
Erythroid Megakaryocytic Granulocytic/Monocytic 
Figure 1.5. Target cells for transformation in AML. In elderly patients and patients with 
secondary AML there is evidence for transformation at the level of the multipotent 
myeloid stem cell. However, other AML types seem to arise in a lineage-committed 
progenitor cell. 
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1.3.2.2. Classification of AML. 
Due to the heterogeneous nature of AMI., sub-classification is important both in terms of 
disease prognosis and the standardisation of treatment strategies, and the most widely 
used system for the classification of AML is the French-American-British (FAB) system. 
This assigns a single lineage to each leukaemia based primarily upon morphological and 
cytochemical characteristics (Table 1.2). Eight AMI, subtypes have been distinguished, 
and are categorised according to the predominant differentiation pathway and the degree 
of maturation. For M1, M2 and M3 subtypes, granulocytic differentiation is 
predominant, for M4 the differentiation pathway is mixed granulocytic/monocytic, for 
M5 predominantly monocytic, for M6 erythroid and for M7 the platelet lineage. 
Leukaemia Frequency Lineage and differentiation characteristics 
AML-MO <5% Morphologically and cytochemically undifferentiated 
AML-M1 20% Myeloblastic 
AML-M2 30% Myeloblastic with maturation 
AML-M3 10% Acute promyelocytic leukaemia 
AML-M4 20% Acute myelomonocytic leukaemia 
AML-M5 15% Acute monoblastic leukaemia 
AML-M6 5% Erythroleukaemia 
AML-M7 <5% Megakaryoblastic (platelet lineage) leukaemia 
Table 1.2. FAB classification of the acute myeloid leukaemias. 
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1.3.7 Apoptosis and the response of leukaemic cells to chemotherapy. 
1.3.7.1 Apoptosis is induced by cytotoxic agents. 
Most, if not all, of the cytotoxic drugs used in the treatment of leukaemias and other 
cancers exert their effects by inducing apoptosis in the target cells. (reviewed by 
Hickman and Boyle, 1996; Hickman, 1992). Among the growing list of drugs which 
have been reported to induce apoptosis are 1) DNA-reactive drugs such as cisplatin, 
chlorambucil, melphalan and bischloronitrosourea, 2) drugs which inhibit DNA 
topoisomerase I and II enzymes, such as camptothecin and etoposide, 3) inhibitors of 
mitotic spindle apparatus such as the Vinca alkaloids, and 4) antimetabolites such as 
methotrexate and phase specific drugs such as cytosine arabinoside and taxol (see table 
1.3). 
At present, the exact mechanisms whereby chemotherapeutic drugs induce apoptosis are 
unknown, but the fact that such a wide variety of drugs with differing modes of action 
can trigger apoptosis, suggests that either apoptosis can be activated by multiple 
mechanisms, or that it occurs via a common pathway which is activated by all these 
drugs. Although the primary action of most cytotoxic drugs is well understood, little is 
known concerning the mechanisms whereby the apoptotic machinery is switched on as a 
result of drug-induced damage. 
In order to explain how such a wide variety of agents with disparate cellular targets all 
induce a common final mechanism of programmed cell death, it has to be assumed that 
cells possess the ability to decipher and assess the specific injury. The response of a cell 
to injury presumably relies on mechanisms whereby the individual cell reaches a decision, 
culminating in either the execution of apoptosis or successful repair of the damage and 
re-entry into the cell cycle. The existence of such a decision point would be an important 
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factor in the response of a cell to a particular injury, allowing the cell to decide whether 
the extent of the damage is such that either it can be successfully repaired, or else the 
damage is so great that the cell has no option but to proceed along an apoptotic 
pathway. 
An understanding of this concept would provide us with a more complete understanding 
of why some cells die readily and others do not, and clearly this has important clinical 
implications. Apoptosis is a regulated phenomenon and the decision of a cell to initiate 
apoptosis may be determined by the relative expression of genes which promote or 
suppress apoptosis. Therefore, the expression of these genes which define the capability 
of a cell to undergo apoptosis following drug treatment may be a vital arbiter of the 
response to chemotherapy in leukaemia. 
The possibility of enhancing the susceptibility of malignant cells to drug-induced 
apoptosis by modulation of the expression of these genes could lead to improved 
chemotherapeutic regimens. 
1.3.7.2. Inhibition of apoptosis and drug resistance. 
Inherent and acquired mechanisms of resistance to drugs are a major obstacle to the 
successful treatment of cancers. In the case of leukaemia, although the majority of 
patients achieve a complete remission with induction therapy, a large proportion will 
subsequently relapse with the development of resistance to a wide spectrum of 
chemotherapeutic agents. Many mechanisms of drug resistance have been described; 
these include increased metabolism of drugs, increased drug efflux, decreased drug 
uptake and amplification of the drug target (reviewed by Dalton, 1997; McKenna and 
Padua, 1997). However, it has become clear that mechanisms other than those affecting 
drug accumulation will determine the response of malignant cells to chemotherapy. As 
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suggested by Dive and Hickman (1991), the response of a tumour cell to a drug may not 
depend exclusively on the initial perturbation or biochemical lesions imposed by the 
drug, but also on how the cell responds to these lesions. In other words, whether or not 
apoptosis is induced in that cell. 
AF discussed earlier, a number of genes have been identified as being important in the 
control of apoptosis, and it has indeed been shown that these factors will influence the 
susceptibility of malignant cells to drug-induced apoptosis. For example, bcl-2 
overexpression in a myeloid leukaemia cell line has been associated with a high level of 
resistance to a range of chemotherapeutic agents (Lotem and Sachs, 1993a). In addition, 
transfection of a human lymphoma cell line with the bcl-2 gene resulted in a dramatic 
increase in resistance to apoptosis, despite the fact that similar levels of drug-induced 
damage were evident in both parent and transfected cells (Fisher et al, 1993), whilst 
downregulation of bcl-2 with antisense oligonucleotides has been shown to induce 
apoptosis and increase the sensitivity of AML blast cells to the drug, cytosine 
arabinoside (Keith et al, 1995). The clinical significance of these in vitro observations 
has been emphasised by the finding that patients with acute myeloid leukaemia (AML) 
whose cells express high bcl-2 have a worse response to chemotherapy (Campos et al, 
1993, Maung et al, 1994). 
The expression of the tumour suppressor gene, p53, is another factor closely involved in 
the control of apoptosis which has been shown to influence the ability of cytotoxic 
agents to induce apoptosis in haematopoietic cells. Haematopoietic stem cells from mice 
deficient in wild-type p53 are more resistant to the induction of apoptosis by a variety of 
agents (Lotem and Sachs, 1993b). Conversely, acute overexpression of wild-type p53 
using an adenovirus vector enhances the sensitivity of normal human fibroblasts to . 
Again, the clinical relevance of these in vitro studies has been demonstrated by the 
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finding that mutation of the p53 gene in AML patients is a strong prognostic indicator of 
response to chemotherapy and survival (Wattei et al, 1994; Kurosawa et al., 1995). 
The relevance of these observations is to demonstrate that mechanisms exist which can 
rescue leukaemic cells from drug-induced apoptosis. Thus, the suppression of apoptosis 
by mechanisms which act downstream of the initial site of cellular perturbation may 
represent an important mode of drug resistance. The identification of those factors which 
modulate this downstream response to cellular damage is therefore critical to an 
understanding of why some tumour cells fail to undergo apoptosis. Presumably, 
individual cells possess a threshold which defines whether that cell survives or initiates 
apoptosis. It seems probable that cellular factors are involved which act as sentinels of 
damage, and one obvious example would be the product of the tumour suppressor gene, 
p53. Exposure of cells to DNA-damaging agents results in an increase in p53 levels by a 
post-transcriptional mechanism (Kastan et al, 1991) which probably involves an increase 
in protein translation and an increase in p53 protein half-life. One identified signal for 
p53 induction is the presence of DNA strand breaks. It has been demonstrated that p53 
protein will bind to the ends of single stranded DNA and to sequences of DNA 
containing mismatches (Jayaraman and Prives, 1995; Lee et al, 1995), and it has been 
suggested that binding of p53 to these sites might be a signal for p53 activation. 
However, it does not seem likely that DNA-binding would lead to an increase in either 
the transcriptional rate or the half-life of p53 and there must be alternative signals, or 
some protein which binds to p53 after DNA damage; the binding of hsp70 to p53 springs 
to mind. Interestingly, it has recently been shown that the exposure of cells to hypoxia 
results in p53 induction and leads to apoptosis in a p53-dependent manner demonstrating 
that signals other than DNA damage induce p53-dependent apoptosis. This is interesting 
because hypoxia is a recognised inducer of hsp expression which leads one to speculate 
whether hsp could be involved in the apoptotic response of the cell to hypoxia. In this 
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manner hsp induction may play a dual role; as a signal to the cell that potentially lethal 
stresses are being exerted, and possibly a direct role in the apoptotic pathway via the 
modulation of p53 function. 
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Normal cell growth: 
Cell number 
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0 
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Figure 1.5. Normal haemopoiesis relies on a balance between the demands of 
proliferation and differentiation and the removal of unwanted cells by apoptosis. 
Dysregulation of the apoptotic process by genetic lesions involving regulatory proteins 
such as bcl-2 and p53 are implicated in loss of this balance and leukaemogenesis. 
Cell number 
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1.3.8. Heat shock protein 70 (hsp70) and apoptosis. 
Studies focusing on the genetics of apoptosis have identified hsp70 as being one of the 
prominent genes whose expression is induced during the early phases of the process. For 
example, studies using the regressing rat prostate gland as a model of apoptosis have 
demonstrated that the early stages of the process are accompanied by an increase in 
hsp70 expression (Buttyan et al., 1988), whilst sodium butyrate-induced apoptosis in 
lymphoid cells is preceded by a transient over-expression of hsp70 (Filippovich et al., 
1994). It is impossible to say whether this indicates that hsp70 expression is integral to 
the onset of apoptosis, or simply that these increased hsp70 levels are part of the normal 
(perhaps abortive) stress response. What is clear, however, is that over-expression of 
certain hsp, and in particular hsp70, confers resistance to apoptosis induced by a number 
of different agents and in a variety of cell types. 
1.3.8.1. Heat shock proteins and thermotolerance. 
As described earlier, hsp overexpression is directly related, both quantitatively and 
temporally to the development of thermoresistance. Heat shock is one agent which has 
been shown to induce apoptosis in a variety of cell types, and although early studies did 
not identify the cytotoxic effect of heat as acting via this mode of cell death, the 
observation that a mild hyperthermic exposure induces a thermotolerant state which is 
quantitatively related to the expression of hsp, in particular hsp70, was the first 
suggestion of a relationship between hsp and apoptosis (Li and Werb, 1982; Landry et 
al., 1982). Cell lines which have been stably transfected with hsp-encoding genes, 
including both hsp70 and hsp25, are protected from hyperthermia, as assessed by colony 
forming assays (Landry et al., 1989) and more recently by measuring indicators of 
apoptosis (Li et al., 1996). 
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1.3.8.2. Hsp protect against apoptosis induced by a variety of stimuli. 
Hsp70 overexpression also protects cells against apoptosis induced by agents other than 
heat shock. For example, a mild heat shock of neuronal cells protects these cells against 
apoptosis induced by transfer to a serum-free medium (Mailhos et al., 1993) whilst 
transfection with the hsp70 protects susceptible cells from apoptosis induced by TNF 
(Jaatella et al., 1992). The involvement of hsp in apoptosis is also suggested by 
experiments examining apoptosis of haemopoietic cells induced by quercetin, a 
bioflavanoid which specifically inhibits hsp70 translation (Wei et al., 1994), while hsp70 
antisense mRNA has been shown to induce apoptosis in haemopoietic cells (Wei et al., 
1995). 
The potential involvement of hsp in protecting tumour cells against apoptosis induced by 
chemotherapeutic agents is suggested by data which shows that elevated hsp expression 
is associated with chemoresistance both in human tumours (Ciocca, 1993). Similar 
observations have been made in experimental models; in heat-shocked rat tumour cells 
the induction of hsp70 is associated with vincristine resistance (Lee et al, 1992) while 
Chinese hamster cells over-expressing the human hsp70 gene are more resistant to a 
variety of cytotoxic agents (Huot et al, 1991). 
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Experimental aims. 
As has been outlined in the introduction, hsp expression displays several important 
characteristics which would appear to be extremely relevant to the study of 
leukaemogenesis. Hsp expression is intimately linked with differentiation and cell cycle 
control, possibly via the ability of hsp to interact with and modulate the function of 
growth factors such as p53. In addition, hsp overexpression protects cells against a 
variety of stresses, including cytotoxic drugs which mediate their effects via the 
induction of apoptosis. Hsp expression in leukaemia is therefore interesting in terms of 
both the development of the malignant cell and in the problems associated with the 
treatment of these diseases, ie. the development of chemoresistance. 
The primary aims of this research project are therefore to address this potential link 
between hsp expression and haematological malignancy by answering the following 
questions: 
1. Is hsp expression abnormal in leukaemic cells isolated from patients with myeloid 
leukaemia, both in terms of the subcellular localisation and the levels of hsp? 
2. Is there a correlation between hsp expression and disease status, either in terms of 
disease progression or the potential prognostic relevance of hsp expression? 
3. Relating to the previous point, do levels of hsp expresion influence the susceptibility 
of leukaemic cells to apoptosis? 
4. In particular, does hsp over-expression protect leukaemic cells against apoptosis 
induced by chemotherapeutic agents? 
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Chapter 2 
Materials and Methods 
75 
2.1. Collection and storage of leukaemic cells. 
2.1.1. Leukaemic patients. 
Leukaemic cells were harvested from patients attending Warwick Hospital, either as in- 
patients or as out-patients presenting at the Haematology clinics. These patients included 
those with de novo disease and those whose disease had relapsed. The initial diagnosis of 
leukaemia was made in the Haematology Department and the disease classified according to 
morphological and cytochemical criteria. Samples were also collected, when possible, from 
patients during the course of treatment. However, this was not possible in every case due to 
the very low numbers of mononuclear white blood cells which were present in the peripheral 
blood of patients undergoing ablative chemotherapy. 
2.1.2. Harvesting of mononuclear cells from whole blood. 
Peripheral blood mononuclear cells were separated from whole blood samples, or on 
occasions from bone marrow aspirates, collected from inpatients of Warwick Hospital or 
those attending the Haematology Clinic at Warwick Hospital. These samples were in all cases 
collected into tubes containing EDTA as an anticoagulant. 
Blood or bone marrow samples were diluted with an equal volume of sterile 
physiological saline, and, using a pasteur pipette, carefully overlayed on top of an equal 
volume of lymphoprep (Nycomed) in a 15 ml. centrifugation tube or sterilin universal 
container. 
Samples were centrifuged at 800 xg for 15 minutes at room temperature, taking care to leave 
the centrifuge brake off in order to avoid excessive swirling of the separated layers. Following 
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centrifugation most of the upper serum layer was removed with a sterile pasteur pipette, and 
the mononuclear cells, which form a distinct band on top of the separation medium, were 
aspirated and resuspended in 15 mis of RPMI 1640 (G`bco, U. K). 
Samples were centrifuged at 400 xg for 10 minutes to wash the cells, and resuspended in a 
suitable volume of RPMI 1640. At this stage, the cell concentration cells was determined 
using an automated haematology analyser (Abbott Cell-dyn 3500), and the cell suspension 
was adjusted to 106 cells/mL using RPMI 1640. 
2.1.3. Freezing of mononuclear cells. 
Cell suspensions were adjusted as above to a concentration of approximately 106 cells/mL in 
RPMI 1640, and foetal calf serum (Gibco) was added to a final concentration of 10% (v/v/). 
Mononnuclear cells (0.9 mL) were then aliquoted into biofreeze vials (Costar) and 0.1 ml of 
dimethyl sulphoxide (DMSO) was added to act as a cryo-preservant. The vials were wrapped 
in tissue and placed at -70°C in an insulated box to allow a slow rate of freezing. Vials were 
then transferred to liquid nitrogen within 3 days. 
2.1.4. Thawing of cells and measurement of cell viability. 
Vials of cryopreserved cells were rapidly thawed by incubation of the vial in a 37°C 
waterbath and the thawed cell suspensions were transferred to a sterile universal container. 
Cells were washed by the addition of 10 mL of RPM 1640 culture medium followed by 
centrifugation at 400 xg for 5 minutes, and then resuspended in lmL of RPMI 1640 culture 
medium 
Cell viability was assessed in each case by flow cytometric analysis of propidium iodide- 
stained cells. To l00µ1 of the mononuclear cell suspension, l0µ1 of DNA staining buffer 
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comprising 50pg/mL propidium iodide (Sigma) and 0.5 mg/mL Rnase A (in PBS), was 
added, and this was incubated for 15 minutes at room temperature. Cells were then 
analysed for uptake of propidium iodide by flow cytometric analysis. 
As in other cell viability assays which are based on dye exclusion, non-viable cells take 
up the dye, and the advantage of using propidium iodide is that uptake of the dye can be 
measured by flow cytometry permitting the analysis of a large number of cells. 
2.1.5. Leukaemic cell lines. 
Four myeloid leukaemia cell lines were used during the course of this study to investigate 
the kinetics of the heat shock response following hyperthermia, and to study the 
relationship between hsp levels and apoptosis in myeloid cells. All four cell lines were 
obtained from the ECAAC culture collection of cells and tissues. KU812 and KG1 a are 
lines derived from patients with myeloid leukaemia, HL-60 is a myelomonocytic cell line 
and THP-1 is derived from a patient with pro-monocytic leukaemia. 
Cell lines were maintained as described in the specification data from the ECAAC. 
Briefly, KU812, HL-60 and THP-1 were maintained in suspension in RPM 1640 
containing Glutamax TM, plus 10% foetal calf serum (FCS) and 50µg/mL gentamicin (all 
obtained from Gibco). The KGIa cell line was maintained in Dulbecco's Modified 
Essential Medium (Gibco), supplemented with 10% FCS and 50µg/mL gentamicin. All 
cell lines were cultured at 37°C in a humidified incubator, and maintained in continuous 
logarithmic growth with sub-culturing by 1: 4 dilution in fresh complete medium at 48-72 
hour intervals. 
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2.2. Analysis of hsp expression. 
Immunochemical analysis of hsp expression throughout the course of this project was 
performed using a range of monoclonal antibodies to the major hsp families (see Table 
2.1). Anti-hsp70 (72/73) and anti-hsp60 (clone LKl) were both obtained from Sigma, 
and used at a dilution of 1: 50 for immunocytochemical analysis and 1: 100 for 
immunofluorescent staining. ML30 was provided by Dr. N. Mann from the University of 
Warwick, and was used at a final concentration of 5µg/mL for both techniques. A 
monoclonal antibody to hsp90 was obtained from Stressgen biotechnologies Ltd, and 
this was diluted as for the anti-hsp70 and hsp60 antibodies. 
Monoclonal Antibody SpecificLIX 
Anti-hsp60 Clone LKI Produced using recombinant human hsp60 as 
immunogen, recognising an epitope located between 
residues 383-447 of human hs 60. 
ML30 Recognises amino acids 275-295 of the 65kDa hsp 
from Mycobacterium leprae and M. tuberculosis. Will 
cross-react with human hsp65. 
Anti-hsp70 (72/73) Produced using purified hsp70 from bovine brain as 
immunogen. The antibody localises both the 
constitutive (hsp73) and the inducible (hsp72) forms 
of hs 70. 
Anti-hsp90 Clone AC-16, recognises both the constitutive and 
inducible forms of hsp90. Does not bind to the native 
unbound form of hs 90. 
Table 2.1. Monoclonal antibodies to the major hsp families used in the analysis of hsp 
expression in normal and leukaemic mononuclear cells. 
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2.2.1. Cytospin preparations of mononuclear cells. 
Hsp expression in normal and leukaemic mononuclear cells was investigated by 
immunocytochemical staining of cytospin cell preparations. For all leukaemic patients 
involved in this study, cytospins were prepared using freshly harvested mononuclear cells 
as it was found that cryopreservation and subsequent thawing of cells affected the 
morphological appearance of the cells. Cytospins were prepared with a Shandon 
cytocentrifuge, using 50-100 µl of cells suspended at 105-106 cells/mL in RPMI 1640 
culture medium containing 5% bovine serum albumin (BSA). The addition of BSA to the 
cell suspension resulted in improved preservation of cell morphology, presumably by 
buffering the cells against the deleterious forces of centrifugation onto the glass slide. 
Cells were centrifuged at a setting of 900 xg for 3 minutes, using disposable plastic 
cuvettes, and glass microscope slides used were cleaned before use in 70% ethanol. 
Prepared cytospins were air-dried for at least 60 minutes prior to staining. Those not 
stained immediately were stored at -30°C in a slide tray wrapped in aluminium foil until 
use, and these were allowed to reach room temperature for a minimum of 60 minutes 
prior to removing the foil wrapping. 
2.2.2. Localisation of hsp expression by immunocytochemistry. 
Visualisation of antigen distribution following incubation with specific hsp monoclonal 
antibodies was achieved using an avidin and streptavidin/biotin system labelled with 
horseradish peroxidase. The principle of this procedure is based upon the affinity 
between avidin or streptavidin and biotin to detect a secondary biotin-labelled anti-mouse 
monoclonal which binds to the primary mouse antibody. 
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Cytospins preparations of mononuclear cells were fixed in acetone: methanol (1: 1) for 10 
minutes at room temperature, prior to rinsing with distilled water and incubation in tris 
buffered saline (TBS) for 5 minutes. In order to block non-specific binding, cytospins 
were incubated for 20 minutes with normal rabbit serum (Dako), diluted 1: 20 in TBS. 
Following blocking, the serum was tapped off and the excess blotted away. 
The primary hsp antibody (see above), diluted optimally in TBS, was added and the 
slides incubated in a humid staining tray for 1 hour. Unbound antibody was removed by 
rinsing twice with TBS and slides were placed in a TBS bath for 5 minutes. This was 
followed by incubation with a biotinylated rabbit anti-mouse monoclonal (diluted 1: 50 in 
TBS), for 30 minutes. During this incubation the ABComplex was prepared by 
combining the avidin and streptavidin/biotin reagents according to the manufacturers 
instructions. Slides were rinsed with TBS as before to remove unbound secondary 
antibody, prior to incubation with the ABComplex/HRP for 30 minutes. After rinsing 
with TBS, stained slides were incubated with DAB substrate for 5-10 minutes and then 
rinsed with distilled water. Cells were counterstained with Meyer's haematoxylin and air- 
dried before mounting with a coverslip. Intracellular distribution of hsp antigens was 
examined by light microscopy. 
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2.3. Immunofluorescent analysis of heat shock proteins. 
The method of choice for demonstration and quantitation of heat shock protein antigen 
expression was flow cytometric analysis of immunofluorescence-stained cells. Indirect 
immunofluorescence techniques using a secondary fluorophore-conjugated antibody to 
label cells incubated with a primary hsp monoclonal antibody are highly sensitive. The 
ability to stain either `live' or fixed and permeabilised cells permits the analysis of cell 
surface antigens as well as intracellular hsp expression. Hence, this technique was utilised 
in order to investigate both cell surface and intracellular hsp expression using unfixed and 
fixed haemopoeitic cells respectively. 
Immunofluorescent staining followed by flow cytometric analysis was the method of 
choice for this study, both for examining the possibility of surface lisp expression, and for 
quantifying specific lisp levels (Chapters 3 and 4). Flow cytometric analysis offers several 
advantages over other techniques for protein analysis in this case. Leukaemic cells are 
particularly suited to flow cytometry, naturally existing as single cells in suspension, 
thereby eliminating the need for extensive sample preparation. The technique permits the 
rapid analysis of large numbers of cells (>10,000 cells /min) with high reproducibility. 
Particularly important, and a notable advantage compared with Western blotting, during 
flow analysis cells are examined at the single-cell level. This is particularly advantageous 
when a population of cells displays heterogeneous patterns of expression for a particular 
parameter. In addition, flow cytometry permits the simultaneous analysis of multiple 
parameters. Distinct populations of cells can be identified by specific light scatter 
characteristics, and the ability of the modern flow cytometer to detect fluorescent probes 
with different emission spectra means that double or triple-labelling techniques can be 
utilised for multiparametric analysis. 
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2.3.1. Analysis of surface lisp antigen expression. 
Washed mononuclear cells were suspended in phosphate-buffered saline, pH 7.4 (PBS) 
containing 1% bovine serum albumin (BSA) to a final concentration of 106 cells/rL. Cell 
suspensions (100µL) were added to round-bottomed microtitre plate wells (Costar), to which 
10µL of optimally diluted primary hsp monoclonal antibody was added. In every case, an 
isotype-matched negative control antibody was added to a second aliquot of cells. The 
microtitre plate was covered with an adhesive plate sealer, and the plate incubated at room 
temperature for 60 minutes. The microtitre plate was then centrifuged (up to 2000 rpm prior 
to braking) and the supernatent removed. Cells were then washed twice in PBS in order to 
remove unbound antibody, and the cells were resuspended in 100µL PBS. Finally, 5µL of a 
secondary goat anti-mouse/FITC monoclonal antibody was then added to each microtitre 
plate well, followed by incubation at room temperature for 45 minutes. Cells were washed 
once in PBS prior to resuspension in 200 µL of PBS. Flow cytometric analysis of 
immunofluorescence-stained cells was performed using a Coulter Profile H, and the potential 
presence of surface hsp expression was determined by comparison of fluorescence intensity 
between samples stained with the lisp- and isotype-matched monoclonal antibodies. 
As will be described i Chapter 3, initial experiments revealed the absence of specific staining 
with any of the hsp antibodies used. In order to increase the level of sensitivity, a three-stage 
immuno fluorescence technique was utilised. Cells were stained with the primary hsp 
monoclonal as above, followed by the addition of a biotinylated rabbit anti-mouse monoclonal 
(Dako), diluted 1: 50 in PBS. Cells were incubated for 30 minutes and washed twice as above, 
prior to the addition of a streptavidin/FITC conjugate (also from Dako). After another 30 
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minute incubation, cells were washed once and resuspended in PBS prior to flow cytornetric 
analysis as before. 
2.3.2. Analysis of intracellular hsp expression. 
Mononuclear cells were fixed by the addition, slowly with gentle mixing, of 1mL of 1% 
paraformaldehyde (in PBS). After 15 minutes, cells were centrifuged at 400 xg for 5 minutes 
and following removal of the superpatent were washed twice in PBS. Cells were re- 
suspended in PBS to a final concentration of 106 cells/mL, and for each hsp monoclonal plus 
isotype-matched antibody, 90µL of cell suspension was added to a microtitre plate well. 
10µL of primary antibody plus 10µL of 0.25% saponin (to permeabilise the cells) was added, 
and the microtitre plate covered with an adhesive seal prior to incubation at room 
temperature for 45-60 minutes. The microtitre plate was then centrifuged up to 2000 rpm in 
order to pellet the cells and the supernatent removed, followed by resuspension of the cells in 
30011L of PBS and centrigugation as before in order to wash the cells. The washed cell pellet 
was resuspended in 100µL of PBS, and 10µL of goat anti-mouse/FTTC (Dako) added. The 
plate was incubated in the dark at room temperature for 30 minutes prior to washing once in 
PBS as before and resuspension of the cells in 200µL of PBS. Stained cells were analysed by 
flow cytometry, gating on the cells using side scatter and forward scatter characteristics to 
eliminate debris, and green (FL1) fluoresence of the cells was determined. Specific staining 
with lisp monoclonal antibodies was compared with the isotype-matched antibody. 
In order to compare levels of hsp expression in cells from different patients and in different 
cell samples, the intensity of green fluoresence was recorded as a numerical figure given by he 
84 
mean peak channel of fluoresence, which although not an absolute measure of antigen 
expression, is directly proportional to the level of antigen expression. 
2.3.2. Flow cytometric analysis of p53 and bcl-2 expression. 
Direct irnmunofluorescent staining of haemopoietic cells with FITC-conjugated antibodies to 
bcl 2 and p53 (Dako) was performed according to suppliers specifications. Briefly, washed 
cells (106 cells) were fixed for a minimum of 15 minutes in 1 mL of ice cold 70 % 
ethanol. These were then washed twice in PBS and either 10u1 of anti-bcl-2/FITC or 
10µL anti-p53/FITC antibody were added. Appropriate isotype-matched negative 
control antibodies were added in each case to a second aliquot of cells. Cells were 
incubated in the dark for 45 minutes at room temperature, and washed in PBS prior to 
flow cytometric analysis. 
2.3.2. Dual staining for analysis of cytoplasmic antigens and cell cycle. 
Fixed and permeabilised haemopoietic cells were analysed for hsp expression and cell cycle 
analysis by a dual staining technique utilising indirect hsp staining with a FITC-conjugated 
antibody plus staining of nuclear DNA with propidium iodide (PI). Simultaneous 
measurement of green (FITC) and red (PI) fluorescence by flow cytometry permits analysis 
of hsp expression during different stages of the cell cycle. 
Washed mononuclear cells were suspended in PBS containing 1% BSA to a final 
concentration of 106 celLs/mL. For each analysis, 100ml of mononuclear cell suspension (1 x 
106 cells) was added to each of 2 plastic tubes (or microtitre plate wells) and 1 mL of 0.25% 
para-formaldehyde (in PBS) was slowly added to each tube whilst vortexing. The cells were 
85 
incubated for a minimum of 15 minutes at room temperature in order to fix the cells, prior to 
washing twice in PBS, centrifuging at 300 xg for 5 minutes. In order to permeabilise the 
cells, 1 mL of cold (4°C) 70% methanol was added to each tube, followed by incubation for 
60 mins. at 4°C. Tubes were then centrifuged at 300 xg for 5 minutes, and the supematent 
aspirated. Following a single wash with PBS, cells were resuspended in I OOml of PBS. 
10µL of appropriately diluted anti -lisp monoclonal was added and the cells stained for 45 
minutes at room temperature. In order to remove unbound antibody cells were washed once 
in PBS and resuspended in 100µL of PBS. To each tube, 10µL of secondary goat anti- 
mouselFITC (GAMIFITC) and 200µL DNA staining medium containing 50ug/mL 
propidium iodide and 0.5 mg/mL Rnase A (both from Sigma) in PBS. 
and these were incubated in the dark for 30 minutes. Finally, cells were washed by the 
addition of 2 mL PBS containing 2% FCS and centrifuged at 300 xg for 5 minutes. The 
supernatent was aspirated and the cells resupended in 200pL of PBS prior to flow cytometric 
analysis. 
Stained cells were gated using red fluoresence (PI stain), and green fluorescence of these cells 
was measured. A dual histogram plot of red versus green fluoresence demonstrated the cell- 
cycle specific expression of lisp. 
2.4. Analysis of apoptosis in haematopoietic cells. 
2.4.1. Morphological assessment of apoptosis. 
During apoptosis, cells demonstrate a number of distinct morphological changes which 
can be visualised by light microscopy. The apoptotic process is characterised in most cell 
types by compaction and segregation of chromatin against the nuclear membrane with 
condensation of the cytoplasm. The cells generally shrink, and the latter stages are 
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characterised by nuclear and cytoplasmic budding which leads to the formation of 
membrane-bound fragments which are known as apoptotic bodies. These visible 
morphological changes were used in order to identify apoptotic cells in cytospin 
preparations of haemopoietic cells following staining with Romanovsky 
dye. 
Quantitation of the proportion of apoptotic cells within a population was performed by 
counting a minimum of 500 cells in Romanovsky-stained cytospin preparations, 
identifying apoptotic cells by cell shrinkage associated with nuclear compaction, 
cytoplasmic condensation and the presence of apoptotic bodies. 
2.4.2. Quantitation of apoptotic cell populations: propidium iodide 
staining of ethanol-fixed cells. 
Staining of ethanol-fixed cells with propidium iodide, a (fluorescent) dye which 
intercalates with nucleic acids, has been used routinely for cell cycle analysis and 
quantitation of cellular DNA. It has been observed that apoptotic cells have a reduced 
DNA content. This may be due to loss of smaller DNA fragments following 
endonuclease activation and diffusion of these low molecular weight DNA products from 
the cell. A second explanation is that the marked nuclear condensation which is 
characteristic of apoptosis, renders some nucleic acids inaccessible to propidum iodide 
binding (Darzynkiewicz et al., 1997). 
Flow cytometric analysis of ethanol-fixed and propidium iodide stained cells 
demonstrates that apoptotic cells appear as a `sub-Go /G, ' peak, due to the lower DNA 
content and therefore reduced fluorescence. This permits the percentage of apoptotic 
cells within a population to be quantified using the software incorporated into the flow 
cytometer to set markers around the sub-Go /G, peak of fluorescence. This apoptotic 
population can be clearly demonstrated in leukaemic cell lines following incubation with 
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cytotoxic drugs, e. g HL60 (a promyelocytic leukaemia line) cells treated with 1 Oµg/mL 
bischloronitrosourea (BCNU) produce a characteristic apoptotic peak, and the 
appearance of this peak correlates well with the definitive identification of apoptotic cells 
in a cytospin preparation by morphological criteria. 
Sub-Go/G, 
apoptotic peak 
Method for PI staining. Mononuclear cells were washed twice in PBS by centrifugation 
at 400 xg for 5 minutes. After removal of supernatent, the cells were then fixed by the 
addition, slowly and with gentle mixing, of 1 mL ice cold 70 % ethanol (EtOH). Cells are 
left in EtOH to fix for a minimum of 15 minutes. Once fixed, the cells are stable when 
left at 40C in EtOH for up to 2 weeks in my experience and possibly longer. 
Fixed cells were washed twice in PBS as before and resuspended in 200µ1 of DNA 
staining medium, comprising 50pg/mL propidium iodide and 0.5 mg/mL Rnase A in 
PBS. Cells were stained for a minimum of 30 minutes prior to flow cytometric analysis. 
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2.4.3. Quantitation of apoptotic cell populations: annexin V-FITC 
staining of apoptotic cells. 
One of the features associated with apoptosis is a change in membrane symmetry which 
results in the exposure on the cell surface of phosphatidylserine residues. These 
demonstrate a high affinity for binding to annexin V, and this property has been utilised 
in order to recognise apoptotic cells. This technique was utilised using a commercially 
available kit to verify the integrity of results obtained using the simpler propidium iodide 
staining technique describd above. 
An apoptosis detection kit (R&D Systems) was used according to the manufactures 
insructions to analyse apoptosis in cell lines induced to undergo apoptosis following 
treatment with cytotoxic drugs or hyperthermia. Briefly, cells are incubated with an 
annexin V-FITC conjugate and propidium iodide (PI). Early apoptotic cells will be 
distinguished by their ability to bind annexin V-FITC, but the technique can also 
distinguish between apoptotis and necrosis by the fact that the former exclude PI because 
they still have an intact membrane. Flow cytometric analysis of annexin V-FITC and PI- 
stained cells can therefore be used to distinguish between live, apoptotic and necrotic 
cells. This technique was used in some experiments to verify the integrity of the results 
obtained by the propidium staining of fixed cells. In a comparison of the number of 
apoptotic cells within a population of HL-60 cells taken at different time intervals 
following treatment with 20µg/mL BCNU, there was no significant difference (p=0.021) 
between the number of apoptotic cells detected by these two techniques. 
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Chapter 3. 
Analysis of the cellular 
localisation of heat shock 
proteins in myeloid 
leukaemia cells. 
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3.1 Introduction. 
In mammalian cells the expression of heat shock proteins (hsp) is generally considered to 
be intracellular, restricted to the cytoplasm and including the endoplasmic reticulum and 
rnitochondrial compartments (Mizzen et al., 1989). The pattern of hsp expression under 
normal circumstances would obviously reflect the role of hsp as molecular chaperones, 
with specific hsp family members functioning within intracellular locations in the folding 
and unfolding of cellular proteins (see Introduction, section 1.1.5). However, under 
conditions of stress it has been demonstrated that members of the hsp70 family are found 
in the nuclear compartment. For example, both the constitutive and heat-inducible hsp70 
rapidly accumulate within the nucleus of heat-stressed (42 ° C, 1 hour) human fibroblasts. 
Members of the hsp70 family interact with nuclear oncogenes such as c-myc and p53; 
nuclear co-localisation of hsp70 and viral myc proteins is observed in myc- 
overexpressing cells (Koskinen et al., 1991), whilst the constitutive hsp70 (hsp73) forms 
complexes with mutant p53 in ras-transformed cells and human tumour cells (Nihei et 
al., 1994, Fourie et al., 1997 ). In addition, the formation of hsp: p53 complexes 
containing not only members of the hsp70 family, but also hsp90, is thought to represent 
the components of a molecular chaperone programme which affects the subcellular 
distribution of p53 protein (Merrick et al., 1996). 
As outlined in the Introduction, such interactions may play an important role in terms of 
cell growth and oncogenesis (see Section 1.2.2. ). An examination of the 
cytoplasmic/nuclear distribution of hsp in leukaemia cells is therefore essential in order to 
demonstrate whether abnormal localisation of hsp is associated with leukaemogenesis. 
Another important aspect concerning the localisation of hsp is the possibility that they 
may also be expressed on the cell surface, and if so, then what is the significance of this 
observation? The potential expression of hsp on the surface membrane of cells was still a 
91 
controversial topic at the time of starting this investigation. Although some authors had 
found no evidence of cell surface expression (e. g Ferm et al., 1989), others had reported 
lisp expression on the surface of certain cell types. For example, human y/& T cells 
express a cell surface antigen which is recognised by a monoclonal antibody to hsp58 
(P1), the human homologue of the Escherichia coli groEL protein (Jarjour et al., 1990). 
Also, murine bone marrow-derived macrophages have been shown to express an epitope 
which is recognised by a monoclonal antibody, ML30, which has specificity for 
mycobacterial hsp60 (Wand-Wurttenberger et al., 1991). The significance of lisp 
expression on the surface of such cells is not clear, although it has been suggested that 
lisp recognition may play a role in autoimmunity and microbial infections and recent 
reports have implied that hsp expression on the surface of malignant cells may be 
important in terms of cancer immunity (see Introduction, section 1.1.9). 
No reports exist in the literature concerning the specific localisation of lisp in primary 
leukaemic cells. It was therefore particularly important to analyse the cellular distribution 
of hsp in these cells, since cytoplasmic/nuclear redistribution clearly has biological 
implications. In addition, evidence of abnormal expression of hsp on the surface of cells 
may be relevant both in terms of cancer immunity, and as a mechanism for specifically 
targeting tumour cells with hsp-immunotoxin complexes. 
Working in the Haematology Deparment at Warwick Hospital, I had access to blood 
samples from patients with a variety of haematological malignancies. In particular, I was 
interested in patients with acute myeloid leukaemia (AML) since loss of p53 function in 
AML appears to occur by mechanisms which occur at the protein level rather than by 
specific genotypic alterations. As described in the Introduction (section 1.2.1), p53 
protein in the majority of AML cells is recognised by monoclonal antibodies specific to 
the mutant conformation of p53, despite the fact that genotypic alterations are relatively 
rare (Zhang and Deisseroth, 1992b). In addition, wild type p53 protein in AML, cells has 
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been shown to switch to a mutant conformation in response to growth factor stimulation 
(Zhang and Deisseroth, 1994). In light of the report by Hainaut and Milner (1992) that 
members of the hsp70 family are involved in the switch between a wild-type and 
`mutant' p53 conformation, it is tempting to suggest that in AMI, cells the loss of p53 
function which occurs at the protein level is the result of a switch in conformation 
mediated by hsp70. For this reason, the analysis of hsp expression in leukaemic cells 
focussed primarily on cells from patients with AMI,. 
3.2 Design of experimental protocol. 
3.2.1. Normal and leukaemic haemopoietic cells. 
Cells from patients with a variety of haematological malignancies presenting to the 
Haematology Department at Warwick Hospital were harvested by density gradient 
centrifugation as described in Chapter 2. As previously described, we were particularly 
interested in patients with AML, although availability of clinical material was dictated by 
the number of patients presenting with this disease. At Warwick Hospital, approximately 
10 new patients with AML would present within a 12 month period, and a smaller 
number of patients with the disease in remission would relapse. In initial studies, I 
therefore also examined cells from patients with the other major haematological 
malignancies, namely chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia 
(CLL) and acute lymphocytic leukaemia (ALL). 
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3.2.2. Immunochemical analysis of lisp in haemopopietic cells. 
Flow cytometry. Analysis of the expression and localisation of lisp was performed using 
immunochemical techniques (see Chapter 2, section 2.2). Immunofluorescent staining 
followed by flow cytometric analysis was the method of choice, both for examining the 
possibility of surface hsp expression, and for quantifying specific lisp levels (Chapter 4). 
Immunohistochemistry. Subcellular localisation of hsp expression was in turn analysed 
by immunocytochemical techniques using specific lisp monoclonal antibodies to stain 
cytospin preparations (see Chapter 2, Methods, section 2.2). Examination of stained 
preparations by light microscopy provides details of cell morphology as well as visually 
demonstrating the nuclear/cytoplasmic distribution of lisp in leukaemic cells. 
Monoclonal antibodies. Immunofluorescence and immunohistochemistry were both 
performed using monoclonal antibodies to several of the major heat shock protein 
families. At the outset of this section of experimental investigation, antibodies were 
available which recognised members of the hsp60, hsp70 and hsp9O families (see table 
3.1, below). At the time of performing these analyses, the only anti-hsp70 monoclonal 
antibody available was one which recognised both the constitutive (hsp73) and inducible 
(hsp72) members of this family, and both qualitatative and quantitative analysis of hsp70 
was performed initially using this antibody. Recently, an antibody has become 
commercially available which specifically recognises just the inducible (hsp72) protein. 
The initial studies of hsp70 localisation have therefore been recently repeated using the 
new anti-hsp72 antibody, although not in every case possible on the same patient 
samples due to availability of clinical material. Further details of the monoclonal 
antibodies used can be found in Chapter 2, section 2.2. 
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Monoclonal Antibody Specificity 
Anti-hsp60 Clone LK1 Produced using recombinant human hsp60 as 
immunogen, recognising an epitope located between 
residues 383-447 of human hs 60. 
ML30 Recognises amino acids 275-295 of the 65kDa hsp 
from Mycobacterium leprae and M. tuberculosis. Will 
cross-react with human hsp65. 
Anti-hsp70 (72/73) Produced using purified hsp70 from bovine brain as 
immunogen. The antibody localises both the 
constitutive (hsp73) and the inducible (hsp72) forms 
of hs 70. 
Anti-hsp90 Clone AC-16, recognises both the constitutive and 
inducible forms of hsp90. Does not bind to the native 
(unbound) form of hs 90. 
Table 3.1. Monoclonal antibodies used to determine the localisation of the major hsp in 
haemopoietic cells. These unconjugated antibodies were used as primary monoclonals to 
examine surface expression by indirect immuno fluorescence techniques, and subcellular 
localisation by immunohistochemical staining of cytospin preparations. 
3.3. Results. 
3.3.1. Heat shock proteins are not expressed on the surface of acute 
myeloid leukaemia cells. 
Mononuclear cells from 16 patients with AML were harvested by density gradient 
centrifugation (Lymphoprep) from whole blood samples collected into EDTA 
anticoagulant. Cytospin preparations of harvested cells were made immediately following 
separation, and, where possible, immunofluorescent staining of unfixed cells followed by 
flow cytometric analysis was performed to examine whether hsp expression could be 
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detected on the cell surface. Aliquots of leukaemic cells were also cryopreserved and, in 
certain cases, immunofluorescent staining was performed retrospectively on thawed 
samples. In these instances, cell viability was checked by the ability of cells to exclude 
propidium iodide, and in all cases this exceeded 89%. 
Immunofluorescent staining of unfixed cells using the four monoclonal antibodies listed 
in table 3.2 was performed initially by an indirect two-step protocol, using the primary 
unlabelled hsp monoclonal antibody, followed by a FITC-labelled goat-anti mouse 
antibody. An isotype-matched negative control adjusted to the same immunoglobulin 
concentration was used for each individual aliquot of patient cells to demonstrate non- 
specific binding to the cell surface. In subsequent experiments, a three-step technique 
was employed, using an avidin-biotin conjugate followed by FITC-labelled streptavidin in 
order to enhance the sensitivity of the procedure (see Chapter 2, Methods). Following 
immunofluorescent staining by both techniques, cells were washed and fixed in 2% 
paraformaldehyde prior to flow cytometric analysis (Coulter Epics II). 
Analysis of leukaemic cells from all sixteen AML patients revealed no increase in specific 
staining with any of the four anti-hsp monoclonal antibodies when compared with the 
negative control antibody (Figure 3.1). This was apparent when using both the two-step 
immunofluorescent staining procedure and the more sensitive avidin-biotin technique. 
Final immunoglobulin concentrations of 0.2-20pg/mL of each of the four antibodies 
were employed in order to verify that the lack of hsp antigen was not due to 
inappropriate antigen/antibody ratios. Whilst increasing immunoglobulin concentrations 
led to a slight increase in fluorescence, this was not specific as demonstrated by a similar 
increase, up to saturating concentrations, of the isotype-matched control antibody. 
Analysis of leukaemic cells was performed on both freshly isolated cells, and cells which 
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had been cryopreserved in liquid nitrogen. This is an important point to emphasise since 
it is recognised that cryopreservation can lead to the deterioration of some antigenic 
epitopes. 
Figure 3.1. Flow cytometric analysis of AML cells 
reveals an absence of surface expression for any of 
the major hsp. Patient cells were probed with 
antibodies to ML30, hsp60, hsp70 (72/73) and 
hsp90 followed by a goat anti-mouse/FITC 
a) conjugate. Histograms of cell number versus LFLI 
demonstrate no increase in specific staining with the 
a) hsp72/73 and b) hsp90 monoclonal antibodies 
compared with the isotype-matched negative 
control (red line). 
Similar results (not shown) were obtained in further 
experiments using a more sensitive three-stage 
avidin-biotin immunofluorescent technique, as 
b) described in Chapter 2, Methods, section 2.2). 
As described earlier, at the time of these experiments, the only commercially available 
hsp70 monoclonal antibody available recognised both the constitutive and inducible 
isoforms, although recently an antibody specifically recognising the inducible (hsp72) 
antigen has become available. Accordingly, I have recently re-analysed cells from a 
group of 10 AML samples for the surface expression of this antigen. Again, using both 
double- and triple immunofluorescence techniques, I have been unable to demonstrate 
the presence of hsp72 on the surface of AML cells (results not shown). 
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3.3.2. Hsp are not expressed on the surface of other malignant or 
normal haemopoietic cells. 
Immunofluorescent staining of cells from 6 patients with acute lymphoblastic leukaemia 
(ALL), 4 patients with B-cell chronic lymphocytic leukaemia (B-CLL) and 2 patients 
with chronic myeloid leukaemia revealed no increase in specific staining using any of the 
four antibodies listed in table 3.1. In addition, normal peripheral blood mononuclear cells 
were harvested from 10 healthy volunteers, and again in these cells there was no 
detectable expression of any of the major hsp on the surface membrane of these cells 
(results not shown). 
3.3.3. Hyperthermic treatment of myeloid leukaemia cells does not 
induce surface hsp expression. 
Hsp expression was also analysed on the mononuclear cells from 6 AML patients 
following exposure to a hyperthermic stress (42 °C for 30 minutes). Subsequent to heat 
shock, cells were placed in an incubator at 37 °C for six hours prior to 
immunofluorescent staining. In addition to the four antibodies listed in table 3.1, the 
antibody specific to the highly heat-inducible hsp72 protein was used. Again, no 
detectable expression on the surface of these cells was apparent (results not shown). 
3.3.4. Hsp expression is also undetectable on myeloid cell lines. 
Four haemopoietic cell lines, KU812 (myeloid), KG1a (myeloid), THP-1 
(myelomonocytic), and HL-60 (promyelocytic) were analysed for surface expression of 
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hsp. Exponentially growing cells were stained with primary monoclonal antibodies to the 
five anti-hsp antibodies available and analysed as before by flow cytometry. In repeated 
experiments, none of the four cell lines was found to express hsp on the cell surface 
(results not shown). In addition, cell lines were exposed to a hyperthermic stress by 
incubation of the cells at 42°C for 30 minutes. Analysis of cells following recovery at 
37 °C revealed that surface hsp expression was undetectable on any of the four cell lines 
using samples taken at time intervals of 4,8,16,24 and 48 hours post heat shock. 
3.3.5. Myeloma cell lines undergoing apoptosis express hsp72 and hsp90 
on the cell surface. 
Recently, as part of a novel research project examining the potential use of a bacterial 
toxin (verocytotoxin) to induce apoptosis in myeloma cells, I have been examining the 
influence of hsp expression on the induction of apoptosis by verocytotoxin, as well as 
various cytotoxic agents. In order to examine hsp expression in these cells undergoing 
apoptosis, I developed a double-labelling protocol using annexin V-FITC in combination 
with probing with the hsp antibodies using an RPE-labelled secondary antibody. One of 
the earliest gross morphological events during apoptosis is the loss of cell membrane 
phosholipid asymmetry, resulting in the exposure of phosphotidylserine on the outer cell 
membrane. Annexin V has a selective affinity for negatively charged phospholipids, 
which are normally only found on the inner side of the cell membrane, and the differential 
staining of cells with annexin V has been shown to be specific to cells during the early 
stages of apoptosis. 
These experiments demonstrated that the induction of apoptosis, as indicated by 
increased annexin V binding, is associated with the expression of both hsp72 and hsp90 
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on the cell surface (Figure 3.2). Exposure of myeloma cell lines to recombinant 
verocytotoxin (2-20pghnL) induces apoptosis, the early stages of which are evident by a 
time interval of 6 hours following exposure to verocytotoxin. 
3.4 Intracellular localisation of hsp expression in 
haematopoietic cells. 
The intracellular expression of hsp was next analysed in haematopoietic cells using an 
immunoperoxidase technique to stain cytospin preparations. Fixation of the cells in 
acetone: methanol (1: 1) permeabilises cell membranes and therefore provides information 
on the intracellular location of the antigen of interest. 
3.4.1. Normal mononuclear cells. 
Cytospin preparations of mononuclear cells from 6 normal healthy individuals were 
prepared. Romanowsky staining of these revealed that in each case the cells present were 
>96% lymphocytes and monocytes as assessed by morphological criteria. Immuno- 
peroxidase staining of normal lymphocytes and monocytes reveals that members of the 
hsp6O, hsp70 (72/73) and hsp90 families are all expressed within the cytoplasm of these 
cells, even in the absence of stress. Cytospin preparations of mononuclear cells from six 
normal individuals were probed with the monoclonal antibodies, ML30, anti-hsp70 
(72/73) and anti-hsp90. The expression of all three hsp families was evident in 
lymphocytes and monocytes as a diffuse cytoplasmic staining. No evidence was found of 
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nuclear localisation with any of the three antibodies employed. Plate 3.1 is a 
Romanowsky-stained cytospin of normal mononuclear cells following density gradient 
centrifugation and washing. The mononuclear cell fraction recovered can be seen to be 
comprised of lymphocytes and monocytes. Plate 3.2 demonstrates the typical diffuse 
cytoplasmic staining seen in these normal mononuclear cells with the monc clonal 
antibody to hsp72/73. The same distribution of antigen was seen in these cells when 
probed with ML30 and anti-hsp90 (data not shown). 
Cytospin preparations of cells harvested from normal individuals were also stained with 
an anti-p53 monoclonal antibody, recognising both mutant and wild-type conformations 
of p53. Light microscopic examination of immunostained cells revealed no detectable 
expression of the p53 tumour suppressor gene product in normal mononuclear cells from 
any of the six individuals used in this study. 
3.4.2. Mitogen-stimulated lymphocytes. 
Normal mononuclear cells exposed to concanavalin A (5pg/mL) and pokeweed mitogen 
(l1ig/mL) transformed and proliferated during in vitro culture as evidenced by the 
appearance of mitotic figures and large cells of immature appearance, identifiable by light 
microscopy analysis of Romanowsky-stained cytospin preparations (Plate 3.3). 
Immunoperoxidase staining of cytospins prepared from lymphocytes after 48 hours 
exposure to concanavalin A and pokeweed mitogen revealed that in both cases intense 
staining of the larger transformed lymphocytes was evident with antibodies to hsp72/73 
and hsp90. Plate 3.4 illustrates the intense staining pattern seen for hsp72/73 in the 
larger mitogen-transformed lymphocytes compared with the smaller normal lymphocytes. 
The ability to distinguish morphologically between smaller untransformed lymphocytes 
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and the larger transformed cells within the same field of view acts as a useful internal 
control. Again, the expression of hsp72/73 and hsp90 is largely confined to the 
cytoplasm, although in some transformed lymphocytes there is clearly some nuclear 
staining with the antibody for hsp72/73. 
Intracellular distribution of hsp60 in mitogen-transformed lymphocytes, as determined by 
immunohistochemical staining with ML30 and the anti-hsp60 monoclonal antibodies, 
was confined to the cytoplasmic compartment. Furthermore, unlike hsp72/73 and hsp90, 
there did not appear to be any difference in the pattern or intensity of staining compared 
with normal lymphocytes (results not shown). 
Interestingly, probing with an antibody to p53 (recognising both wild-type and mutant 
conformations) reveals that mitogen-stimulated lymphocytes express p53 located in both 
the both cytoplasm and the nucleus (Plate 3.5). 
3.3.3. Leukaemic cells from patients with AML. 
Cytospin preparations of leukaemic cells from 16 AMI. patients were stained with 
antibodies to hsp60, hsp72/73 and hsp90. In the absence of stress, significant levels of all 
three heat shock protein antigens were evident in all 16 cases, and again the heat shock 
proteins were generally localised within the cytoplasm (plate 3.6). Immunoperoxidase 
staining using an isotype-matched negative control antibody revealed no non-specific 
staining. However, myeloblasts from one patient clearly demonstrated significant nuclear 
localisation of hsp72/73 (plate 3.7). Immunohistochemical staining using the p53 
antibody revealed that no p53 expression was evident in 15/16 samples, but cells from 
that patient which demonstrated nuclear localisation of hsp72/73, also exhibited 
significant nuclear expression of p53 (plate 3.8). This is an interesting observation, 
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although isolated, since this particular patient had developed resistance to standard 
cytotoxic therapy. 
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Plate 3.1. Romanowsky-stained cytospin preparation of normal peripheral blood 
mononuclear cells. 
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Plate 3.2. Immunoperoxidase staining of peripheral blood mononuclear cells with 
monoclonal antibody to hsp72/73, demonstrating a diffuse pattern of distribution 
throughout the cytoplasm. 
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Plate 3.3. Romanowsky-stained cytospin preparation of normal peripheral blood 
mononuclear cells exposed for 48 hrs to the mitogen, concanavalin A (5pg/mL). 
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Plate 3.4. Immunoperoxidase staining of mitogen (concanavalin A, 5pg/mL)- 
transformed normal lymphocytes with anti-hsp72/73. The larger transformed 
lymphocytes demonstrate more intense cytoplasmic staining. 
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Plate 3.5. Immunoperoxidase staining of mitogen-transformed lymphocytes 
demonstrates accumulation of p53 in both the cytoplasmic and nuclear compartments. 
Normal PBMC were exposed to the mitogen, concanavalin A, for 48 hours and cytospin 
preparations stained using an antibody recognising both the wild-type and mutant 
conformations of p53 protein. 
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Plate 3.6. Immunoperoxidase staining of myeloblasts from a patient with acute myeloid 
leukaemia (AML). Cytospin preparations were stained with a) anti-hsp60, b) anti- 
hsp72/73 and c) anti-hsp90. Typically, AML cells demonstrate diffuse cytoplasmic 
staining with all three antibodies. 
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Plate 3.7. Myeloblasts from one patient (1/16) with AML demonstrate nuclear staining 
with an antibody to hsp72/73. These cells were harvested from a patient who remained 
refractory to standard cytotoxic therapy. 
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Plate 3.8. Cells from the same patient also demonstrate nuclear expression of p53 
protein. 
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3.5. Discussion. 
3.5.1. Surface expression of heat shock proteins. 
As described in the Introduction, at the outset of these investigations conflicting reports 
existed in the literature regarding the existence of hsp expression on the cell surface 
membrane. Some authors have found no evidence of surface expression, whilst others 
had reported surface expression of epitopes reactive with antibodies raised against lisp. 
These early observations demonstrated that, at least in a few very specific cell types, 
polypeptides which react with anti-hsp monoclonals and which are in some cases heat- 
inducible, are expressed on the cell surface membrane. The possible relevance of these 
observations has been suggested by several subsequent reports which propose a role for 
hsp molecules in antigen processing and presentation. It has been reported that members 
of the hsp70 family are expressed on the surface of resting antigen presenting cells as 
demonstrated by immunogold labelling with an anti-hsp72/73 monoclonal antibody 
(Manara et al., 1993). Furthermore, these authors found that incubation with a 
monoclonal antibody to hsp72/73 inhibited the antigen presenting function of human 
monocytes. It appears most likely that the appearance of hsp on the cell surface occurs 
as a result of the chaperoning function of hsp, and it has been suggested that this mode 
of peptide transfer through direct interaction with a molecular chaperone would be 
preferable to direct diffusion of peptides to cell surface destinations (Li and Srivastava, 
1994). 
However, in repeated experiments, immunofluorescent staining and flow cytometric 
analysis of a variety of primary leukaemia cells revealed no detectable expression of any 
of the major hsp families on the surface of these cells. Cells from 16 patients with AIM. 
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were examined, as well as 6 patients with ALL and 4 patients with B-CLL, a total of 28 
individuals. The design of the experiments was such that a range of primary hsp antibody 
concentrations was employed in order to ensure that the correct antibody/antigen ratio 
would be achieved. In addition, both an indirect two-step technique, and then 
subsequently a much more sensitive protocol using a three-step avidin-biotin staining 
procedure were used. However, in no analysis of any sample was there any evidence of 
specific cell surface staining for hsp90, hsp72/73 or ML30-reactive epitopes. 
In addition, the effect of a hyperthermic shock on the possible surface expression of 
AML cells was analysed. Leukaemic cells, suspended in RPMI 1640 culture medium, 
were heat shocked (42°C, 30 min. ) and then placed in an incubator at 37°C for six 
hours. After this recovery period, cells were stained as before using monoclonal 
antibodies to ML30, hsp90 and hsp72/73, but in addition with an antibody specific to the 
highly heat-inducible hsp72 protein. Again, repeated experiments failed to demonstrate 
the induction of lisp expression at the cell surface. The data indicate that hsps are 
expressed infrequently, if ever, on the surface of leukaemic cells. 
Indirect immunofluorescence is a sensitive technique which is capable of detecting low 
levels of antigen, and has been one of the techniques which has been utilised by other 
authors to report surface hsp expression in certain sub-sets of haemopoietic cells. Having 
found that surface expression of hsp was not detectable using a two-step indirect 
approach, I subsequently performed a series of experiments using avidin-biotin 
amplification, again finding that none of the major lisp families were expressed on the 
cell surface. Repeated experiments and titration of both primary and secondary antibody 
concentrations were used to ensure that the correct antigen: antibody ration was achieved 
and therefore not the reason for the inability to demonstrate any surface expression ni the 
cells examined. 
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Although I have been unable to demonstrate any evidence of surface hsp expression in 
normal or leukaemic haemopoietic cells, I have recently examined the role of hsp 
expression in myeloma cell lines which have been induced to undergo apoptosis in 
response to the cytotoxic drug, bischloronitrosourea (BCNU). As part of this 
investigation, I have looked for surface expression of hsp, and preliminary experiments 
have indicated that apoptotic cells do in fact express both hsp70 (the specific heat- 
inducible hsp72) and hsp90 on the cell surface. In these experiments, the induction of 
apoptosis by BCNU was demonstrated by increased annexin V binding, which was 
evident on myeloma cells at approximately 6 hours after the addition of BCNU. Double 
labelling of these cells, revealed that early apoptotic cells which were identified by 
annexin V binding expressed hsp on the cell surface. At this stage, the significance of 
these observations remain unclear, although it is feasible that hsp may have a functional 
role in the apoptotic process. It is possible that these hsp function as direct antigenic 
determinants which act as an apoptotic `flag' and a signal to neighbouring phagocytic 
cells. There is a precedent for this hypothesis in the expression of ubiquitin, which itself 
can be classified as an hsp since it is induced by hyperthermia, and is well known to act 
as a flag to phagocytic cells. Alternatively, hsp may be functioning as molecular 
chaperones by interacting with other cellular protein(s) which are transported to the cell 
surface during the apoptotic process. This interesting observation is currently being 
investigated further. 
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3.5.2. Localisation of hsp by immunocytochemical staining. 
Examination of immunostained cytospins of normal mononuclear cells demonstrates that 
these cells express detectable levels of hsp60, hsp70 and hsp90 in the absence of stress. 
No nuclear localisation was evident in any of the preparations from ten normal 
individuals. In each case, hsp60, hsp70 and hsp90 were immunolocalised within the 
cytoplasm, as evidenced by a diffuse cytoplasmic staining pattern. The expression of the 
tumour suppressor gene product, p53, was also analysed in these cells and no evidence 
of cytoplasmic or nuclear p53 accumulation was evident by immunoperoxidase 
techniques. 
The finding that normal mononuclear cells constitutively express detectable levels of hsp, 
even in the absence of any stress, reflects the importance of these molecules as molecular 
chaperones. 
Stimulation of normal peripheral blood lymphocytes with the mitogens concanavalin A 
or pokeweed mitogen induced transformation and proliferation with an associated 
upregulation of hsp70 and hsp90. As outlined in the Introduction (Section 1.1.6), a link 
between hsp expression and cell growth and differentiation is suggested by a number of 
reports which describe changes in hsp expression during the growth and differentiation 
of haemopoietic cell lines (e. g Galea-Lauri et al., 1996, Mivechi et al., 1994). In my 
analysis of mitogen-stimulated lymphocytes, the expression of hsp in these cells was 
predominantly cytoplasmic, although hsp72/73 was also localised within the nucleus. It is 
therefore interesting to note that p53 staining of mitogen-stimulated lymphocytes 
revealed nuclear accumulation of this tumour suppressor gene product. This finding may 
be significant in terms of the relationship between hsp70 and p53, and may have 
relevance to the proliferation of haemopoietic cells. For example, it has been reported 
that wild-type p53 protein in AML cells switches to a mutant conformation in response 
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to growth factor stimulation, leading to the suggestion that conformational changes in 
normal p53 protein represent an important mechanism for the regulation of cell 
proliferation (Zhang and Deisseroth, 1994). Further evidence to support this theory 
comes from the observation that different conformations of p53 protein in AML cells 
relate to the in vitro growth characteristics of the cells, and this can be regulated by 
either exogenous or autocrine haemopoietic growth factors (Zhu et al, 1993). 
Leukaemic cells from AML patients express significant levels of hsp60, hsp70 and hsp90 
in the absence of stress. Light microscopy of immunperoxidase-stained cytospins 
revealed that the expression of all three hsp was predominantly cytoplasmic. In fifteen of 
sixteen cases, no nuclear staining was evident with any of the three hsp monoclonal 
antibodies, but a strong pattern of nuclear staining for hsp72/73 was evident in the 
myeloblasts of one patient. Furthermore, immunoperoxidase staining with an antibody to 
p53 of cytospins from the same patient revealed significant nuclear expression of this 
tumour suppressor gene product, whilst immunostaining of the cells from all fifteen other 
AML patients revealed no significant staining for p53, either cytoplasmic or nuclear. This 
nuclear co-localisation of hsp72/73 and p53 is interesting since these cells were from a 
patient whose disease had undergone a second relapse and had become particularly 
resistant to chemotherapy. However, the relevance of this observation is uncertain, and 
since it was only apparent in this one patient, it is impossible to definitively ascribe a 
clear association between nuclear co-localisation of hsp72/73 and p53 and any clinical 
parameters such as drug resistance or tumour aggressiveness. Clearly, it would be 
desirable to investigate this further, and a much larger sample of AM IL patients including 
a larger number with drug resistant malignant cells would be required. In order to 
address this, cells from AML patients continue to be harvested at Warwick Hospital so 
that a larger study may shed light on any potential association between hsp: p53 
localisation and drug resistance. 
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Chapter 4 
Quantitation of Heat Shock 
Protein expresson in myeloid 
leukaemia cells. 
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4.1. Introduction. 
In Chapter 3, it was demonstrated that both normal and malignant haemopoietic cells, 
and mitogen-stimulated lymphocytes, express detectable intracellular levels of all three 
major hsp families, predominantly localised in the cytoplasm. As described in the main 
Introduction, the significance of hsp expression in tumour cells has important 
implications, both in terms of cell growth and proliferation, and by virtue of their 
protective role which may be important in terms of the response of tumour cells to 
chemotherapy. Indeed, it has been reported that hsp expression in breast cancer cells has 
prognostic implications in terms of drug resistance (Fuqua et al., 1994). At the outset of 
this investigation, no reports existed in the literature describing hsp levels in primary 
leukaemia cells, and an analysis of hsp expression in a variety of patients with myeloid 
leukaemias was therefore undertaken in order to examine whether abnormal levels of hsp 
expression could be detected in these cells. 
4.2 Patients and methods. 
4.2.1. Collection of leukaemic cells. 
Mononuclear cells were harvested by density gradient centrifugation from peripheral 
blood samples of 12 patients with acute myeloid leukaemia (AML), and 9 patients with 
chronic myeloid leukaemia (CML). The AML patients were diagnosed according to the 
French-American-British (FAB) classification of acute myeloid leukaemia (table I) which 
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sub-classifies AML according to morphological criteria. These included 6 de novo cases 
of MAL, 3 patients who transformed to frank AML (2 myelodysplastic and 1 chronic 
myeloid leukaemia) and 3 patients whose disease had relapsed (2 patients at first relapse, 
I patient second relapse). Of the 9 patients presenting with CML, retrospective 
cytogenetic analysis was available for only 3 of these patients, and this demonstrated that 
all three possesses the Philadelphia chromosome translocation. 
All leukaemic cells used in this study were harvested from blood samples collected on 
the day of initial presentation, prior to the administration of any chemotherapeutic drugs. 
In addition, none of the patients exhibited a temperature above 37.5 0 C. Normal 
mononuclear cells from ten healthy volunteers were also harvested. 
AML FAB type Patient 
M2 Myeloblastic with maturation K. W, S. B, M. K, C. J, M. B 
M3 Acute promyelocytic K. H 
M4 Acute myelomonocytic L. R, B. T, A. M 
M5 Acute monoblastic M. S, M. M 
M7 Megakaryoblastic 
.. G 
Table 4.1. Classification of AML patients according to the French-American- British 
(FAB) system 
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4.2.2. Quantitation of intracellular heat shock proteins in leukaemic 
cells. 
Measurement of intracellular hsp levels was performed by immunofluorescent analysis of 
fixed and permeabilised patient cells using the same antibodies described in chapter 3. 
The development of the optimal staining procedure is described in Chapter 2, Materials 
and Methods. Flow cytometric analysis was used to quantify hsp levels, again because of 
the same advantages described in the previous chapter. 
4.3 Results. 
4.3.1. Expression of hsps in normal mononuclear cells. 
Normal peripheral blood mononuclear cells (PBMC) exhibited positive immuno- 
fluorescence staining with antibodies to the three major heat shock protein families, 
hsp60, hsp72/73 and hsp90. Figure 4.1 illustrates the typical flow cytometric histograms 
of fluorescence staining with the three anti-hsp antibodies for one individual. 
Figure 4.1. Representative profiles of flow cytometric analysis of a) hsp60, b) 
hsp72/73 and c) hsp90 protein levels in normal mononuclear mononuclear cells. 
Immunofluorescent staining is presented as cell numbers versus log fluorescence 
intensity. Comparison with an isotype-matched negative control is indicated by the 
dotted line. 
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Typically, the cells fluoresce as a single narrow peak, indicating a relatively 
homogeneous pattern of hsp expression in these mature blood cells. 
The values for the mean peak channel (MPC) of fluorescence obtained by flow 
= cytometric analysis in the ten samples of normal PBMC were as follows; Hsp6O; mean 
6.3, range 2-12.5, hsp72/73; mean = 16.3, range 4-30, hsp90; mean = 32.3, range 13-52. 
4.3.2. Expression of lisps in CML mononuclear cells. 
Figure 4.2. Flow cytometric profile of a) hsp60, b) hsp72/73 and c) hsp90 expression in 
mononuclear cells harvested from a patient with CML (patient LM). The dotted line 
represents the isotype-matched negative control. Broad peaks of protein expression 
represent heterogenous levels of hsp in these patients. 
Table 4.2 summarises the flow cytometry data for the 9 CML patients and shows the 
mean values and the range of fluorescent staining for each hsp family. Levels of hsp were 
not significantly different to those seen in normal PBMC's when analysed in terms of the 
mean peak channel of fluorescence. However, as figure 3.2 illustrates, cells stain as a 
broad fluorescent peak indicating a heterogeneous pattern of expression. This pattern of 
expression would be expected in CML if hsp levels are related to the differentiation of 
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haemopoietic cells, since this disease is typified by the appearance in the peripheral blood 
of myeloid cells representing all stages of differentiation from immature myeloblasts to 
mature neutrophils. Indeed, all the CML samples in this study contain myeloid cells at 
various stages of maturation as can be seen from the haematological data in table 4.2. 
It is interesting to note in Fig. 4.2 that fluorescence peaks for hsp90 staining demonstrate 
two distinct cell populations in this patient. One population of cells stained with a lower 
fluorescence intensity, within the range seen for normal PBMC's. The second distinct 
population of cells stained more intensely, comparable to the level of staining with anti- 
hsp90 seen in the cells from AML patients (see below). Cells from other patients (3/8) 
also showed two peaks of fluorescence for hsp90 staining. 
4.3.3. Expression of hsps in AML mononuclear cells. 
Table 4.3 demonstrates that mononuclear cells from AML patients had a significantly 
higher level of expression (p<0.01) of all three hsp's compared with cells from CML 
patients or normal PBMC. Within the AML patients as a group, a wide range of hsp 
expression was evident, with a nine-fold difference in mean fluorescence intensity of 
hsp72/73 staining observed between individual patients. Hsp60 and hsp90 staining also 
showed a wide heterogeneity in terms of fluorescence staining, although less pronounced 
than seen for hsp72/73. 
In most AML patients, expression of the hsp in the mononuclear cell fraction was seen as 
a narrow peak of fluorescence intensity, presumably representing the almost 
homogeneous nature of the cell populations which were predominantly immature blast 
cells. 
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a) b) c) 
Figure 4.3. Immunofluorescent staining of AML cells (patient SB) with monoclonal 
antibodies to a) hsp60, b) hsp72/73 and c) hsp90 reveals that these cells express higher 
protein levels for all three hsp faiiiilies, compared with either normal mononuclear cells 
or cells from patients with CML. 
Figure 4.3 illustrates the immunofluorescence profile of patient SB whose mononuclear 
cells were almost entirely myeloblasts (96%). The fluorescence peaks show a narrow 
window of staining, indicating a uniform pattern of expression in all the blast cells. 
However, other AML patients demonstrated dual staining peaks as was seen in some of 
the CML cells. For example, patient KW (figure 4.4) had a much lower proportion of 
myeloblasts in the peripheral blood, and the presence of both immature blasts and more 
mature cells was reflected by two distinct peaks of staining intensity for hsp72/73 and 
hsp9O, but not hsp60. The gap between these two peaks is more marked than was seen 
in the CML cells. 
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Figure 4.4. Immunfluorescent staining profile of AML mononuclear cells harvested from 
patient SB using monoclonal antibodies to hsp60, hsp72/73 and hsp90. Although 
analysis of the peripheral blood from this patient revealed that the white cell population 
consisted almost entirely of myeloblast cells (96%), two staining populations are evident 
for b) hsp72/73 and c) hsp90, but not a) hsp60. 
Patient D. G, whose mononuclear cells consisted entirely of myeloblasts by 
morphological criteria, also demonstrated two distinct staining peaks for hsp90 
expression. This pattern of dual staining peaks for hsp90, but not hsp70 or hsp60, was 
found in two other AML cases where the cell population appeared homogeneous by 
morphological examination alone. 
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Patient WBC x10 /l % Blasts °Immature 
myeloid % 
Hsp60 
(MPC) 
Hsp70 
(MPC) 
Hsp90 
(MPC) 
LM 209 12 74 10 12 32 
FB 184 0.5 36 10 17 48 
TM 255 0 69 8 13 25 
AL 213 8 41 16 18 31 
VW 172 35 54 9 10 17 
SKD 52.2 10 24 7 10 65 
EO 171 0 28 9 16 44 
NP 72.9 18 58 15 22 30 
RW 46.1 9 26 5 18 34 
--Immature myeloid % represents immature cells of the myeloid series, i. e. myeloblasts, 
promyelocytes, myelocytes and metamyelocytes. 
Mean peak Hsp60: 9.9 Hsp70: 15.1 Hsp90: 36.22 
fluorescence (Range=5-16) (Range=10-22) (Range=l7-65) 
Table 4.2. Haematological data from CML patients indicating the peripheral blood white 
cell count and the percentage of myeloblasts in each sample. The expression of members 
of the hsp60, hsp70 (72/73) and hsp90 proteins has been quantified by 
immunofluorescent staining and flow cytometric analysis, the level of expression of each 
being expressed in terms of the mean peak channel of fluorescence (MPC). 
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Patient WBC x10 9 /l % blast cells Hsp60 
(MPC) 
Hsp70 
(MPC) 
Hsp90 
(MPC) 
LR 27.9 62 13 180 32 
BT 44.1 99 27 54 95 
KW 43.7 40 18 20 72 
MM 39.8 82 22 44 81 
MS 31.0 95 21 60 83 
MB 82.9 88 17 30 27 
CJ 13.8 81 16 20 18 
MK 107 26 11 90 38 
SB 121 96 14 39 49 
nn Ina 1 00 16 40 48 
KH 31.9 93 10 50 84 
AM 42.1 91 27 75 92 
Mean peak Hsp60: 17.6 Hsp70: 58.5 Hsp90: 59.7 
fluorescence (Range=l0-27) (Range=20-180) (Range=18-95) 
Table 4.3. Haematological data of AML Patients and hsp expression in terms of the 
mean peak channel (mpc) of fluorescence for the three major hsp families. 
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4.4. Discussion. 
4.4.1. Cytoplasmic expression of heat shock proteins in primary 
leukaemic cells. 
The expression of hsp60, hsp70 (72/73) and hsp90 can all be detected in normal 
peripheral blood mononuclear cells (PBMC's) by indirect immunofluorescence using 
monoclonal antibodies against these three major heat shock protein families. 
Fluorescence profiles for these cells demonstrate a relatively homogeneous pattern of hsp 
expression with no large differences apparent between lymphocytes and monocytes from 
the same individual, evidenced by a single narrow peak of staining, or between the 
mononuclear fraction of the ten healthy individuals examined. 
The expression of all three heat shock proteins examined is clearly elevated in leukaemic 
cells and more heterogeneous than is observed in normal PBMC. In AML cells, 
significantly higher levels of all three hsp families were evident compared with either 
normal PBMC or CML cells. Both AML and CML cells exhibit a wide range of hsp 
expression, not only between individual patients, but within the groups as a whole. The 
significance of these differences in hsp expression is not clear, but several explanations 
are possible. The first, and possibly most plausible explanation, is that hsp levels are a 
marker of the differentiation state of these cells. Decreased expression of hsp70 and 
hsp90 is associated with myeloid differentiation of HL-60 cells (Beere et al, 1993, YOU 
et al, 1989, Shakoori et al, 1992), and levels of hsp60 mRNA decrease during TPA- 
induced differentiation of HL-60 or K562 cells (Lu & Seligy, 1992). A further indication 
of the association between hsp's and differentiation is the observation that heat shock 
itself, or chemical agents which elicit a heat shock response, induce differentiation of 
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HL-60 cells (Richards, 1988). The large differences in hsp levels between AML cells, 
which are predominantly immature myeloblasts, and CML cells may therefore be due to 
simple differences in the stages of myeloid differentiation between the cells. If this is the 
case, the heterogeneity seen in AML cells could imply that some myeloblasts are more 
mature and the possibility that hsp levels could be a marker of different. ation state in 
AML demands further investigation. Also, therapy aimed at inducing differentiation, e. g 
the retinoids, would be expected to drive towards lower levels of hsp expression. 
A second explanation is that hsp expression is a marker of cell proliferation. By virtue of 
their role as molecular chaperones, lisp's perform a perform a variety of roles which 
could be utilised in a developmentally regulated manner to control proteins necessary for 
cell growth and proliferation (Pechan, 1991). Hsp expression has been shown to be 
regulated by mitogenic stimuli in a variety of cell types, including haematopoietic cells 
(Ferris et al, 1988, Fincato et al, 1991), and both immunoperoxidase staining and flow 
cytometric analysis of concanavalin A and pokeweed mitogen-stimulated lymphocytes 
demonstrated markedly increased levels of hsp70 and hsp90 (see Results Chapter 1). 
Immunofluorescent histograms of CNL patients demonstrated in some cases two 
distinct peaks suggesting that the presence of immature and more differentiated myeloid 
cells expressed high and low levels of lisp respectively. However, in some AML cells 
where morphologically the cells were homogenous and virtually all immature 
myeloblasts, two distinct populations were evident for hsp90 expression. This may 
represent the presence of an actively proliferating population of cells which have a 
distinct level of hsp90 expression., although this would seem unlikely since the 
proliferating compartment of leukaemias, like most other cancers, is represented by a 
very small percentage of the overall population of tumour cells. In these cases, it may be 
more likely that this dual pattern of hsp90 expression is the result of a biphenotypic 
leukaemia, a situation which arises when leukaemic transformation gives rise to the 
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clonal proliferation of two populations which may represent different stages of myeloid 
differentiation. 
Although leukaemic cells from different patients showed marked differences in levels of 
expression, no correlation was observed in the expression of the different hsp families. 
This is perhaps not unsurprising, since although all heat shock proteins have similar 
modes of action, they have exclusive roles to play in terms of specific interactions with 
cellular proteins. 
An important feature of the pattern of hsp expression in leukaemic cells, and in particular 
those from AML patients, is the wide range of hsp expression in cells from individuals 
with the same diagnosis. Analysis of the clinical data from these patients, in terms of 
survival, drug therapy and the stage of the disease, revealed no apparent correlation with 
the level of hsp expression. At this stage, it is not evident whether the high levels of hsp 
expression in AML simply represent the malignant phenotype of these cells, i. e. their lack 
of myeloid differentiation, or whether elevated hsp expression has a biological role, 
particularly in terms of the response to chemotherapy. 
As outlined in the introduction, hsp induction in response to a variety of environmental 
insults appears to afford cells a protective effect. Do the elevated levels of these proteins 
therefore provide leukaemic cells with a survival advantage which may relate to altered 
proliferative potential of the malignant clone? Furthermore, how do levels of hsp 
expression relate to the susceptibility of cells to drugs used in the standard treatment of 
these malignant disorders? 
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Chapter 5 
Heat shock protein expression and 
apoptosis in myeloid leukaemia cells. 
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5.1. Introduction. 
Normal haemopoiesis is dependent upon a complex network of haemopoietic growth 
factors. These regulatory cytokines are essential for the control of growth and 
differentiation as well as maintenance of viability, and removal of such factors results in 
apoptosis (reviewed by Sachs, 1996 ). During normal myeloid cell differentiation, 
apoptosis plays a regulatory role and myeloid precursor cells which become deprived of 
haemopoietic growth factors undergo apoptotic cell death. Likewise, leukaemic blast 
cells from most patients with AML are also dependent upon the presence of these 
`survival' factors and cannot be maintained in vitro without the addition of 
haematopoietic growth factors (Lotem and Sachs, 1996). However, myeloblasts from a 
small proportion of AML patients exhibit independent growth without the requirement 
for exogenous growth factors. This observation has clinical significance since it has been 
shown that AML patients whose cells survive in vitro independently have a poor 
prognosis (Lowenburg et al, 1993, Hunter et al, 1993). 
As outlined in the Introduction, apoptosis is a physiological mode of cell death which 
plays a major role in the maintenance of homeostasis in several systems of the body. It 
takes place during embryogenesis and metamorphosis, and plays an important role in 
tissue turnover by maintaining the balance between cell number and cellular proliferation. 
It is generally accepted that deregulation of the apoptotic process may contribute to the 
development of the malignant state by permitting the expansion of a population of cells 
capable of genetic progression to malignancy (reviewed by Allen et al., 1993, Kerr et al., 
1994, Lotem and Sachs, 1996). In addition, the susceptibility of tumour cells to 
apoptosis has important therapeutic implications since cytotoxic drugs have been shown 
to exert their effects via induction of this mode of cell death (Lotem & Sachs, 1992, Sens 
& Dlncalci, 1992). 
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In Chapters 3 and 4 it was demonstrated that hsp expression in myeloid leukaemia cells 
is heterogenous, which leads one to question whether the levels of hsp expression 
observed have any biological relevance in terms of susceptibility to apoptosis. The 
posssible relevance of hsp expression to apoptosis can be approached from two angles. 
Firstly, hsp induction in response to environmental insults has been shown to have a 
protective effect; does hsp expression therefore influence the induction of apoptosis by 
cytotoxic drugs? Secondly, hsp expression is clearly linked to cell growth and 
differentiation, probably by virtue of hsp interaction with growth regulatory factors, e. g 
c-myc, p53. The expression of these two growth factors is known to be involved in 
apoptosis (totem and Sachs, 1996) which implies that hsp expression may in turn be 
implicated in the process. 
A relationship between hsp expression and apoptosis is suggested by several lines of 
evidence. The induction of hsp by heat shock or overexpression by introduction of a 
vector containing hsp gene affords resistance to a variety of agents known to induce 
apoptosis in haematopoietic cells, e. g heat shock, TNF (Li et al , 1991; Jaattela et al , 
1992). In addition, it has been reported that the cytotoxic drug, bischloronitrosourea 
(BCNU), will induce hsp expression (Kroes et al, 1991). Furthemore, there is evidence 
that hsp may have a role in the control of apoptosis. As described in detail in the 
Introduction, members of the hsp70 family will form complexes with p53, a tumour 
suppressor gene product. It has been found that mutant forms of p53 are preferentially 
associated with the constitutive hsp70 (hsc70) (Hainaut et al, 1992) and the Escherichia 
coil hsp 70 analogue, DnaK, will also bind to p53 and enhances its DNA binding 
capacity. This implies that chaperones, potentially hsp70, may play a role in regulating 
tumour suppressor function as suggested by Lane et al (1993), and therefore be involved 
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in escape from apoptosis. Neurones are protected by heat shock from apoptosis induced 
by transfer into serum free medium, i. e lacking viability factors (Mailhos et al, 1993), and 
thymocytes are similarly protected from glucocorticoid-induced apoptosis (Migliorati et 
al, 1993 ). This latter observation is particularly interesting as glucocorticoids can induce 
apoptosis in thymocytes by a p53-independent mechanism (Clarke eta!, 1993). 
I have therefore examined the apoptotic process in cells from AML patients in order to 
discover whether a difference in susceptibility to cell death exists between samples from 
different patients, and between samples taken from the same patient during different 
stages of the disease. The possibility that the in vitro susceptibility of malignant cells to 
apoptosis may relate to clinical factors such as disease aggression and response to 
chemotherapy requires investigation. 
5.2 Experimental design 
5.2.1. Assessment of apoptosis by propidium iodide staining of cultured cells. 
Flow cytometry has become a method of choice for analysis of apoptosis in a variety of 
cell systems. A variety of techniques utilising flow cytometry have been developed with 
methods based upon changes in cell morphology, function of the plasma membrane, 
DNA degradation and DNA stability to denaturation (reviewed by Darzynkiewicz et al, 
1997). The method of choice for identifying and quantifying apoptotic cells was flow 
cytometric analysis of propidium iodide-stained cells. Propidium iodide (PI) is a highly 
polar compound which intercalates with nucleic acids in a stoichiometric manner, 
enabling the quantitation of total nuclear DNA content. 
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(a) (a) Cell populations are examined by forward 
scatter (FS), which is a function of cell size, 
and red fluorescence staining (FL3) which is 
a function of propidium iodide binding and 
therefore DNA content. 
(b) A bitmap (1) is drawn around the cells of 
interest to include apoptotic cells plus cells in 
G,, S and G2/M phases of the cell cycle. This 
excludes doublets and cell debris from the 
debris 
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(b) analysis. 
(c) Gated cells are displayed as a histogram 
doublets of cell number versus FL3 intensity and the 
use of region analysis software integral to the 
Coulter Epics flow cytometer permits quanti- 
tation of cells within each phase of the cell 
cycle including the apoptotic population. 
FL3 (DNA content) 
Early experiments with normal mononuclear cells and cells from leukaemic patients 
demonstrated that propidium iodide staining successfully identified apoptotic populations 
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following culture in the absence of any added growth factors. As described in chapter 2, 
the data from propidium iodide staining correlated well with morphological analysis of 
cytospin preparations in which apoptotic cells were counted visually under light 
microscopy. 
5.2.2. Patient samples. 
Mononuclear cells were harvested by density gradient centrifugation (see Chapter 2, 
section 2.1) from peripheral blood samples or bone marrow aspirates collected into 
EDTA from 9 patients with AML. Samples were collected at initial presentation, and 
when possible, during induction of remission by standard chemotherapeutic regimens and 
in certain cases upon subsequent relapse (Table 5.1). A total of 20 samples were 
analysed 
Cryopreserved cells from AML patients were rapidly thawed in a 37 °C waterbath, and 
washed in RPMI medium. Cell viability was determined in each case by the trypan blue 
dye exclusion test and in all samples viability was >88%. An aliquot of cells from each 
patient sample was analysed for hsp70 and p53 expression (as described in materials and 
methods), and cells were resuspended in RPMI 1640 medium without any added serum 
or exogenous growth factors. 
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Sample Comments 
JJ a) PRV-AML transformation 
JJ b) Relapse 1, drug resistant 
JJ C) Relapse 2 
EH a) Presentation de novo AML 
EH b) Relapse I 
EH c) Relapse 2 
EH d) Relapse 2+ Tx 
BT a) Relapse 1 
BT b) Relapse 2 
LM CML-AML transformation 
MC a) Presentation de novo AML 
MC b) Relapse I 
MM a) Relapse 1 
MM b) Relapse 2, drug resistant 
MM C) Relapse 2+ Tx 
DG Presentation de novo AML 
MW Relapse 1 
PC a) Presentation de novo AML 
PC b) Relapse I 
PC c) Relapse 1+ Tx 
Table 5.1. Leukaemic mononuclear cells from nine patients with AML were harvested 
by density gradient centrifugation. Samples were collected at initial presentation, and 
where possible, during subsequent treatment and/or relapse. 
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5.3. Results 
53.1. AML cells undergo apoptosis in the absence of exogenous growth 
factors. 
AML cells cultured in vitro rapidly undergo apoptosis as evidenced by the appearance of 
a sub-Gi peak with propidium iodide-stained cells. Morphological analysis by light 
microscopy of giemsa-stained cytospins reveals the presence of significant numbers of 
apoptotic cells after 48 hours incubation in RPM! 1640 medium alone (Plates 5.1 and 
5.2). with the characteristic features of condensed chromatin and formation of 
membrane-bound apoptotic bodies. 
In vitro culture of AML cells in the absence of added serum rapidly led to the 
appearance of apoptotic cells as determined by the presence of sub-diploid peaks during 
flow cytometric analysis of propidium iodide-stained cells. Figure 5.1 illustrates that 
AML cells demonstrated a time-dependent increase in apoptotic numbers, with 
apoptotic cells observed in some samples as early as 6 hours. By 48 hours, some AML 
cells (5/20) demonstrated greater than 90% apoptosis. By contrast, cells from other 
samples are more resistant to apoptosis, in one case the proportion of apoptotic cells 
being just 3% after 48 hours. Figure 5.1 illustrates that AML cells fall generally into two 
groups, some highly susceptible and others relatively resistant to induction of apoptosis. 
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Figure 5.1. AML cells undergo apoptosis in vitro when cultured in serum-free medium. 
The percentage of apoptotic cells in mononuclear cells harvesyed from individual 
patients was determined by propidium iodide staining and flow cytometric analysis to 
quantify the sub-G1 apoptotic peak. The susceptibility of different sample to apoptosis 
varies considerably. 
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5.3.2. Susceptibility to apoptosis correlates with hsp70 expression in 
AML cells. 
As was found with the earlier analysis of hsp expression in AML cells (see Chapter 4), a 
broad range of hsp72/73 expression is evident in samples from different AML patients 
and between samples from the same patient taken at different stages of the disease, with 
a six-fold variation in hsp72/73 levels between `high' and `low' expressers (Table 5.2). 
The expression of p53 oncoprotein was also examined in these cells. Cells were scored 
as positive for p53 expression if the number of positive cells was greater than 10% as 
compared with the isotype-matched negative control antibody. In table 5.2, patients are 
arranged in order of the susceptibility of AML cells to in vitro apoptosis as determined 
by the number of apoptotic cells after 48 hours. 
A comparison of hsp72/73 expression with the susceptibility of cells to apoptosis, as 
measured by the percentage of apoptotic cells after 48 hours, demonstrated that there is 
a significant correlation (p = 0.009) between apoptotic numbers and the mean peak 
channel (mpc) of fluorescence staining with anti-hsp72/73 (Figure 5.2). 
5.3.3. Expression of p53 is associated with high levels of hsp70. 
The expression of the p53 tumour suppressor gene has an established role in the process 
of apoptosis, . Analysis of p53 expression in these cells by flow cytometry reveals that 
the majority of the AML samples showed no specific p53 staining, and that where 
specific staining did occur, this was weak (figure 5.3). However, it does appear that 
AML samples exhibiting high apoptotic rates score positive for p53 expression (see table 
5.2). 
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Patient bsp70 (mpc) p53 % Apoptosis (48 hrs) 
EH a) 122 + 99 
MC a) 240 + 98 
JJ a) 170 + 97 
MM c) 131 - 93 
MM a) 156 + 90 
LM 212 + 76 
MW 176 + 64 
PC b) 130 - 63 
EH d) 251 - 48 
EH c) 198 - 45 
BT a) 92 - 35 
PC c) 113 - 35 
MM b) 44 + 28 
BT b) 66 - 23 
JJ b) 139 - 13 
PC a) 121 - 12 
MC b) 58 - 11 
JJ c) 144 - 11 
EH b) 90 - 7 
DG 43 - 3 
Table 5.2. Leukaemic cells from nine AML patients collected at various stages of the 
disease (see Table 5.1) demonstrate variable degrees of apoptosis after 48 hr in vitro 
culture. Samples are arranged in order of susceptibility to apoptosis and show the level 
of hsp72/73 expression. Samples were scored as positive for p53 expression if the 
number of positive cells was greater than 10%. 
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Figure 5.2. The percentage of apoptotic cells from 20 ANTI, patients after 48hr in vitro 
culture correlates significantly (P = 0.009) with hsp72/73 expression. 
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Figure 5.3. p53 expression in AML cells was measured by flow cytometric analysis of 
patients cells stained with a mononclonal antibody recognising both the wild-type and 
mutant forms of p53. Specific staining was compared with an isotype-matched negative 
control antibody (a), and analysis region M1 was set so that 98% of these cells were 
negative. Specific staining with p53 antibody was measured by the number of positively 
staining cells within this region as indicated. In table 5.2, positive expression of p53 in 
cells of patients with AML was taken if the percentage of cells within analysis region 
M1 was 10% or greater. 
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Figure 5.4. Variable but low levels of Bcl-2 expression were demonstrable in ANTI, 
cells. Fixed cells were stained with a primary antibody to bcl-2 followed by a 
secondary FITC-labelled goat anti-mouse antibody. Specific bcl-2 protein levels were 
expressed in terms of the mean peak channel (mpc) of fluorescence. 
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5.3.4. Correlation of hsp90 and bcl-2 with susceptibility to apoptosis. 
In order to determine whether hsp90 demonstrated a similar correlation with the 
susceptibility of AML cells to apoptosis induced by serum withdrawal, the expression 
of this hsp was determined in a second series of AML cell samples (table 5.3) as there 
was insufficient material from the first series for these additional determinations. In 
addition, hsp70 expression was also measured as well as bcl-2, a recognisc, d inhibitor 
of apoptosis in lymphoid cells. 
Sample Comments 
RS CML-AML transformation 
MM Relapse 2+ Tx 
KH AML presentation 
MM Relapse 2 
BT Presentation + Tx 
EH Relapse 2+ Tx 
JJ PRV-AML 
JJ PRV-AML, bone marrow 
DG AML Presentation 
LR AML Presentation 
AM AML Presentation 
LR AML bone marrow 
PC Relapse 1+ Tx 
Table 5.3. In vitro apoptosis of AMI, cells was examined in a second series of patients 
As before a strong correlation was found between hsp70 expression and apoptosis (p = 
0.0004: data not shown). Both bcl-2 and hsp90 could be reliably quantified in these 
cells (figures 5.4 and 5.5 respectively). The data indicated that there was a negative but 
not significant correlation between apoptosis and bcl-2 (figure 5.6) expression, and 
there was no correlation with hsp90 expression (figure 5.7). 
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5.3.5. Susceptibility to apoptosis and patient prognosis in AML. 
Susceptibility to apoptosis was analysed in relation to patient survival. Patient cells 
included in this study were taken from some patients at initial disease presentation, and 
in other cases from patients previously in remission whose disease 
had relapsed. There 
was no significant correlation (p=0.67) between the susceptibility of myeloid 
leukaemic 
cells to apoptosis and the survival rate of the patients 
included in this study. 
5.4. Discussion. 
The results presented in this chapter demonstrate that AML cells undergo apoptosis 
when cultured in vitro in the absence of added serum reflecting the requirement of 
haemopoietic cells for viability factors which inhibit the induction of apoptosis. The 
results demonstrate that there is a marked variation in the susceptibility to apoptosis of 
AML cells from different patients, and indeed there are differences between samples 
from the same patients taken at different stages of the disease. However, I was unable 
to demonstrate any correlation between the rate of apoptosis and clinical factors such 
as patient survival or the development of drug resistance. 
Examination of the stage of disease does initially appear to suggest that there is some 
relationship between the stage of the disease and the levels of hsp70 and, following on 
from this, the susceptibility of these cells to apoptosis. Examination of the results in 
table 5.2 shows that there was a difference in hsp70 and susceptibility to apoptosis 
between cells harvested from patients at initial presentation compared with cells taken 
from the same patients at relapse and second relapse. For example, mononuclear cells 
from patient JJ (see table 5.1) were highly susceptible (97%) to apoptosis at initial 
presentation of the disease, but the cells were more resistant (13%) at first relapse and 
highly resistant (7% apoptosis after 48 hours serum starvation) at second relapse. 
Also, cells from patients EH and MC were highly susceptible to apoptosis at initial 
presentation, whilst cells collected during subsequent relapse demonstrated a greatly 
increased resistance to apoptosis induced by serum starvation. This is a very interesting 
observation which suggests that leukaemic cells during relapse have undergone 
alterations in the susceptibility to apoptosis which may play a role in the response of 
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these cells to cytotoxic therapy. However, patient PC showed a relative 
increase in 
susceptibility to apoptosis between cells harvested at initial presentation and cells 
from 
samples taken later during disease relapse. It is therefore impossible to 
draw any 
conclusions from these results, especially when based upon such a small sample of 
patients. This aspect therefore requires further investigation in order to establish 
whether there is a relationship between disease state and apoptosis. 
When the rate of apoptosis in vitro was compared with the expression of hsp70 in the 
AML cells upon isolation, it is clear that there is a highly significant correlation 
between the two in two independent series of AML cell samples. Thus, although hsp70 
expression protects cells against apoptosis induced by a variety of agents , 
paradoxically it appears that there is an inverse relationship between the level of hsp70 
and the rate of apoptosis induced by withdrawal of growth factors in these AML cells. 
This finding is in contrast to the initial expectations at the outset of this investigation. 
Two factors which are widely regarded as playing important roles in apoptosis are p53 
and bcl-2. The former is thought to initiate apoptosis, at least where this is induced by 
DNA damage, and the latter to protect. In these studies, p53 was weakly and 
inconsistently expressed so that although p53 expression was not reliably quantified, 
there did appear to be some correlation between p53 and apoptosis. Expression of bcl- 
2 did demonstrate a negative relationship with the susceptibility to apoptosis 
suggesting that bcl-2 may play some role in the protection of AML cells against 
apoptosis, although this correlation was not statistically significant. 
The question which arises from these results is whether hsp70 itself plays a role in 
apoptosis, or if high levels of hsp70 simply reflect that the most susceptible cells are 
already `stressed' and therefore more susceptible to a further insult such as removal of 
viability factors. However, if this were the case it would be expected that hsp90, 
another stress protein, would also correlate with apoptosis, and this did not appear to 
occur. If the association of hsp70 elevation with apoptosis is not merely coincidental, 
either its importance is through interaction with the p53 pathway or else through an 
independent pathway. 
Of particular interest in this context is the observation that constitutive members of the 
hsp70 family (hsc70) interact with the product of the p53 tumour suppressor gene. The 
biological significance of hsp70-p53 complexes is poorly understood, although it has 
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been shown that binding of hsp70 could be part of a regulated process leading to 
changes in p53 conformation. According to this hypothesis, hsp70 regulates folding 
from mutant , with promoter 
function, to wild-type conformation which has suppressor 
function. (Hainaut & Milner, 1992). Further evidence of this relationship between 
hsp70 and p53 is suggested by the report that mutant p53 proteins can transactivate 
the hsp70 gene promoter (Tsutsumiishii et al. 1995). 
Hsp70 appears to play a role in the balance between control of cell growth and 
differentiation, and loss of cells via apoptosis. Our finding that AML cells which 
express high levels of hsp70 are more susceptible to apoptosis is paradoxical in view of 
the protective nature of hsp, although it has been shown that HL60 cells treated with 
N-methylformamide (NMF) will differentiate or undergo apoptosis according to the 
concentration of NMF used, and that differential expression of hsp70 correlates with 
the path taken (Beere et al, 1993). Differentiation is associated with decreased levels 
of hsp70, while the induction of apoptosis by higher levels of NMF correlates with 
maintainance of hsp70 levels. The authors of this report suggest that hsp70 acts, 
similar to p53, as a cellular `sensor' permitting the cell to discriminate between 
different levels of cellular damage, and is therefore a key mediator in the response to 
drug-induced damage. 
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Chapter 6 
Analysis of the heat shock response and 
apoptosis in leukaemic cell lines 
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6.1. Introduction. 
In chapter 5, I reported a significant correlation between hsp70 protein levels and the 
susceptibility to apoptosis of primary AML cells. Paradoxically, this predisposition to 
apoptosis induced by serum withdrawal was greater in those cells expressing higher 
levels of hsp70, suggesting that either these cells were already `stressed', or that high 
levels of hsp70 actually provide a pro-apoptotic signal to the cell. 
In order to analyse whether hsp70 overexpression does influence the apoptotic process 
in leukaemic cells, myeloid leukaemia cell lines were used to study the relationship 
between hsp expression and the susceptibility to apoptosis. Heat shock of cultured 
cells was used to increase the expression of the major hsp, and the heat shock response 
was studied by measuring both the kinetics and quantitative expression of the major 
hsp following hyperthermic shock. By such an approach, the influence of hsp 
overexpression on the susceptibility of cells to apoptosis induced by serum starvation 
could be studied. In addition, the enhancement of hsp expression by hyperthermic 
shock provides a model to determine whether increased hsp expression protects 
leukaemic cells against the deleterious effects of cytotoxic drugs. 
6.2. Analysis of the kinetics of the heat shock response in 
myeloid leukaemia cell lines. 
Four myeloid leukaemia cell lines were used, THP-1 (myelomonocytic), KGIa 
(myeloid), HL-60 (promyelocytic) and KU812 (myeloid). These were maintained as 
described in the Methods and Materials section. Cell lines were subjected to 
hyperthermic conditions by incubation at 42 °C for periods of 15,30 and 60 minutes, 
prior to returning the cells to the incubator at 37 ° C. The expression of the major hsp 
and cell cycle analysis was then determined by double immunofluorescence staining 
and flow cytometric analysis of cells removed from culture at various time intervals. 
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6.2.1. Hyperthermic shock rapidly induces hsp70 and hsp9O 
expression. 
Hyperthermia resulted in increased expression of hsp25, hsp70 and hsp90 in all cell 
lines studied. Hsp70 and hsp90 induction were the most pronounced in all four lines, 
both in terms of the magnitude and the rapidity of the response (see figure 6.1). As 
shown in figure 6.1, heat-shock of HL-60 cells results in an increase in hsp90 
expression which is evident after only 4 hours. The increase in hsp9O levels was more 
rapid in cells exposed to a longer heat shock, but in all experiments, similar maximum 
levels of hsp90 were reached (after -16 hours) irrespective of the duration of the 
hyperthermic treatment. Finally, the kinetics of hsp90 decay varied according to the 
duration of heat shock. Higher levels of hsp90 expression were maintained for longer 
in those cells incubated at 42°C for 60 minutes than in those exposed to the higher 
temperature for 30 and 15 minute periods. 
As expected, the highly heat-inducible hsp72 demonstrated the most significant 
increase in expression following hyperthermia, a 15-17 and a 10-12-fold increase in 
hsp72 protein levels being seen 16 hours post-heat shock in the KU812 and HL-60 cell 
lines respectively. For hsp72 induction, the duration of hyperthermic treatment was 
directly proportional to the maximum levels of protein expression seen, with higher 
levels being reached in those cells subjected to a 60 minute heat shock. In terms of the 
kinetics of the response, the time interval before detectable induction of hsp72 
expression did not vary significantly according to whether a 15,30 or 60 minute heat 
shock was used. However, at 24 hours, levels of hsp72 had decreased more rapidly in 
cells incubated at 42° C for shorter periods. These distinctive patterns of hsp90 and 
hsp72 induction, to a maximum at approximately 16 hours followed by a decrease 
dependent upon the duration of hyperthermic treatment, were similar in the other three 
cell lines studied. 
The kinetics of hsp25 induction varied slightly between the cell lines (results not 
shown), but in all cases the magnitude of the response was less than that seen for 
hsp90 and hsp70. The most rapid response for the induction of hsp25 was seen in HL- 
60 cells, with an increase in protein expression evident 4 hours post-heat shock, and 
reaching a maximum ät 16 hours (3.2-fold increase compared with control cells). In the 
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KU812, KG1a and THP-1 cell lines, induction of hsp25 was not detected until 8 hours 
post-treatment, with maximum induction reaching between 2.4 (in the KU812 cells) 
and 3.7-fold (in T'HP-1 cells) the protein levels seen in the control cells which were 
maintained throughout at 3711C. 
Although the magnitude and rapidity of hsp25 induction was not as great as seen for 
hsp70 and hsp90, hsp25 levels remained elevated for longer that any of the other hsp 
families examined. In THP-1 and KU812 cells the levels of hsp25 were still maximal at 
24 hours post-heat shock. 
Hyperthermic treatment at 4211 resulted in no detectable change in levels of hsp60 in 
three of the myeloid cell lines tested, even in cells exposed to the elevated temperature 
for 60 minutes (results not shown). A significant increase in hsp60 was evident only in 
the THP-1 cell line, with levels reaching a maximum at 16 hours post heat shock which 
was 4-5-fold higher than control cells. 
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Figure 6.1. Induction of hsp90 and hsp72 in HL-60 cells by hyperthermic exposure 
(420C) for various time intervals. Cells were incubated in a 4211C waterbath for 15,30 
and 60 minutes and the kinetics of hsp90 and hsp72 induction measured by comparison 
with control cells maintained at 370C. Hsp90 and hsp72 are shown in terms of the 
mean peak channel of fluorescence (mpc). Results plotted are the means of triplicate 
experiments. 
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6.2.2. Hyperthermia induces the expression of p53 in some myeloid 
cell lines. 
Expression of p53 was examined in leukaemic cell lines following hyperthermic shock 
(42°C for 30 min. ). Immunofluorescent staining with an antibody recognising both 
wild type and mutant p53 revealed that acumulation of p53 protein ocurred in the 
KGla and KU812 cell lines, this increase being evident 8 hours post-heat shock. 
Double immun-fluorescence staining of ethanol-fixed cells using a FITC-labelled p53 
antibody and propidium iodide to stain DNA, revealed that the induction of p53 
occurred independently of the cell cycle, with levels increased throughout in Gi ,S and 
G2/M (figure 6.2). These flow cytometry histograms of propidium iodide staining 
(FL3) versus p53 levels (LFL1) show that there is a slight increase in LFLI in cells in 
the G2IM phase of the cell cycle, but this is non-specific staining as shown by a similar 
pattern with the isotype-matched negative control antibody. This artifact is probably 
due to the larger size of cells in the G2/M phase. 
However, in both KGIa and KU812 cells, hyperthermia-induced expresion of p53 was 
associated with a small, but reproducible, accumulation of cells in the G2/M phase 
(Table 6.1). In exponentially growing KU812 cells, the proportion of cells in the G2/M 
phase was consistently measured as being between 12-14 % of the total population and 
this increased to 20-28 % following incubation at 42°C for 60 minutes. A similar 
increase in the G2/M population was evident in KG1a cells following hyperthermia, and 
in both cases this was concomitant with a reduction in the number of cells in the Go/G1 
phase of the cell cycle. This accumulation of cells at the G2/M boundary was detectable 
at a time interval coincident with the measurable induction of p53, i. e at 6-8 hours 
post-heat shock. 
No increase in p53 levels was evident in the THP-1 line following hyperthermic 
treatment, and, as expected, HL-60 cells (which have large deletions in the p53 gene) 
expressed no detectable p53 in either the control or heat-shocked cells. 
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HL-60 
THP-1 
KU812 
KG1a 
Control, 37" C Heat shock, 420C, 30' 
Go/G, S G2/M Go/G, S Gz/M 
65.4 9.5 25.1 62.9 11.5 25.6 
55.6 25.0 19.4 52.4 28.3 19.3 
65.0 18.8 13.2 51.2 21.2 27.6 
61.4 10.1 28.5 45.4 15.6 39.0 
Table 6.1. Cell cycle analysis of myeloid cell lines in exponentially growing cells and 
following hyperthermia (42°C, 30 min. ). Distribution of cells in each phase of the cell 
cycle was measured by flow cytometric analysis of propidium iodide-stained cells, and 
in the heat-shocked cells at an interval of 8 hours after hyperthermic treatment. 
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6.2.3. Induction of hsp by hyperthermia does not protect against 
apoptosis induced by serum withdrawal. 
KU812 and KG 1a cells were exposed to a hyperthermic shock (42 °C for 15 min. ), and 
allowed to recover at 37°C for 3 hours. Control cells were maintained throughout at 
3711C. Cells were then washed and resuspended in RPM! 1640 medium containing no 
foetal calf serum (FCS), and cell cycle analysis was performed by propidium iodide 
staining of cells removed at subsequent intervals of 4,18,24 and 48 hours. As shown 
in table 6.2, withdrawal of serum from exponentially growing KU812 and KGla cells 
resulted in the appearance of apoptotic cells, evident at a time interval of 18 hours 
after the resuspension of cells in growth medium lacking FCS. As expected, the 
proportion of apoptotic cells increased with time. This was demonstrated by the 
number of propidium iodide-stained cells appearing as a sub-G, peak in the samples 
removed at 24 and 48 hour intervals. KU812 and KGla cells exposed to hyperthermic 
treatment expressed higher levels of hsp25, hsp72/73 and hsp90, as described in 
section 6.2.1. When the rate of apoptosis following removal of growth factors was 
examined, there was no decrease in the susceptibility of cells to apoptosis compared 
with control cells maintained at 37 11 C. 
Control cells (37°C) Heat shocked (42°C, 30 min) 
Time (hrs. ) KU812 KG la KU812 KG la 
0 3.5 2.1 5.6 2.3 
4 3.7 1.7 4.9 4.2 
18 11.3 4.6 17.3 8.7 
24 24.7 19.9 35.2 23.4 
48 75.6 45.3 85.2 48.1 
Table 6.2. Culture of KU812 and KGIa cell lines in the absence of added FCS results in 
the induction of apoptosis. Hyperthermia (42°C, 30 min. ) does not appear to protect 
against apoptosis withdrawal. Figures shown are the means of triplicate experiments. 
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6.3. Induction of apoptosis by chemotherapeutic agents. 
A range of chemotherapeutic agents, with differing modes of action (table 6.3) were 
used to investigate the stress response of leukaemic cell lines. As described in the 
introduction, at least one cytotoxic drug (bis-chloronitrosourea) will induce hsp70 
expression and so the response of leukaemic cell lines to a range of concentrations of 
this drug was investigated. In addition, cells were exposed to the drugs, vincristine, 
cytosine arabinoside and doxorubicin at the concentrations indicated in figure 6.3. 
Drug Mode of action 
Vincristine A Vinca alkaloid whose primary mode of action is inhibition of mitosis. 
Inhibits formation of mitotic spindle by blocking the polymerisation of 
tubulin. Widely used in treatment of leukaemias and lymphomas. 
Cytosine arabinoside A pyrimidine nucleoside analogue. Incorporation into DNA as ara-CTP 
leads to termination of DNA strand synthesis. One of the mainstays in the 
treatment of AML. 
Bischloronitrosourea An alkylating agent, forms covalent bonds with biologic nucleophiles 
(BCNU) changing their chemical structure and activity. Results in damaged DNA 
and also altered protein structures. 
Doxorubicin An anthracycline antibiotic which intercalates with DNA and inhibits 
DNA-dependent DNA polymerase and DNA-dependent RNA 
polymerase. Widely used in treatment of acute leukaemias and certain 
solid tumours. 
Table 6.3. Four classes of cytotoxic drug widely used in the treatment of leukaemias 
were utilised in the analysis of apoptotic induction and hsp expression in myeloid 
leukaemia cell lines. 
6.3.1. Cytotoxic drugs induce apoptosis in myeloid cell lines. 
Treatment of all four myeloid leukaemia cell lines with BCNU, cytosine arabinoside, 
vincristine and doxorubicin (table 6.2) resulted in the appearance of apoptotic cells as 
determined by the presence of a sub-diploid peak in propidium iodide-stained cells. A 
linear response of increasing apoptosis in myeloid cells exposed to increasing 
concentrations of BCNU was evident in all cell lines in terms of the induction of 
apoptosis (figure 6.3). Similar results were obtained with the other three classes of 
cytotoxic drug, demonstrating that chemotherapeutic drugs with different primary 
modes of action all exert their cytotoxic effects via the induction of apoptosis. 
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Figure 6.3. Apoptosis induced by the alkylating agent, bischloronitrosourea (BCNU) 
in myeloid cell lines. 
6.3.2. BCNU induces hsp70 (72/73) expression in leukaemic cell lines. 
Cytotoxic concentrations of BCNU induced transient levels of hsp72/73 
overexpression, detectable 4-6 hours after exposure to the cytotoxic drug, and this 
preceded the onset of apoptosis. Levels of hsp70 induction by BCNU were not as 
great as the levels which can be induced by heat shock (hyperthermia). Despite 
relatively high levels of hsp70 being induced in the cells treated with the highest 
concentrations of BCNU, this stress response did not protect against apoptosis as 
evidenced by the higher levels of apoptosis seen in these cells. 
Analysis of hsp70 expression 4 hours after exposure to BCNU demonstrated that the 
induction of hsp70 occurred in all cells rather than in a small number. Cell cycle 
analysis of hsp70 expresion in these drug-exposed cells revealed that there was no cell 
cycle-specific response, with all cells expressing similarly elevated hsp70 levels in all 
phases of the cell cycle (see figure 6.4). 
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Figure 6.4. Increased Hsp70 
expression in KU812 cells 
demonstates that hsp70 induction 
occurs is not cell-cycle-specific and 
occurs in all phases of to cell cycle. 
Exposure of these myeloid cell lines to the three other drugs described in table 6.2 had 
variable effects on the stress response in terms of hsp70 induction. Vincristine at 
cytotoxic concentrations led to an increase in hsp70 levels, although these were not as 
great as those seen with BCNU, while doxorubicin also induced hsp70 expression to 
levels which were similar to those seen with BCNU, and similarly this preceded the 
onset of apoptosis. However, cytotoxic concentrations of cytosine arabinoside did not 
alter the detectable levels of hsp70 despite inducing apoptosis within a similar time 
range to the other three drugs tested. 
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Figure 6.5. Effect of the alkylating agent BCNU on hsp72/73 expression and 
apoptosis in HL60 cells. Hsp70 expression was analysed in these cells using an 
antibody to both the constitutive (hsp73) and inducible (hsp72) forms of hsp70 at a 
time interval of 6 hours post addition of BCNU. The percentage of apoptotic cells was 
determined at 24 hours. . 
6.3. Mild hyperthermia protects cells aginst the lethal 
effects of cytotoxic drugs. 
6.3.1. Hyperthermic shock protects myeloid cell lines against the 
cytotoxic effects of BCNU. 
Prior exposure of KGla and KU812 cells to a sub-lethal heat shock leads to elevated 
levels of heat shock proteins as disussed earlier. Whwn these cells were exposed to the 
alkylating agent, bischloronitrosourea, BCNU, it was found that these cells with higher 
levels of hsp were partly resistant to the cytotoxic effects of BCNU as evidenced by a 
decrease in the number of apoptotic cells after 24 hours compared with control cells 
which have been maintained throughout at 37°C. (Figure6.6) 
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Figure 6.6. Mild hyperthermic shock (42°C, 30 min. ) partly abrogates the apoptotic 
response of a) HL-60 and b) KG 1a myeloid cell lines following exposure to the 
alkylating agent, bischloronitrosourea. 
6.3.2. Resistance induced by hyperthermia is independent of bcl-2. 
The expression of bcl-2 protein in the myeloid cell cell lines was determined by 
immunofluorescent staining and flow cytometry. All four cell lines expressed 
detectable, but low levels of bcl-2. Following heat shock at 42 0C for 30 min., bcl-2 
expression in KGIa and KU812 cells was unchanged when compared with control 
cells mainatained throughout at 37°C (Figure 6.7). Similar results (not shown), were 
obtained for THP-1 and HL-60 cells. 
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Figure 6.7. Expression of bcl-2 protein in KU812 and KGIa cells is unchanged by 
hyperthermia. Histograms of fluorescence intensity are shown as % positivity within 
analysis region Ml. This was set up using an isotype-matched control antibody so that 
98% of cells are outside the analysis region. 
6.4. Degree of heat shock is either protective or enhances drug- 
induced apoptosis. 
The apoptotic response of myeloid cell lines to BCNU following prior hyperthermic 
treatment was found to depend upon the severity of the heat shock. As described, heat 
shock at 42°C for 30 minutes induced protection against the cytotoxic effects of 
BCNU in all four cell lines, but exposure to higher temperatures had the opposite 
effect and actually enhanced BCNU-induced apoptosis (Table 6.4). 
Heat shock of myeloid cell lines using temperatures above 42 °C increases both the 
basal rate of apoptosis in all four cell lines, and has a synergistic effect on the 
susceptibility of cells to apoptosis induced by BCNU. Thus at higher temperatures 
(43 °C and 44 1 C), which are associated with levels of hsp72/73 even higher than those 
produced at 42 °C, overexpression of hsp fails to offer a protective effect. 
159 
FL! (bcl-2) FL! (bcl-2) 
BCNU 
µg/mL 
0 
10 
20 
HL-60 THP-1 KU812 KGIa 
42°C 43°C 44°C 4211C 43°C 440C 42°C 43°C 44°C 42° 
C 
43° 
C 
44° 
C 
3.8 
6.2 
22.5 
5.6 
11.4 
35.6 
32.6 
75.1 
78.2 
2.2 
15.3 
25.9 
3.6 
14.9 
26.8 
16.2 
25.6 
32.1 
2.1 2.5 
5.3 9.8 
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35.6 
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29.6 
Table 6.4. Effect of different degrees of heat shock on the apoptotic response of 
myeloid cell lines to bischloronitrosourea (BCNU). Cells exposed to varying 
hyperthermic temperatures for 30 min. were exposed to BCNU (0,10 and 20 pg/mL) 
after 6 hours recovery at 37 ° C. The percentage of apoptotic cells was measured 16 
hours after the addition of the cytotoxic drug. 
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Chapter 7 
Discussion and concluding remarks. 
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7.1. Introduction. 
The initial aim of my research was to examine heat shock protein (hsp) expression in 
primary human leukaemia cells, and to establish whether this expression was abnormal 
either in terms of protein levels or the cellular localisation of hsp. At the outset of this 
work, a growing body of evidence from a variety of cell systems, including 
haematopoietic cells, suggested that hsp expression is linked to cellular growth and 
differentiation. For example, hsp70 and hsp90 expression is induced in T-lymphocytes 
following mitogenic stimulation (Ferris et al., 1988; Haire et al., 1988; Fincato et al., 
1991), whilst the differentiation of HL-60 and K562 (myeloid leukaemia) cell lines is 
associated with changes in hsp60, hsp70 and hsp90 expression (Mivechi et al., 1994). 
It was also established at this time, that hsp70 expression is regulated throughout the 
cell cycle in normal cells and involves interaction of hsp70 with specific proteins at 
specific points in the cell cycle (Pelham, 1986). The identity of these proteins 
associated with hsp70 was unknown, and this remains largely unclear today, although 
it appeared likely that these were cell cycle-specific growth regulatory factors. One 
such factor, which was known to interact with hsp70, is the protein product of the 
tumour suppressor gene, p53. Research into the biology and function of p53 protein 
has proliferated over the last decade, not least because it has been found that mutations 
within the p53 gene represent the most common genetic abnormalities found in human 
cancers to date (Lane, 1994). Roles for p53 have been identified in a number of central 
cellular processes, including cell cycle regulation, DNA repair, and control of 
apoptosis following genetic injury (reviewed by Ko and Prives, 1996, and see 
Introduction, section 1.2). What was most exciting in terms of this project, is the fact 
that the formation of hsp70/p53 complexes is an association which modulates the 
function of p53 (Hupp et al., 1992). It was intriguing that abnormal levels of hsp 
expression had been reported in virally- and chemically-transformed cells (Finlay et al., 
1988), as well as in some human tumour cell lines (Ferrarini et al., 1992). One of the 
hypotheses upon which this project developed was therefore the possibility that hsps 
play an indirect role in the control of cellular differentiation via their ability to interact 
with proteins which have a direct regulatory role. Thus, could the abnormal levels of 
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hsp expression seen in some tumour cells play a role in tumourigenesis via 
dysregulation of the normal growth/differentiation processes, or are they simply a 
reflection of the malignant phenotype of these cells? In order to address this question, 
the expression of three major hsp families, hsp6O, hsp70 and hsp90 was analysed 
by 
immunochemical means in leukaemic cells collected from patients presenting with a 
variety of haematopoietic malignancies. This analysis determined the localisation of 
hsp 
expression as well as the levels of each of these hsp families in normal and 
leukaemic 
cells. 
The second major aspect of hsp expression in leukaemia addressed in this work 
concerns the relationship between hsp expression and apoptosis. Apoptosis 
(programmed cell death) is a homeostatic mechanism inherent to all cell types, which is 
responsible for the maintenance of cell numbers within a tissue. There is a fine balance 
between the opposing forces of growth/proliferation and cell death via apoptosis, and a 
number of genetic lesions have been identified which impinge upon both these 
processes. Many of these lesions are strongly implicated in carcinogenesis. Apoptosis 
is also a critical component of the cellular response to injury in both normal and 
malignant cells, and this clearly has implications towards the treatment of cancers since 
most, if not all, chemotherapeutic drugs exert their effects via the induction of 
apoptosis (reviewed by Lyons and Clarke, 1997). 
What is the relevance of hsp expression in terms of the regulation of apoptosis? The 
evidence available during the early stages of my work suggested that hsp expression 
may be integrally linked to apoptosis in two ways. Firstly, the protective nature of hsps 
may prevent apoptosis in response to cellular injury, and this may have implications for 
the unwanted survival of leukaemic cells during chemotherapy. Secondly, the balance 
between cell growth/differentiation and apoptosis may be controlled by the interaction 
of hsps with regulatory factors involved in both processes, a point which was 
emphasised earlier in this section with relation to the roles of p53 protein. The role of 
hsp expression in the cellular response to stress is well established; over-expression of 
hsps protects cells against the deleterious effects of a variety of cellular insults, and this 
includes both environmental and pathophysiological agents which are known to induce 
apoptosis. For example, hyperthermia induces apoptosis in a variety of cell systems, 
and this can be inhibited by overexpression of hsps either by a prior sub-lethal heat 
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shock, or by transfection of cell lines with hsp-encoding genes, including both hsp70 
and hsp25 (Li et al., 1996). Other reports in the literature which suggest that lisps may 
influence apoptosis include the observation that hsp70 expression affects apoptosis 
induced by quercetin, a bioflavanoid, in leukaemic cell lines ( Wei et al., 1994), hsp70 
protects cells against apoptosis induced by tumour necrosis factor (Jaatela et al., 
1992), and the induction of hsps by mild heat shock protects th)mocytes against 
glucocorticoid-induced apoptosis (Miglioroti et al. 1992). These observations suggest 
that hsp expression in tumour cells may be extremely important in protecting them 
against apoptosis, induced for example by hypoxia or by cytolytic immune 
mechanisms. Furthermore, the induction of hsp expression may protect cells against 
cytotoxic drugs used in the treatment of cancers. It is recognised that most, if not all, 
cytotoxic drugs used in the treatment of cancers exert their effects via the induction of 
apoptosis, and the inherent propensity of a malignant cell to undergo apoptosis is 
therefore a major determinant of the success of chemo-therapeutic regimens. The 
hypothesis upon which I worked was that leukaemic cells may be able to mount a 
stress response following exposure to cytotoxic drugs, involving the induction of lisps. 
This may protect them against the deleterious effects of cytotoxic drugs, and would 
therefore be an important mechanism leading to the development of chemoresistance. 
During the early stages of this project it was known that exposure of human tumour 
cell lines to at least one cytotoxic agent, bischloronitrosourea (BCNU), induces hsps 
(Kroes et al., 1991), suggesting that they may indeed be an important mechanism of 
resistance to standard chemotherapy. 
To summarise, the study of lisp expression in relation to apoptosis in leukaemic cells 
was considered from two mutually exclusive standpoints: (1) dysregulation of 
apoptotic pathways, or failure to activate apoptosis in response to genetic injury, is 
generally accepted to be a route towards carcinogenesis, and (2) hsp-mediated 
inhibition of apoptosis induced by cytotoxic drugs may be a factor in the development 
of chemoresistance. 
In this brief introduction, I have attempted to outline how the aims of this work were 
formulated in the context of the available knowledge concerning the possible 
relationship between hsp expression and apoptosis. This clearly has associated 
implications for leukaemogenesis and the treatment of haematological malignancies. At 
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the outset of these investigations, no publications existed in the literature which 
examined the expression of hsp in primary leukaemia cells, only a few reports which 
described patterns of hsp expression in haematopoietic cell lines, particularly in terms 
of the differentiation of these cells. It was therefore an original line of investigation 
which, as will become clear during the discussion of my results, evolved via an 
elementary examination of hsp expression in leukaemic cells towards an Livestigation 
of the possible relevance of hsp overexpression. 
7.2 Localisation of hsp in normal and leukaemic 
haematopoietic cells 
7.2.1. Cell surface expression of heat shock proteins. 
The cellular localisation of lisp is generally considered to be intracellular, confined to 
the cytoplasmic compartment under normal conditions of growth. The specific 
localisation of major hsps presumably reflects their role as molecular chaperones 
(reviewed by Scwarz et al., 1996; Lund, 1995). However, at the outset of these 
investigations, conflicting reports existed in the literature regarding the existence of 
hsp expression on the cell surface membrane. Some authors had found no evidence of 
surface expression (Ferm et al., 1989), whilst others had reported surface expression 
on certain cells. For example, human y/S T cells express a cell surface antigen which is 
recognised by a monoclonal antibody to hsp58 (P1), the human homologue of the 
Escherichia coli groEL protein (Jarjour et al., 1990). Also, murine bone marrow- 
derived macrophages have been shown to express an epitope which is recognised by 
ML30, a monoclonal antibody which has specificity for mycobacterial hsp60 (Wand- 
Wiirttenberger et al., 1991), and surface expression ofhsp72, the inducible form of 
hsp70, has been reported on some tumour cell lines and fresh tumour cells (Ferrarini et 
al., 1992). At this time, the significance of surface lisp expression in these cells 
remained unclear, but the possibility that cell surface expression of hsp may be a 
marker of the malignant phenotype in leukaemic cells required investigation, since 
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there were no reports in the literature concerning the specific localisation of hsps in 
primary haematopoietic cells. 
As presented in Chapter 3, repeated experiments based upon immunofluorescent 
staining and flow cytometric analysis of a variety of primary leukaemia cells revealed 
no detectable expression of any of the major hsp families on the surface of these cells. I 
examined cells from 16 patients with acute myeloid leukaemia (AML), as well as 6 
patients with acute lymphoblastic (ALL) and 4 patients with B-cell chronic 
lymphocytic leukaemia (B-CLL), a total of 28 individuals. Even using the most 
sensitive avidin-biotin procedure, I found no evidence of specific cell surface staining 
for hsp90, hsp72/73 or ML30-reactive epitopes. Having carefully analysed cells from 
such a relatively large number of leukaemic patients, it was decided that cell surface 
expression of lisp is not a feature of leukaemia cells. However, I also considered the 
possibility that cell surface expression of lisp may be a marker of stress. The effect of a 
hyperthermic shock on leukaemic cells was therefore analysed in order to determine 
whether such a cellular stress could induce lisp expression on the surface of AMI, cells. 
Cells from 6 patients with AML, as well as normal peripheral blood mononuclear cells 
from 4 healthy individuals were exposed to hyperthermic stress (42 ° C, 30 min. ), and 
stained as before using monoclonal antibodies to ML30, hsp90 and hsp72/73. In 
addition, they were also stained with an antibody specific to the highly heat-inducible 
hsp72 protein. Again, repeated experiments failed to demonstrate the induction of lisp 
expression at the cell surface. In addition to primary leukaemia cells, I also analysed 
four haemopoietic cell lines, KU812 (myeloid), KG1a (myeloid), THP-1 
(myelomonocytic), and HL-60 (promyelocytic) for evidence of hsp expression on the 
cell surface. Again, no specific staining was evident using any of the 4 monoclonal 
antibodies described, either under conditions of normal growth or following heat 
shock. The data indicates that lisps are expressed infrequently, if ever, on the surface 
of leukaemic cells. 
During the course of these investigations, several new reports have appeared in the 
literature which suggest that hsp expression occurs on the cell surface membrane of 
some tumour cells, and the possible biological significance of this has been investigated 
by one group of investigators in particular. Multhoffet al. (1995) have reported that 
the highly stress-inducible hsp72 antigen is found on the surface of some tumour cells, 
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including Ewing's sarcoma and osteosarcoma cells, following a non-lethal heat shock. 
Similar treatment of normal cells, including peripheral blood lymphocytes and 
fibroblasts derived from healthy volunteers, did not result in accumulation of hsp72 at 
the cell surface. The authors suggested that this difference between tumour cells and 
normal cells may provide a means by which to elicit a stress-inducible immune 
response which specifically targets tumour cells. Recent reports from the same 
laboratory have described cell surface expression of hsp72 on a variety of tumour cells 
following non-lethal heat shock. These include a human lung carcinoma cell line 
(Botzler et al., 1996), a colonic carcinoma cell line (Multhoff et al., 1997) and also, 
interestingly, on a myeloid leukaemia (K562) cell line (Multhoff, 1998). In the latter 
case, they demonstrated that heat shock-induced cell surface expression of hsp72 was 
associated with an increased sensitivity of K562 cells to lysis mediated by natural killer 
cells, thus reinforcing their earlier assertion that cell surface expression of lisp may be a 
tumour-specific immunogenic determinant. 
This final observation leads me on to an interesting postscript regarding the possibility 
of lisp expression on the surface of leukaemic cells. Although I have been unable to 
demonstrate any evidence of surface hsp expression in either normal or leukaemic 
haemopoietic cells, I have recently examined the role of lisp expression and 
mechanisms of apoptosis in myeloma cell lines. These experiments have investigated 
the influence of lisp expression on the susceptibility of myeloma cell lines to apoptosis, 
induced by both cytotoxic drugs and a bacterial toxin, verocytotoxin. As part of this 
investigation, I have looked for surface expression of lisp, and preliminary experiments 
have indicated that apoptotic cells do in fact express both hsp70 (the specific heat- 
inducible hsp72) and hsp90 on the cell surface. In these experiments, the induction of 
apoptosis by the cytotoxic agent, bischloronitrosourea (BCNU), was demonstrated by 
increased annexin V binding, which was evident on myeloma cells at approximately 6 
hours after the addition of BCNU. Double labelling of these cells, revealed that early 
apoptotic cells, which were identified by annexin V binding, expressed hsp72 and 
hsp90 on the cell surface. At this stage, the significance of these observations remains 
unclear, although it is feasible that lisp may have a functional role in the apoptotic 
process. It is possible that these hsp function as direct antigenic determinants which 
act as an apoptotic `flag' and a signal to neighbouring phagocytic cells. There is a 
precedent for this hypothesis in the expression of ubiquitin, which itself can be 
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classified as an hsp since it is induced by hyperthermia, and is well known to act as a 
flag to phagocytic cells. Alternatively, hsp may be functioning as molecular chaperones 
by interacting with other cellular protein(s) which are transported to the cell surface 
during the apoptotic process. The observations by Multhoffs group concerning stress- 
induced surface hsp expression along with my observations that apoptotic cells express 
hsp72 and hsp90 on the cell surface, demands a re-investigation of the potential role of 
lisps in leukaemia cells. It would therefore be interesting to re-analyse leukaemic cells 
following stresses known to induce apoptosis. 
7.2.2. Localisation of hsp by immunocytochemical staining. 
Expression of all the major hsp families appears to be generally confined to the 
cytoplasmic compartment of cells, and their specific sub-cellular localisation under 
conditions of normal growth presumably reflects their role as molecular chaperones. 
Following heat shock, members of the hsp family are rapidly translocated to the 
nucleus where their major role is to prevent the aggregation of damaged and unfolded 
proteins within the nucleus. This is an example of how hsp distribution may be altered 
in response to specific cellular circumstances. At the outset of this project, there was 
no evidence to suggest that the intracellular distribution of hsps altered during different 
phases of the cell cycle. However, the original observation by Pelham (1986) that 
hsp70 interacts with a variety of different proteins during different phases of the cell 
cycle, suggests that hsp localisation during growth and proliferation may change 
according to the nature of hsp: protein interactions. Again, the established finding that 
hsp70 can bind to p53 protein suggests an important mechanism by which it could 
regulate the accumulation or localisation of this tumour suppressor protein. Thus, it 
was hypothesised that the distribution of hsp, in particular hsp70, may reflect the 
malignant phenotype or growth characteristics of the leukaemic cell. 
In Chapter 3, the results of an immunocytochemical analysis of both normal and 
malignant haematopoietic cells is presented. Examination of immunoperoxidase-stained 
cytospins of normal mononuclear cells demonstrates that these cells express detectable 
levels of hsp6O, hsp70 and hsp90 in the absence of stress. No nuclear localisation was 
evident in any of the preparations from ten normal individuals. In each case, hsp60, 
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hsp70 and hsp90 were immunolocalised within the cytoplasm, as evidenced by a 
diffuse cytoplasmic staining pattern. The expression of the tumour suppressor gene 
product, p53, was also analysed in these cells and no evidence of cytoplasmic or 
nuclear p53 accumulation was evident by immunoperoxidase techniques. The 
finding 
that normal mononuclear cells constitutively express detectable levels of hsp, even in 
the absence of any stress, reflects the importance of these molecules as molecular 
chaperones. 
Stimulation of normal peripheral blood lymphocytes with the mitogens concanavalin A 
or pokeweed mitogen induced transformation and proliferation with an associated 
upregulation of hsp70 and hsp90. As outlined in the Introduction (Section 1.1.6), a 
link between hsp expression and cell growth and differentiation is suggested by a 
number of reports which describe changes in hsp expression during the growth and 
differentiation of haemopoietic cell lines (e. g Galea-Lauri et al., 1996, Mivechi et al., 
1994). In my analysis of mitogen-stimulated lymphocytes, the expression of hsp in 
these cells was predominantly cytoplasmic, although hsp72/73 was also localised 
within the nucleus. It is therefore interesting to note that p53 staining of mitogen- 
stimulated lymphocytes revealed nuclear accumulation of this tumour suppressor gene 
product. This finding may be significant in terms of the relationship between hsp70 and 
p53, and may have relevance to the proliferation of haemopoietic cells. For example, it 
has been reported that wild-type p53 protein in AML cells switches to a mutant 
conformation in response to growth factor stimulation, leading to the suggestion that 
conformational changes in normal p53 protein represent an important mechanism for 
the regulation of cell proliferation (Zhang and Deisseroth, 1994). Further evidence to 
support this theory comes from the observation that different conformations of p53 
protein in AML cells relate to the in vitro growth characteristics of the cells, and this 
can be regulated by either exogenous or autocrine haemopoietic growth factors (Zhu 
et al, 1993). 
Leukaemic cells from AML patients express significant levels of hsp60, hsp70 and 
hsp9O in the absence of stress. Light microscopy of immunperoxidase-stained 
cytospins revealed that the expression of all three hsp was predominantly cytoplasmic. 
In fifteen of sixteen cases, no nuclear staining was evident with any of the three hsp 
monoclonal antibodies. However, in one patient, a strong pattern of nuclear staining 
for hsp72/73 was evident in the myeloblasts. These cells also exhibited cytoplasmic 
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accumulation of hsp72/73, but the nuclear staining was more intense. Furthermore, 
immunoperoxidase staining with an antibody to p53 of cytospins from the same patient 
revealed significant nuclear expression of this tumour suppressor gene product, whilst 
immunostaining of the cells from all fifteen other AML patients revealed no significant 
staining for p53, either cytoplasmic or nuclear. This nuclear co-localisation of 
hsp72/73 and p53 is interesting since these cells were from a patient whose disease had 
undergone a second relapse and had become particularly resistant to chemotherapy. It 
is tempting to speculate that this co-localisation of hsp70 and p53 has some 
significance in terms of the profound clinical drug resistance which was observed in 
this one patient. It is well established that p53-dependent mechanisms of apoptosis are 
involved in cytotoxic drug-induced cell death (reviewed by Bellamy, 1997). Could the 
co-expression of high levels of nuclear hsp70 and p53 reflect an interaction between 
the two which is modulating the normal function of p53 protein and therefore affecting 
the induction of apoptosis by chemotherapeutic agents? The relevance of this 
observation is uncertain, and since it was only apparent in this one patient, it is 
impossible to definitively ascribe a clear association between nuclear co-localisation of 
hsp72/73 and p53 with any clinical parameters such as drug resistance or tumour 
aggressiveness. 
At the time of writing, no reports exist in the literature which describe localisation of 
hsp70, or any other hsp, in leukaemia cells. However, there are publications in which 
the prognostic significance of hsp70/p53 expression in a variety of human tumours has 
been analysed. A significant correlation between hsp70 expression and high levels of 
p53 has been reported in endometrial carcinomas, and this was associated with poorly 
differentiated carcinoma (Nanbu et al., 1996), whilst a significant number of malignant 
oral lesions are characterised by the presence of hsp70/p53 complexes as determined 
by co-immunoprecipitation (Kaur et al., 1996). In a large study of 169 patients with 
breast tumours, nuclear accumulation of p53 by immunocytochemistry was shown to 
be associated with a poor clinical outcome, but there was no association between 
either cytoplasmic or nuclear hsp70 staining and accumulation of p53 protein. In fact, 
hsp70-positive tumour cells predicted a better overall survival (Elledge et al., 1994). 
The prognostic significance of hsp70/p53 interactions obviously still remains unclear. 
Clearly, it would be desirable to investigate this further, and a much larger sample of 
AML patients including a larger number with drug resistant malignant cells would be 
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required. In order to address this, cells from AML patients continue to be harvested at 
Warwick Hospital so that a larger study may shed light on any potential association 
between hsp/p53 localisation and drug resistance. 
7.3. Cytoplasmic expression of heat shock proteins in haematopoietic 
cells. 
Having established that cellular localisation of lisp expression in haematopoietic cells 
is, with the one exception in the patient with drug-resistant AML, confined to the 
cytoplasm, the next stage in my investigation was to quantify levels of the major hsp 
families in both normal and leukaemic haematopoietic cells. In Chapter 4, the results of 
an analysis of hsp expression in normal mononuclear cells and cells from both chronic 
and acute myeloid leukaemia patients is presented. In normal peripheral blood 
mononuclear cells (PBMC), the expression of hsp60, hsp70 (72/73) and hsp90 can all 
be detected by indirect immunofluorescence using monoclonal antibodies against these 
three major heat shock protein families. Fluorescence profiles for these cells 
demonstrate a relatively homogeneous pattern of hsp expression with no large 
differences apparent between lymphocytes and monocytes from the same individual, 
evidenced by a single narrow peak of staining, or between the mononuclear fraction of 
the ten healthy individuals examined. 
The expression of all three heat shock proteins examined is clearly elevated in 
leukaemic cells and more heterogeneous than is observed in normal PBMC. In AML 
cells, significantly higher levels of all three hsp families were evident compared with 
either normal PBMC or CML cells. Both AML and CML cells exhibit a wide range of 
hsp expression, not only between individual patients, but within the groups as a whole. 
The significance of these differences in hsp expression is not clear, but several 
explanations are possible. The first, and possibly most plausible explanation, is that hsp 
levels are a marker of the differentiation state of these cells. Decreased expression of 
hsp70 and hsp90 is associated with myeloid differentiation of HL-60 cells (Beere et al, 
1993, Yufu et al, 1989, Shakoori et al, 1992), and levels of hsp60 mRNA decrease 
during TPA-induced differentiation of HL-60 or K562 cells (Lu & Seligy, 1992). A 
further indication of the association between hsps and differentiation is the observation 
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that heat shock itself, or chemical agents which elicit a heat shock response, induce 
differentiation of HL-60 cells (Richards, 1988). The large differences in hsp levels 
between AML cells, which are predominantly immature myeloblasts, and CML cells, 
may therefore be due to simple differences in the stages of myeloid differentiation 
between the cells. If this is the case, the heterogeneity seen in AML cells could imply 
. 
hat some myeloblasts are more mature and the possibility that hsp levels could be a 
marker of differentiation state in ANTI, demands further investigation. Also, therapy 
aimed at inducing differentiation, e. g the retinoids, would be expected to drive towards 
lower levels of hsp expression. 
A second explanation is that hsp expression is a marker of cell proliferation. By virtue 
of their role as molecular chaperones, hsps perform a perform a variety of roles which 
could be utilised in a developmentally regulated manner to control proteins necessary 
for cell growth and proliferation (Pechan, 1991). Hsp expression has been shown to be 
regulated by mitogenic stimuli in a variety of cell types, including haematopoietic cells 
(Ferris et al, 1988, Fincato et al, 1991), and my investigations revealed that 
immunoperoxidase staining and flow cytometric analysis of concanavalin A and 
pokeweed mitogen-stimulated lymphocytes demonstrated markedly increased levels of 
hsp70 and hsp90 (see Results, Chapter 4). 
Immunofluorescent histograms of CML patients demonstrated in some cases two 
distinct peaks suggesting that the presence of immature and more differentiated 
myeloid cells expressing high and low levels of hsp respectively. However, in some 
AML cells where morphologically the cells were homogenous and virtually all 
immature myeloblasts, two distinct populations were evident for hsp90 expression. 
This may represent the presence of an actively proliferating population of cells which 
have a distinct level of hsp90 expression., although this would seem unlikely since the 
proliferating compartment of leukaemias, like most other cancers, is represented by a 
very small percentage of the overall population of tumour cells. In these cases, it may 
be more likely that this dual pattern of hsp90 expression is the result of a biphenotypic 
leukaemia, a situation which arises when leukaemic transformation gives rise to the 
clonal proliferation of two populations which may represent different stages of myeloid 
differentiation. 
Although leukaemic cells from different patients showed marked differences in levels 
of expression, no correlation was observed in the expression of the different hsp 
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families. For example, those cells expressing the highest levels of hsp70 did not have 
the highest levels of hsp60 or hsp90. This suggests that individual hsp families play 
different roles with relation to the control of cell growth and differentiation, probably 
via their interaction with distinct protein substrates within the cell. Although all heat 
shock proteins have similar modes of action in terms of their `molecular chaperone' 
function, they have exclusive roles to play in terms of specific interactions with cellular 
proteins. 
An important feature of the pattern of hsp expression in leukaemic cells, and in 
particular those from AML patients, is the wide range of hsp expression in cells from 
individuals with the same diagnosis. Analysis of the clinical data from these patients, in 
terms of survival, drug therapy and the stage of the disease, revealed no apparent 
correlation with the level of hsp expression. At this stage, it is not evident whether the 
high levels of hsp expression in AML simply represent the malignant phenotype of 
these cells, i. e. their lack of myeloid differentiation, or whether elevated hsp expression 
has a biological role, particularly in terms of the response to chemotherapy. 
As outlined in the introduction, hsp induction in response to a variety of environmental 
insults appears to afford cells a protective effect. Do the elevated levels of these 
proteins therefore provide leukaemic cells with a survival advantage which may relate 
to altered proliferative potential of the malignant clone? Furthermore, how do levels of 
hsp expression relate to the susceptibility of cells to drugs used in the standard 
treatment of these malignant disorders? 
In order to address these questions, apoptosis of AML cells was studied following the 
withdrawal of growth factors, i. e by culturing cells in the absence of serum. 
7.4. Hsp expression and the susceptibility of AML cells to 
apoptosis induced by serum withdrawal. 
The results presented in Chapter 5 demonstrate that AML cells undergo apoptosis 
when cultured in vitro in the absence of added serum, i. e. in the absence of exogenous 
viability factors. There is however, a marked variation in the rate of apoptosis of AML 
cells from different patients, and indeed variation between samples taken on different 
occasions from the same patients. Analysis of the results found no correlation between 
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the susceptibility of AML cells to apoptosis and patient survival, nor is there a 
relationship with clinical drug resistance. In addition, there is no obvious correlation 
between the rate of apoptosis and whether the cell sample was taken at presentation or 
at relapse. 
However, when the rate of apoptosis in vitro was compared with the expression of 
hsp70 in the AML cells upon isolation, it is clear that there is a highly significant 
correlation between the two in two independent series of AML cell samples. Thus, 
although hsp70 expression protects cells against apoptosis induced by a variety of 
agents, it appears that there is an inverse relationship between the level of hsp70 and 
the rate of apoptosis induced by withdrawal of growth factors in these AML cells. This 
paradoxical finding is in contrast to the initial expectations at the outset of this 
investigation. 
Two factors which are widely regarded as playing important roles in apoptosis are p53 
and bcl-2. The former is thought to initiate apoptosis, at least where this is induced by 
DNA damage, and the latter to protect. In my studies, p53 was weakly and 
inconsistently expressed in AML cells. Although p53 expression was not reliably 
quantified, there did appear to be some correlation between p53 and apoptosis. Those 
cells expressing the highest levels of p53, as determined by flow cytometric analysis, 
also appeared to express high levels of hsp70, and in turn be more susceptible to 
apoptosis. Expression of bcl-2 did demonstrate a negative relationship with the 
susceptibility to apoptosis suggesting that bcl-2 may play some role in the protection of 
AML cells against apoptosis, although this correlation was not statistically significant. 
A large number of studies have examined the expression of both bcl-2 and p53 in a 
variety of human tumour types, including haematopoietic cells. For example, the 
susceptibility of a myeloid leukaemia cell line (M1) to apoptosis induced by the 
chemotherapeutic agents, methotrexate and verapamil, is associated with high levels of 
bcl-2 expression (Lotem and Sachs, 1993), whilst bcl-2 protein expression and p53 
gene mutation in chronic lymphocytic leukaemia (CLL) is associated with in vitro 
sensitivity to chemotherapeutic agents and disease progression (Morabito et al., 1997; 
Agelar-Santelises et al., 1996). Banker et al., 1997, recently analysed spontaneous and 
drug-induced apoptosis in AML cells, demonstrating variable levels of spontaneous 
apoptosis in cells from a large sample of 56 de novo AML patients. Immunofluorescent 
analysis of bcl-2 protein expression revealed that cells expressing the highest levels of 
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bcl-2 protein show low levels of apoptosis, but reduced apoptosis was seen in both the 
presence and absence of bcl-2 overexpression. No association between levels of bc1-2 
and the susceptibility of cells to drug-induced apoptosis was noted, and there was no 
correlation between the susceptibility of cells to spontaneous or drug-induced 
apoptosis and disease progression. These results, plus those I present in this thesis, 
suggest that there is no clear association between in vitro measurements of apoptotic 
susceptibility and clinical parameters in AML cells. 
I also analysed hsp70 expression and susceptibility to apoptosis in a longitudinal study 
examining cells harvested from three patients with chronic myeloid leukaemia (CML) 
who eventually transformed to acute AML. In most patients with CML, the leukaemia 
presents as two distinct clinical phases: the chronic phase during which there is a 
proliferation of the myeloid lineage, but there is a normal differentiation capacity 
resulting in the appearance of cells in the peripheral blood representing all stages of 
myeloid differentiation, from immature myeloblasts through to mature granulocytes. 
All patients eventually transform to an acute phase of the disease, and this is associated 
with a differentiation block and therefore accumulation of myeloblasts (reviewed by 
Guinn and Mills, 1997). It was therefore interesting to examine whether hsp expression 
and levels of in vitro apoptosis changed during disease progression. My results 
demonstrated that in all three patients, levels of hsp60, hsp70 and hsp90 were higher in 
individual patients' cells following transformation to the acute disease. I found that p53 
expression was unaltered in all three patients in the CNL to AML transformation, but 
in vitro susceptibility to apoptosis increased in 2/3 patients following transformation. 
These results suggest that hsp expression is higher in AML cells due to the 
undifferentiated state of these cells in comparison to CML cells, and, again, higher 
levels of hsp expression were associated with enhanced susceptibility to apoptosis. 
Although I demonstrated no change in p53 protein levels in these three patients, it has 
been reported that p53 mutations and/or accumulation of p53 protein is associated 
with the progression of CML (Guinn and Mills, 1997; Guerrasio et al., 1997). 
The question which arises from these results is whether hsp70 itself plays a role in 
apoptosis, or if high levels of hsp70 simply reflect that the most susceptible cells are 
already `stressed' and therefore more susceptible to a further insult such as removal of 
viability factors. However, if this were the case it would be expected that hsp90, 
another stress protein, would also correlate with apoptosis, and this did not appear to 
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occur. If the association of hsp70 elevation with apoptosis is not merely coincidental, 
either its importance is through interaction with the p53 pathway or else through an 
independent pathway. 
Of particular interest in this context is the observation that constitutive members of the 
hsp70 family (hsc70) interact with the product of the p53 tumour suppressor gene. The 
biological significance of hsp70-p53 complexes is poorly understood, although it has 
been shown that binding of hsp70 could be part of a regulated process leading to 
changes in p53 conformation. According to this hypothesis, hsp70 regulates folding 
from mutant , with promoter 
function, to wild-type conformation which has suppressor 
function. (Hainaut & Milner, 1992). Further evidence of this relationship between 
hsp70 and p53 is suggested by the report that mutant p53 proteins can transactivate 
the hsp70 gene promoter (Tsutsumiishii et al. 1995). 
Hsp70 appears to play a role in the balance between control of cell growth and 
differentiation, and loss of cells via apoptosis. My finding that AML cells which 
express high levels of hsp70 are more susceptible to apoptosis is paradoxical in view of 
the protective nature of hsp, although it has been shown that HL60 cells treated with 
N-methylformamide (NMF) will differentiate or undergo apoptosis according to the 
concentration of NMF used, and that differential expression of hsp70 correlates with 
the path taken (Beere et al, 1993). Differentiation is associated with decreased levels 
of hsp70, while the induction of apoptosis by higher levels of NMF correlates with 
maintainance of hsp70 levels. The authors of this report suggest that hsp70 acts, 
similar to p53, as a cellular `sensor' permitting the cell to discriminate between 
different levels of cellular damage, and is therefore a key mediator in the response to 
drug-induced damage. 
In order to examine how hsp expression influences the response of the leukaemic cell 
to potentially lethal damage, the next stage of my research was to examine the 
response of myeloid leukaemia cell lines to heat shock and the induction of apoptosis 
by cytotoxic drugs used in the treatment of leukaemia. This analysis includes the 
question of how levels of hsp relate to the induction of apoptosis in myeloid cells, and 
how high levels of hsp induced by hyperthermia influence the susceptibility of these 
cells to apoptosis induced by other means, in particular via chemotherapeutic agents. 
176 
7.5. The heat shock response and apoptosis in myeloid 
leukaemia cell lines. 
7.5.1. Hyperthermia induces hsp expression in myeloid cell lines. 
In Chapter 6, the results of an analysis of the heat shock response in myeloid leukaemia 
cell lines is presented. Analysis of the kinetics and magnitude of the heat shock 
response following hyperthermic treatment revealed that in all cell lines, hsp25, hsp70 
and hsp90 were induced by sub-lethal heat shock (42° C, 30 min. ). Furthermore, in 
two myeloid cell lines, KG1a and KU812, hyperthermia induced an increase in the 
levels of p53 protein. This is interesting because hypoxia, a recognised inducer of the 
heat shock response, also induces accumulation of p53 protein, (Graeber et al., 1994), 
demonstrating that mechanisms other than DNA damage can affect the expression of 
p53. This, together with my finding that heat shock induces p53 expression, suggests 
that both the heat shock response and p53 induction share, at least in part, some 
common signalling pathway. 
Having elucidated the kinetics of the heat shock response, the effect of serum 
withdrawal on myeloid cell lines was investigated. My earlier results with primary 
AML cells showed that high levels of hsp70 expression correlated with increased 
susceptibility to apoptosis following culture in the absence of exogenous growth 
factors, i. e. no added foetal calf serum (FCS). Four myeloid leukaemia cell lines, 
KU812, KG1a, TIP-1 and HL-60, were used to investigate the effect of 
hyperthermia-induced overexpression of lisps on the susceptibility of cells to undergo 
apoptosis during culture in the absence of FCS. As expected, all four cell lines were 
induced to undergo apoptosis following resuspension in RPMI 1640 culture medium 
with no added FCS, but it was found that high levels of hsp expression following 
hyperthermia had no effect on the rate of apoptosis as compared with control cells 
maintained throughout at 3711C. Thus, overexpression of hsp does not protect against 
this model of apoptosis. Interestingly, a mild sub-lethal heat shock protects neuronal 
cells against apoptosis induced by subsequent severe thermal stress, but it does not 
protect the same cells against apoptosis induced by withdrawal of nerve growth factors 
177 
(Wyatt et al., 1996). The mechanism of apoptosis effected by removal of viability 
(growth) factors therefore appears to differ from apoptosis induced by a variety of 
other agents where hyperthermic induction of hsp expression is protective. These 
include the protection of thymocytes against radiation-induced apoptosis (Gordon et 
al., 1997), inhibition of apoptosis induced by both TNF-a and monocyte cytotoxicity 
in Wehi-s fibrosarcoma cells (Jaatela and Wissing, 1993), and the protection of murine 
L929 cells against apoptosis induced by Fas/APO-1 (Mehlen et al., 1996). 
7.5.2. Overexpression of hsp induces chemoresistance in myeloid 
leukaemia cell lines. 
One of the most important aims of this research was to establish whether hsp 
overexpression in tumour cells could play a role in the development of 
chemoresistance by protecting these cells against apoptosis induced by 
chemotherapeutic agents. Hyperthermic induction of hsps was therefore used as a 
model to investigate the influence of hsp lexpression on susceptibility to cytotoxic 
drugs. Apoptosis was induced in all myeloid leukaemia cell lines by the cytotoxic 
agents, bischloronitrosourea (BCNU), vincristine, cytosine arabinoside, and 
doxorubicin, four drugs with different primary modes of action. These experiments 
also revealed that exposure of myeloid cell lines to BCNU, vincristine and doxorubicin 
results in an increase in hsp72/73 expression, agreeing with the earlier reported 
observation that BCNU induces hsp70 expression (Kroes et al., 1991). This finding 
suggests that leukaemic cells mount a stress response following exposure to 
chemotherapeutic agents, which because of the established protective nature of hsp 
may suggest an important role in protecting leukaemic cells and therefore 
counteracting the efficacy of chemotherapeutic regimens. However, as described in 
Chapter 6, the induction of hsp expression by BCNU only appeared to occur following 
exposure to lethal concentrations of the cytotoxic drug, suggesting that rather than 
affording a demonstrable degree of protection, these elevated levels of hsp72/73 
observed represent an abortive stress response prior to the onset of apoptosis. As 
demonstrated It was therefore interesting that induction of the heat shock response 
induced resistance to BCNU in all cell lines tested. Although it is known that p53 
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overexpression plays a role in the apoptotic response to cytotoxic drugs, my finding 
that resistance to apoptosis occurred following hyperthermia in THP-1 cells, in which 
p53 expression remained unaltered, and in HL-60 cells which have a large deletion in 
the p53 gene, suggests that this resistance occurred via p53-independent mechanisms. 
In these myeloid cell lines, hyperthermia-induced resistance to apoptosis also appeared 
to be independent of bcl-2 expression, since hyperthermia did not alter the levels of 
bcl-2 protein expression. 
The potential involvement of hsp in protecting tumour cells against apoptosis induced 
by chemotherapeutic agents is suggested by data which shows that elevated hsp 
expression is associated with chemoresistance both in human tumours (Ciocca, 1993). 
Similar observations have been made in experimental models; in heat-shocked rat 
tumour cells the induction of hsp70 is associated with vincristine resistance (Lee et al, 
1992) while Chinese hamster cells over-expressing the human hsp70 gene are more 
resistant to a variety of cytotoxic agents (Huot et a1,1991). 
During the course of this research, a number of reports have also highlighted the 
potential role of hsp as mediators of chemoresistance. Hyperthermic treatment of 
Ehrlich ascites tumour cells resulted in resistance to vinblastine. Cycloheximide 
prevented the acqisition of the resistance suggesting that de novo synthesis of hsp is 
involved in this resistance (Gabai et al., 1995). Transfection of Wehi-s fibrosarcoma 
cell line with the human hsp25 or hsp70 gene conferred resistance to 
chemotherapeutic agents including camptothecin, etoposide and actinomycin-D 
(Samali and Cotter, 1996) 
Elevated hsp25 levels in CHO cells and a melanoma cell line associated with resistance 
to cisplatin (Wachsberger et at, 1997), hsp70 and hsp25 overexpressed in a cisplatin- 
resistant human ovarian cancer cell line . Much lower levels of these hsp in non- 
resistant parental line. showing cross-resistance to adriamycin, vincristine and 
etoposide Hyperthermia further enhanced the drug resistance and induced resistance in 
parental cell line (Kamishima et al., 1997) 
Taken together with these observations, my finding that high levels of hsp following 
hyperthermia protect myeloid cells against cytotoxic drug-mediated apoptosis suggests 
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that hsp expression expression in myeloid cells influences their susceptibility to 
apoptosis . 
In view of the variable levels of hsp70 found in AML cells, as reported in 
Chapter 4, this suggests that hsp expression in leukaemia may have some prognostic 
significance. Although I have been unable throughout the course of this project to 
demonstrate a clear relationship between hsp expression and clinical factors such as 
1jatient survival or drug resistance, as discussed earlier other workers have reported a 
correlation between hsp expression (particularly hsp70 and hsp25) and prognosis, in a 
variety of malignancies. Clearly, the question of whether hsp levels influnce the 
efficacy of chemotherapy and/or the aggressiveness of the disease in leukaemia 
demands further investigation. Analysis of a larger group of patients with myeloid 
malignancies would therefore be worthwhile. 
7.6. Summary: What is the relationship between heat shock 
protein expression and apoptosis? 
In Chapter 5, it was demonstrated that hsp70 expression correlated with the 
susceptibility of cells from patients with AML to apoptosis induced by serum 
starvation. This suggests that hsp70 may play a role in the regulation of apoptosis, 
either as a direct factor influencing the outcome of pro-apoptotic signals, or indirectly 
via interaction with other factors involved in the regulation of this process. 
I have found that hsp70 can protect against apoptosis in myeloid cells exposed to 
chemotherapeutic agents, as demonstrated by the fact that mild hyperthermia protects 
cells against the alkylating agent, BCNU. This finding dos not implicitly suggest that 
one hsp species in particular is responsible for this protective effect. Rather, it could be 
members of several hslp families including hsp70, hsp90 and hsp25 which are acting in 
cohort to inhibit apoptosis. It may also be possible that another factor, one which is 
induced by heat shock, is responsible. 
The finding that the degree of hyperthermia influences the protective nature of the heat 
shock response suggests that hsp70 may play a more integral role in control of the cell 
cycle and apoptosis than simply as a protective factor. I found that at higher 
temperatures (43-44°C) which are associated withhigher levels of hsp70, the protective 
capacity of heat shock is diminished. Thus, very high levels of hsp70 appear to be a 
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signal that the cell is irretrievably damaged. The fact that high levels of hsp70 correlate 
with susceptibility to apoptisis induced by serum starvation also suggests that hsp70 
may be a marker of cellular damage. It is possible that hsp70 may itself be directly 
involved in the control of apoptosis via its capacity to interact with other proteins 
known to be involved in apoptosis. 
A unifying theory concerning hsp70 and apoptosis, is that hsp70 acts as a `cellular 
sensor' of damage. At low levels of expression it is capable of providing a protective 
role, either directly through its role as a molecular chaperone which involves the re- 
folding and repair of damaged proteins, as well as the denaturation and removal of 
unwanted polypeptide structures. At higher levels of expression, hsp70 is associated 
with the onset of apoptosis; this may simply reflect the fact that hsp70 is a marker of 
cellular damage, or it is possible that hsp70 plays a direct role in the induction of 
apoptosis via the ability of hsp70 to interact with cell cycle-regulatory proteins. 
These possibilities demand further investigation, and it will be interesting to discover 
which proteins hsp70 is associated with during the processes involved in the conflicting 
balance between celluar proliferation and apoptosis. 
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